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Metabolic syndrome, which occurs commonly in populations around the world, 
has been associated with an increased risk for developing cardiovascular disease 
and diabetes. Typically, measures of excess weight, elevated blood pressure, 
dyslipidemia, hyperglycemia, and inflammation are considered key elements of 
the syndrome. In addition to these abnormalities, oxidative stress, which is an 
imbalance between prooxidants and antioxidants, has also been implicated in the 
pathogenesis of cardiovascular disease and diabetes and serves as a common 
feature of metabolic syndrome. This has at least two possible imphcations. First, 
oxidative stress may be involved in the pathogenesis of metabolic syndrome. 
Second, oxidative stress may contribute to the complications that arise from the 
syndrome. Thus, understanding factors that serve to maintain the balance 
between prooxidants and antioxidants may help to increase the understanding 
about its pathophysiology and to define possible avenues for prevention and 
treatment. 
The etiology of metabolic syndrome is multi-factorial and the reports of 
National Cholesterol Education Program Adult Treatment Panel III (NCEP/ATP 
III) recognized the importance of cardiovascular risk factors of what they referred 
to as a "constellation of Lipid and non-Hpid risk factors of metabolic origin" and 
designated this cluster as metabolic syndrome. The aUied lipid disorder consists 
of elevations of serum triglycerides, apohpoprotein B (apo B) and small LDL 
particles, and low levels of HDL. These multiple abnormalities almost certainly 
promote the development of atherosclerosis. All of the steps in the progression of 
atherosclerosis in one way or another are inflammatory and it is well 
documented that inflammatory mediators (such as CRP and TNF-a) play a 
paramount role in the initiation, progression and rupture of atherosclerotic 
plaques. Thus markers of inflammation and endothelial dysfunction may provide 
additional information about a patient's risk of developing metabolic syndrome 
and may become new targets for treatment. 
On the other hand, evidence has emerged suggesting that the free radical 
generation or inadequate antioxidant defenses may lead to alteration in 
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structure and function of fat, protein, carbohydrate, RNA or DNA molecule. As 
far as the management of these disturbances in the body itself is concerned, an 
HDL-associated enzyme paraoxonase (PON-1) has emerged as one of the best 
prototypes in context of metabolic syndrome. In this regard, an understanding to 
the mechanism and potential role played by antioxidants, gained an outstanding 
importance. This has further stimulated intense research efforts to validate the 
beneficial effects of exogenous antioxidants or certain medicinal interventions 
against diabetes, hypertension and metabohc syndrome. 
The first chapter of the thesis highlights and reajffirms the involvement of 
abnormal Upid profile together with the elevated waist circumference and 
inflammatory markers in prediction of metabolic syndrome in diabetic and 
hypertensive population. It has been established that CRP levels >3.0 mg/1 adds 
a prognostic evidence for metabohc syndrome. Subsequently, our findings 
demonstrating such higher values of CRP put both diabetic and hypertensive 
subjects at a higher risk to develop metabolic syndrome. However, the 
comparatively lowered PON-1 activity and significantly lesser time for oxidation 
of sdLDL among hypertensive subjects reflected them to be a much easier prey. 
This adds to a novel finding in the field of metabohc syndrome suggesting and 
giving an idea to find \irgent preventive measures to control hypertension as well 
as diabetes. 
The second chapter of the thesis therefore accounts for the strategies 
involved in the treatment of diabetes and h3T)ertension. To explain the depth of 
its significance, this chapter has been bifurcated in two divisions. The treatment 
modalities for diabetic subjects included monotherapy with either metformin or 
insuhn. Our aim was to scrutinize all the traits of metabolic syndrome before and 
after the supplementation of these hypoglycemics with the recommended doses 
for a considerable period of time. It was noticed that despite of beneficial changes 
in lipoprotein profile, such a monotherapy was not able to recompense for 
increased inflammatory markers and the DNA damage incurred in diabetic 
population. The second unit to this chapter throws hght on the efficacy of 
antihypertensive drugs over the various abnormal parameters of metaboUc 
syndrome. Our results have demonstrated a significant elevation in PON-1 
activity together with a reduction in lipid peroxidation as well as levels of 
inflammatory markers in hypertensive subjects treated with either ramipril or 
losartan as a once-daily anti-hypertensive agent. Besides, it was also witnessed 
that none of the two therapies could prevent the DNA damage up to any 
conspicuous level. 
If oxidative stress is the pathogenic mechanism leading to metabolic 
syndrome as well as diabetes, the ability of a drug to prevent or reverse oxidant 
stress can account for its clinical usefulness. In view of this, the third chapter 
discusses the role of antioxidants, particularly vitamin C and vitamin E in 
prevention of the metabolic abnormalities aroused in the alioxan-induced 
diabetic rabbits. Our results with vitamin C and E clearly demonstrated 
significant improvement in each of the component of metabohc syndrome, the 
former showing much favorable results however. In addition, the DNA damage 
was also recovered partially, when they were supplemented with vitamin C. 
Such a favorable effect with antioxidants may be attributed to their ability to 
maintain the balance between excess fi'ee radicals and reduced antioxidant 
defenses. 
Hitherto, it has been recognized that metaboUc syndrome represents a 
very heterogeneous cluster of components that need a tailored but integrated 
approach. Moreover, the challenge for developing a new drug that will 
substantially reduce multiple risk factors is formidable. In this direction, the 
present study successfully highhghts the importance of antioxidants in 
amehorating the complications of metabohc syndrome. It may thus be implicated 
that antioxidants might provide a better prevention to metabohc syndrome as 
compared to that conferred by hypoglycemics or antihypertensives. This may also 
suggest a strong association between diabetes, oxidative stress and metabohc 
syndrome. 
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Metabolic syndrome, which occurs commonly in populations around the world, 
has been associated with an increased risk for developing cardiovascular disease 
and diabetes. Typically, measures of excess weight, elevated blood pressure, 
dyslipidemia, hyperglycemia, and inflammation are considered key elements of 
the syndrome. In addition to these abnormalities, oxidative stress, which is an 
imbalance between prooxidants and antioxidants, has also been implicated in the 
pathogenesis of cardiovascular disease and diabetes and serves as a common 
feature of metabolic syndrome. This has at least two possible imphcations. First, 
oxidative stress may be involved in the pathogenesis of metabohc syndrome. 
Second, oxidative stress may contribute to the complications that arise from the 
syndrome. Thus, understanding factors that serve to maintain the balance 
between prooxidants and antioxidants may help to increase the understanding 
about its pathophysiology and to define possible avenues for prevention and 
treatment. 
The etiology of metabolic syndrome is multi-factorial and the reports of 
National Cholesterol Education Program Adult Treatment Panel III (NCEP/ATP 
III) recognized the importance of cardiovascular risk factors of what they referred 
to as a "constellation of lipid and non-lipid risk factors of metabohc origin" and 
designated this cluster as metabolic syndrome. The allied lipid disorder consists 
of elevations of serum triglycerides, apoHpoprotein B (apo B) and small LDL 
particles, and low levels of HDL. These multiple abnormalities almost certainly 
promote the development of atherosclerosis. All of the steps in the progression of 
atherosclerosis in one way or another are inflammatory and it is well 
documented that inflammatory mediators (such as CRP and TNF-a) play a 
paramount role in the initiation, progression and rupture of atherosclerotic 
plaques. Thus markers of inflammation and endothehal dysfunction may provide 
additional information about a patient's risk of developing metabolic syndrome 
and may become new targets for treatment. 
On the other hand, evidence has emerged suggesting that the free radical 
generation or inadequate antioxidant defenses may lead to alteration in 
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structure and function of fat, protein, carbohydrate, RNA or DNA molecule. As 
far as the management of these disturbances in the body itself is concerned, an 
HDL-associated enzyme paraoxonase (PON-1) has emerged as one of the best 
prototypes in context of metabolic syndrome. In this regard, an understanding to 
the mechanism and potential role played by antioxidants, gained an outstanding 
importance. This has further stimulated intense research efforts to validate the 
beneficial effects of exogenous antioxidants or cei'tain medicinal interventions 
against diabetes, hypertension and metabohc syndrome. 
The first chapter of the thesis highlights and reaffirms the involvement of 
abnormal lipid profile together with the elevated waist circumference and 
inflammatory markers in prediction of metabolic syndrome in diabetic and 
hypertensive population. It has been established that CRP levels >3.0 mg/1 adds 
a prognostic evidence for metabohc syndrome. Subsequently, our findings 
demonstrating such higher values of CRP put both diabetic and hypertensive 
subjects at a higher risk to develop metabolic syndrome. However, the 
comparatively lowered PON-1 activity and significantly lesser time for oxidation 
of sdLDL among hypertensive subjects reflected them to be a much easier prey. 
This adds to a novel finding in the field of metabohc syndrome suggesting and 
giving an idea to find urgent preventive measures to control hj^ertension as well 
as diabetes. 
The second chapter of the thesis therefore accounts for the strategies 
involved in the treatment of diabetes and hypertension. To explain the depth of 
its significance, this chapter has been bifurcated in two divisions. The treatment 
modalities for diabetic subjects included monotherapy with either metformin or 
insuHn. Our aim was to scrutinize all the traits of metabolic syndrome before and 
after the supplementation of these hjT)oglycemics with the recommended doses 
for a considerable period of time. It was noticed that despite of beneficial changes 
in lipoprotein profile, such a monotherapy was not able to recompense for 
increased inflammatory markers and the DNA damage incurred in diabetic 
population. The second unit to this chapter throws light on the efficacy of 
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antihypertensive drugs over the various abnormal parameters of metabolic 
syndrome. Our results have demonstrated a significant elevation in PON-1 
activity together with a reduction in lipid peroxidation as well as levels of 
inflammatory markers in hypertensive subjects treated with either ramipril or 
losartan as a once-daily anti-hypertensive agent. Besides, it was also witnessed 
that none of the two therapies could prevent the DNA damage up to any 
conspicuous level. 
If oxidative stress is the pathogenic mechanism leading to metabolic 
syndrome as well as diabetes, the abihty of a drug to prevent or reverse oxidant 
stress can account for its chnical usefulness. In view of this, the third chapter 
discusses the role of antioxidants, particularly vitamin C and vitamin E in 
prevention of the metabolic abnormalities aroused in the alloxan-induced 
diabetic rabbits. Oiu* results with vitamin C and E clearly demonstrated 
significant improvement in each of the component of metabohc syndrome, the 
former showing much favorable results however. In addition, the DNA damage 
was also recovered partially, when they were supplemented with vitamm C. 
Such a favorable effect with antioxidants may be attributed to their abihty to 
maintain the balance between excess free radicals and reduced antioxidant 
defenses. 
Hitherto, it has been recognized that metabolic syndrome represents a 
very heterogeneous cluster of components that need a tailored but integrated 
approach. Moreover, the challenge for developing a new drug that will 
substantially reduce multiple risk factors is formidable. In this direction, the 
present study successfully highlights the importance of antioxidants in 
amehorating the complications of metabohc syndrome. It may thus be implicated 
that antioxidants might provide a better prevention to metabolic syndrome as 
compared to that conferred by hypoglycemics or antihypertensives. This may also 
suggest a strong association between diabetes, oxidative stress and metabolic 
syndrome. 
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METABOLIC SYNDROME 
The metabolic syndrome is conceptualized as a constellation of metabolic and 
anthropometric abnormalities (Meigs, 2002), which include hyperglycemia, 
hypertension, dyslipidemia, central obesity, and excess body weight. 
Measures of insulin resistance, inflammation, thrombosis, hyperuricemia, 
and renal function have also been considered for inclusion. The triad of 
hyperglycemia, hj^jertension, and hyperuricemia was described as early as 
1923 (Kylin, 1923). A major milestone in the history of this syndrome 
occurred in 1988, when Reaven proposed the concept of syndrome X, which he 
described as the co-occurrence of resistance to insulin-stimulated glucose 
uptake, glucose intolerance, hyperinsulinemia, increased very low-density 
lipoprotein triglyceride, decreased high-density lipoprotein (HDL) cholesterol, 
and hypertension (Reaven, 1988). This study stimulated renewed interest in 
the syndrome. 
In 1998, the World Health Organization (WHO) proposed a formal 
definition of the metabolic syndrome (Alberti and Zimmet, 1998). Three years 
later, the National Cholesterol Education Programme Adult Treatment Panel 
III (NCEP/ATP III) proposed its definition of the metabolic syndrome 
(National Institutes of Health, 2001). The European Group for the study of 
Insulin Resistance (EGIR) also developed a definition (Balkan et al., 2002). 
The attention that the NCEP/ATP III report brought to the metabohc 
syndrome has ignited an intense interest, as evidenced by the numerous 
publications and meetings concerning the metabolic syndrome. Efforts by 
WHO, NCEP/ATP III, and EGIR to develop standard definitions have been 
critical in trying to determine the prevalence of this syndrome. Although they 
share similarities, they also differ considerably. 
To meet the WHO definition, a person must have glucose intolerance 
or insulin resistance plus two of the following four criteria: central obesity, 
hypertension, dyslipidemia, and albuminuria. In 1999, a modification to the 
WHO definition was proposed: the blood pressure threshold was lowered from 
160/90 mm Hg to 140/90 mm Hg, and the albumin: creatinine ratio threshold 
was raised from 20 mg/g to 30 mg/g (World Health Organization, 1999). To 
meet the NCEP/ATP III definition, a person must have three of the following 
five abnormalities: abdominal adiposity, hypertension, hypertriglyceridemia, 
low HDL, or hyperglycemia. Of note is that WHO and NCEP/ATP III 
included diabetes in their definitions, but there has been extensive debate 
about the appropriateness of including persons with diabetes in prevalence 
estimates of metabolic syndrome. The EGIR definition specifically excludes 
diabetes and to meet the definition, a person must have two of the following 
four criteria: abdominal obesity, hypertriglyceridemia, hypertension, and 
insulin resistance. Although all three definitions include a measure of 
abdominal obesity, elevated blood pressure, dyslipidemia, and hyperglycemia, 
the exact measures and cut points used to define elevations differ among the 
three definitions as represented in the Table I (TI). 
RISK FACTORS FOR METABOLIC SYNDROME 
The metabolic syndrome is comprised of a clustering of metabolic risk factors 
in one individual. The syndrome has been identified as a multidimensional 
risk factor for cardiovascular diseases (CVD). It is also associated with an 
increased risk for type 2 diabetes, which in turn is a major risk factor for 
CVD. The metabolic risk factors for CVD that make up the metabolic 
syndrome do not directly cause type 2 diabetes but are frequently associated 
with it. Specifically, following five criteria are listed as the major metabolic 
risk factors for metabolic syndrome: Atherogenic dyslipidemia {that 
comprises of elevated apolipoprotein B (apo-B), including elevated serum 
triglycerides (TGs) plus small low density lipoprotein (LDL) particles and low 
levels of HDL}, elevated blood pressure, elevated plasma glucose, prothrombic 
state, and finally the proinflammatory state. • 
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Atherogenic dyslipidemia 
This lipid disorder consists of elevations of serum TGs, apo-B and small 
(LDL) particles, and low levels of HDL. It can be differentiated from elevated 
LDL cholesterol, which is the major risk factor for CVD. Many controlled 
clinical trials show that LDL-lowering therapy reduces risk for CVD 
(National Cholesterol Education Program, 2002). The connection between 
atherogenic dyslipidemia and CVD risk is more complicated than for LDL 
cholesterol; the multiple lipid abnormalities of atherogenic dyslipidemia 
make it difficult to dissect the contributions of each abnormality to CVD. 
These multiple abnormalities almost certainly promote the development of 
atherosclerosis. An important point to make, however, is that elevated total 
apo-B overlaps with LDL cholesterol. In normal persons, apo-B is mainly 
carried in LDL, whereas only small amounts are present in very low density 
lipoproteins (VLDL). When triglycerides are elevated, however, a somewhat 
greater portion of apo-B is found in VLDL. With atherogenic dyslipidemia, 
the LDL cholesterol level in the LDL fraction underestimates the number of 
LDL particles present, because these particles are partially depleted of 
cholesterol. In atherogenic dyslipidemia, the total apo-B level frequently is 
abnormally elevated. There is growing evidence that all apo-B-containing 
lipoproteins are atherogenic. Whether the different types of lipoproteins that 
carry apo-B (such as VLDL, large LDL, and small LDL) have the same or 
different atherogenic potential is uncertain. Suggestive evidence points to 
small LDL particles being particularly atherogenic, but the evidence is not 
unequivocal. Some of the apparently higher atherogenicity of small LDL may 
be related to an increased number of LDL particles in the LDL fraction. 
Another important component of atherogenic dyslipidemia is a low 
level of HDL cholesterol. This reduced level may raise the risk for CVD. At 
least three possibilities exist (Vega and Grundy, 1996). First, HDL may 
protect directly against the development of atherosclerosis. Second, a low 
HDL level may indicate the increase in atherogenic apo-B-containing 
lipoproteins. Third, low HDL is commonly associated with the nonlipid risk 
factors of metabolic syndrome and hence is a powerful marker for risk 
(National Cholesterol Education Program, 2002). A low HDL may also be 
directly atherogenic because of a deficit in the protective effect of HDL. 
Elevated blood pressure 
An elevation of blood pressure is one of the components of metabolic 
syndrome (Grundy et al., 2004). How aberrations in metabolism produce 
higher blood pressure is uncertain. Conversely, it is certain that a higher 
blood pressure commonly accompanies other metabolic risk factors (Shen et 
al., 2003). Blood pressure often is only moderately elevated in persons with 
the metabolic syndrome. Because blood pressure regulation is a complex 
process, it is not surprising that the metabolic connections between the 
various risk factors and blood pressure regulation are difficult to dissect. The 
frequency of association between blood pressure and those other risk factors 
justifies lumping them together as a multidimensional risk factor, however 
(Shen et a l , 2003). 
In the context of metabolic syndrome, it is necessary to return to the 
relationship between insulin resistance, blood pressure, and risk of CVD, 
specifically to emphasize that no more than 50% of patients with essential 
hypertension are insulin resistant but that this subset of patients is at 
greatest risk of CVD (Zavaroni et al., 1992). For example, patients with 
essential hypertension with electrocardiographic evidence of ischemic 
changes are somewhat glucose intolerant and hyperinsulinemic as compared 
with either a normotensive control group or patients with essential 
hypertension whose electrocardiograms are entirely normal (Jeppesen et al., 
2000). 
Changes in endothelial function those are likely to contribute further 
to increased risk of CVD also vary as a function of differences in insulin-
mediated glucose disposal in patients with essential hypertension. For 
example, the first step in the process of atherogenesis is the binding of 
mononuclear cells to the endothelium (Ross, 1986), and there is evidence of 
increased adherence of the cells isolated from patients with hypertension to 
the cultured endothelial cells (Chen et al., 1999). The relationship between 
insulin resistance and binding of isolated mononuclear cells to endothelium 
was similar in normotensive and hypertensive volunteers, because the more 
insulin resistant an individual, regardless of blood pressure status, the 
greater is the adherence of their isolated mononuclear cells to endothelium. 
The abnormality in the binding of isolated mononuclear cells to endothelium 
was seen only in the subset of patients with essential hypertension who were 
also insulin resistant. 
Elevated plasma glucose 
An increase in plasma glucose to above normal levels typically develops late 
in the course of the metabolic syndrome. Glucose elevation comes in several 
forms. The mildest form is called impaired glucose tolerance. This 
abnormality is detected by an oral glucose tolerance test, which is performed 
in persons with normal plasma glucose (<100mg/dl). Impaired glucose 
tolerance is defined as a plasma glucose level of 140 to 199 mg/dl two' hours 
after a 75-g oral glucose load. A second level of abnormality is impaired 
fasting glucose, which is defined as a fasting glucose of 100 to 125 mg/dl. It 
has been called pre-diabetes by the American Diabetes Association (Genuth 
et al., 2003). The third level is categorical hyperglycemia, which is designated 
as diabetes. Diagnosis of diabetes can be made with a fasting glucose level of 
126 mg/dl or higher or a 2-hour glucose level of 200 mg/dl or higher (Genuth 
et al., 2003). Lesser increase in plasma glucose (impaired glucose 
tolerance/impaired fasting glucose) may not directly cause CVD, although 
they are associated with increased risk for CVD (Qiao et al., 2003). They also 
are strong risk factors for development of categorical diabetes (Unwin et al., 
2002). All levels of increase-impaired glucose tolerance, impaired fasting 
glucose, and diabetes-commonly are associated with other metabohc risk 
factors and must be considered as components of the metabolic syndrome 
(Alberti and Zimmet, 1998). 
Although most insulin-resistant/hyperinsulinemic individuals do not 
become frankly hyperglycemic, they are at increased risk of developing type 2 
diabetes. The role of insulin resistance as an important contributor to the 
development of human disease began with the evidence that resistance to 
insulin-mediated glucose disposal was a characteristic defect in patients with 
type 2 diabetes (Ginsberg et aL, 1975). These initial observations have been 
confirmed on many occasions, and it has been shown that insulin resistance 
(or hyperinsulinemia as a surrogate measure of insulin resistance) is a 
powerful and independent predictor of the development of type 2 diabetes 
(Lillioja et al., 1993). Most insulin-resistant individuals maintain normal or 
near-normal glucose tolerance by secreting the large amounts of insulin 
needed to prevent the increase in plasma glucose and free fatty acid 
concentrations seen in patients with type 2 diabetes mellitus (Reaven, 1995). 
Type 2 diabetes only occurs when insulin-resistant individuals are no longer 
able to maintain the degree of compensatory hyperinsulinemia needed to 
maintain normal glucose homeostasis. Once hyperglycemia ensues, insulin-
resistant individuals are at increased risk of developing the specific 
microangiopathic changes seen in patients with type 2 diabetes. Diabetic 
retinopathy, nephropathy, and neuropathy are the consequences of 
hyperglycemia, per se, not insulin resistance. 
Prothrombic state 
Several defects in the coagulation and fibrinolytic systems commonly are 
associated with other metabolic risk factors (Miller, 1994). These defects in 
aggregate can be called a prothrombic state. Examples of prothrombic defects 
include plasminogen activator inhibitor-1 (PAI-1), fibrinogen, and factor VII 
and platelet abnormalities. Theoretically, a prothrombic state could be 
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associated with CVD in several ways. Some of the prothrombic factors may be 
involved in the atherogenic process itself (Selwyn, 2003); these and others are 
likely to enhance the thrombotic response to acute plaque ruptures or plaque 
erosions (Libby, 2002). The pathogenesis of the prothrombic state varies, but 
because several aberrations in coagulation and fibrinolysis are common in 
persons who have the other metabolic risk factors, there is a growing view 
that these aberrations should be added to the list of metabolic risk factors. 
Elevated PAI-1 levels, the principal inhibitor of fibrinolysis, are 
reported in many clinical and population studies of obese subjects, and they 
correlate with an abnormal pattern of obesity in men and women (Sakkinen 
et al., 2000) and other components of the metabolic syndrome inclusive of 
hyperinsulinemia, hypertension, high triglycerides, low HDL, and small LDL 
particles (Festa et al., 1999). In patients with type 2 diabetes, PAI-1 antigen 
localizes in endothelial and smooth muscle cells of the intima and medial 
layers of the arterial wall (Pandolfi et al., 2001). The accumulation of PAI-1 
in arterial segments is accompanied by reduced plasma fibrinolysis. These 
findings provide insights into the higher clinical occurrence of thrombosis on 
ruptured plaques of patients with type 2 diabetes (Silva et al., 1995). 
High levels of factor VII, a key component of the extrinsic coagulation 
cascade, may also contribute to a pro-thrombotic state, providing a potential 
mechanism for increased cardiovascular risk. This hypothesis was supported 
to some extent by the results of the Northwick Park Heart Study (NPHS; 
Meade et al., 1986). Similarly, the elevated levels of fibrinogen have been 
shown to be a strong and independent cardiovascular risk factor in 
prospective epidemiological studies (Ernst and Resch, 1993; Koenig, 2003). In 
addition, several in vivo studies have provided evidence that the loss of 
insulin's regulating action over platelet aggregation and activation in insuhn 
resistance could contribute to the enhanced atherothrombotic risk associated 
with the metabolic syndrome (Lowe et al., 1980; Zahavi et a l , 1981). Thus, it 
may be postulated that the metabolic syndrome has a permissive role on 
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thrombus formation, propagation and clot stability, and thereby increases the 
severity of the resultant ischemic event following plaque disruption and 
erosion. 
Proinflammatory state 
A final component of the metabolic syndrome is a proinflammatory state. In 
reference to CVD risk, this term is commonly used to indicate that 
atherogenesis is an inflammatory process. All of the steps in the development 
of atherosclerosis in one way or another are inflammatory. In classic terras, 
an inflammatory process has two major components: tissue injury and 
response to injury. Most of the metabolic risk factors such as lipid 
abnormalities, hypertension, hyperglycemia, and thrombotic factors 
potentially inflict direct injury on the arterial wall. Responses to arterial 
injury include infiltration of phagocytes and uptake of lipids, release of 
bioactive molecules by macrophages, and proliferation and collagen 
deposition by smooth muscle cells (Verma et al., 2003). These responses 
apparently elicit secondary inflammatory responses that include increased 
synthesis of acute phase reactants by the liver. One of these secondary 
products, C-reactive protein (CRP), provides a marker for the activity of the 
inflammatory process. Evidence is growing that persons with metabolic 
syndrome have high levels of CRP (Ridker et al., 2003). 
The pro-inflammatory response includes an increased secretion of 
Interleukin-16 (IL-16) and Tumor-necrosis factor-a (TNF-a), which then 
result in the release of the messenger cytokine, IL-6, especially from 
macrophages. IL-6, after engagement of its receptor on the liver, helps in the 
secretion and release of CRP and serum amyloid A (SAA). Recent evidence 
points to the role of vascular cells, such as smooth muscle cells, m the 
production of CRP. CRP mRNA and protein have been shown to be expressed 
in the cells of the lesion of magnitude more than that observed in plasma 
(Calabro et al., 2003; Kobayashi et al., 2003). 
Cytokines, particularly IL-1, TNF-a, and IL-6, are the main inducers of 
the acute phase response (Baumann and Goldie, 1994). TNF-a is pro-
inflammatory cytokine secreted by monocytes-macrophages, endothelial cells, 
and, to a large extent, by adipocytes. Several studies have shown that levels 
of TNF-a are important regulator of insulin sensitivity (Hotamisligil, 1993) 
and that neutralization of TNF-a improves insulin sensitivity in fa/fa rats but 
not in obese humans with diabetes (Arner, 2003). In human subjects, TNF-
mRNA and protein correlate positively with body adiposity and decrease in 
obese subjects with weight loss. Insulin sensitivity was not studied, however 
(Dandona et al., 1998). Obesity is one of the major features of the metabolic 
syndrome. TNF-a levels also correlate strongly with BMI (Nieman, 1997). 
TNF-a is overexpressed in adipose and muscle tissue of obese individuals 
compared with tissues from lean individuals (Fernandez-Real and Ricart, 
1999). 
TNF-a and IL-6 decrease the activity of lipoprotein lipase in mice and 
cultured mouse adipocytes (Arner, 2003). TNF-a also promotes insulin 
resistance via decrease in insulin receptor tyrosine kinase activity, 
insulin receptor substrate-1 (IRS-1) phosphorylation, and GLUT4 
synthesis/translocation (Hotamisligil et al., 1996). In contrast to IL-6, 
however, increased TNF-a secretion from adipose tissue has been shown only 
in rodents but not in humans. 
HIGH-DENSITY LIPOPROTEIN IN METABOLIC SYNDROME 
By definition, many subjects with the metabolic syndrome have low levels of 
HDL. Each of the features of the metabolic syndrome, including central 
adiposity, elevated plasma triglyceride, hypertension, and insulin resistance, 
is associated with a low concentration of HDL. Whether this reflects a causal 
relationship between these features and the concentration of HDL is not 
known. It is possible that a low level of HDL is just one of the several 
manifestations of same underlying condition, the metabohc basis of which 
10 
remains obscure. HDLs in subjects with the metabolic syndrome tend to be 
smaller and denser than normal (Chang et al., 1985). Whether this is a 
consequence of having the metabolic syndrome or a simple consequence of the 
low HDL level is not known. It is known, however, that the particle size of 
HDL correlates inversely with the concentration of plasma triglyceride. 
Subjects with plasma triglyceride concentrations more than 150 mg/dl tend to 
have predominantly smaller HDL (Yu and Mamo, 2000). When the 
triglyceride level falls below this value, there seems to be a quantum shift 
into a larger HDL size. Whether the elevated triglyceride in the metabolic 
syndrome accounts for the associated small size of the HDL particles is not 
known. 
Several potentially pro-atherogenic forces operate in people with the 
metabolic syndrome. An increase in concentration of the remnants of 
triglyceride-rich lipoproteins has the capacity to deposit cholesterol in 
macrophages, converting them into foam cells (Goulinet and Chapman, 1997). 
There is also an increase in the concentration of small, dense LDLs, particles 
that are especially susceptible to oxidation (Lemieux et al., 2001) and subject 
to an enhanced uptake by macrophages. Subjects with the metabolic 
syndrome frequently manifest a pro-inflammatory state (Fielding and 
Fielding, 1995). Under normal conditions, pro-atherogenic forces such as 
these are opposed by HDLs. Not only do HDLs promote the efflux of 
cholesterol from cells, including macrophages (Mackness et al., 1993) but 
they also have antioxidant (Calabresi et al., 2002), anti-inflammatory 
(Rosenson and Lowe, 1998), and anti-thrombotic (Yuhanna et al., 2001) 
properties. They also stimulate endothelial nitric oxide production (Laws et 
al., 1997). In the metabolic syndrome, however, the HDL concentration is low 
and there is a reduced capacity to counter the cholesterol accumulation in 
macrophages and a decreased ability to prevent the oxidation of small dense 
LDL. This loss of the protection normally provided by HDL has the capacity 
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to amplify the already powerful pro-atherogenic forces that exist in the 
metabolic syndrome. 
TRIGLYCERIDE AND LOW-DENSITY LIPOPROTEIN METABOLISM 
IN METABOLIC SYNDROME 
Triglyceride-rich lipoprotein 
Multiple factors contribute to altered metabolism of triglyceride and 
triglyceride-rich lipoproteins in the metabolic syndrome. Excess adiposity and 
insulin resistance foster increased hepatic production of VLDL and reduced 
intravascular catabolism and plasma clearance of VLDL and intestinally 
derived chylomicron particles. A major determinant of increased VLDL 
secretion in the metabolic syndrome is higher hepatic triglyceride content, 
derived in part from increased free fatty acid delivery from adipose tissue 
(Hotamisligil et al., 1995) and return of triglyceride-rich lipoprotein remnants 
to the liver. Changes in adipose tissue cytokines, including higher TNF-a 
(Yamauchi et al., 2001) and reduced adiponectin (Fisher and Ginsberg, 2002), 
also may increase hepatic VLDL production and impair peripheral clearance. 
Finally, insulin resistance and compensatory hyperinsulinemia can promote 
directly the increased hepatic secretion of VLDL particles (Ginsberg, 2002). 
Intravascular catabolism and plasma clearance of triglyceride-rich 
lipoprotein involve complex interactions among lipases, apolipoproteins, lipid 
transfer proteins, and receptors (Krauss and Burke, 1982). Insulin resistance 
results in reduced activity of endothelial-bound lipoprotein lipase (LPL), 
which contributes to impaired triglyceride hydrolysis and uptake of 
chylomicron and VLDL lipids by muscle and adipose tissue. Insulin-resistant 
states also result in increased levels of apo-CIIl, an inhibitor of LPL, and 
impaired apo-E-mediated receptor uptake of triglyceride-rich lipoproteins and 
their lipolytic remnants. Delayed postprandial clearance of diet-derived lipids 
in individuals with the metabolic syndrome can result from reduced 
intravascular catabolism of chylomicrons and competition with VLDL for 
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LPL activity. The net effect of changes in triglycehde-rich lipoprotein 
metabolism in the metabolic syndrome is an increase in plasma transport 
and prolonged plasma residence of these lipoproteins and their potentially 
atherogenic catabolic products. This in turn leads to increased levels of 
intermediate-density lipoproteins (IDL), the immediate metabolic precursors 
of LDL. 
Low-density lipoprotein 
At least seven subspecies of LDL can be distinguished on the basis of size and 
density. The subspecies, in turn, have been grouped into four subclasses that 
range from the largest, most buoyant (LDL-I) to the smallest and densest 
(LDL-IV) (Alaupovic, 2003). The differing subspecies of LDL have been shown 
to vary in lipid and carbohydrate composition and in conformation of apoB 
(Berneis and Krauss, 2002). 
Multiple factors contribute to LDL heterogeneity, including differences 
in properties of their VLDL and IDL precursors and differences in 
intravascular transformation and catabolism. Evidence to date suggests that 
larger, more buoyant species arise from LPL-mediated lipolysis of smaller, 
relatively cholesterol-rich and triglyceride poor VLDL and IDL and by direct 
hepatic secretion (Karpe et al., 1993). In contrast, smaller, denser LDL 
species can derive from VLDL of progressively increasing size and 
triglyceride content by a process that involves LPL and hepatic lipase (HL) 
activities (Deckelbaum et al., 1984). Small, dense LDL also can arise by HL-
mediated lipolysis of larger LDL and IDL after triglyceride enrichment of 
these particles through the action of cholesteryl ester transfer protein (Sakai 
et al., 1991). Cholesteryl ester transfer protein is not necessary for the 
production of small, dense LDL, however, as demonstrated by the presence of 
small triglyceride-enriched LDL particles in patients with genetic deficiency 
of cholesteryl ester transfer protein (Ehnholm et al., 1984). ApoE is also 
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believed to play a role in the conversion of VLDL to its smaller metabolic 
products, and loss of the protein is characteristic of most of the particles. 
Several studies have shown a significant univariate relationship of 
reduced LDL peak particle size with increased risk of CVD. In most of these 
studies, however, the strength of this relationship was reduced substantially 
after adjustment for other risk factors [triglyceride (Stampfer et al., 1996) 
and total/HDL-C (Gardner et al., 1996)]. Evidence supports the selective 
benefit of lowering small, dense LDL particle concentrations on the risk of 
CVD (Miller et al., 1996). In vitro studies have suggested that small, dense 
LDL particles confer increased atherosclerotic risk through various 
mechanisms, including reduced LDL receptor affinity (Campos et al., 1996) 
and slower plasma clearance, increased transport into the sub endothelial 
space (Bjornheden et al., 1996), increased binding to heparan sulfate 
proteoglycans in the arterial wall, and increased susceptibility to oxidation 
(Chait et al., 1993). 
HYPERTENSION AND METABOLIC SYNDROME 
Within the metabolic syndrome cluster, there are several mechanisms 
through which one abnormality could favor the development of another. High 
blood pressure may modify peripheral tissue (skeletal muscle and fat) 
perfusion, either by microvascular rarefaction or through more functional 
subtle disturbances, thereby limiting vascular-to-tissue hormone and 
substrate exchange. Although attractive and supported by some experimental 
(Clark et al., 1995) and clinical (Baron et al., 1994) evidence, the vascular 
hypothesis for the development of insulin resistance has been challenged 
seriously by studies showing that in humans, physiologic hyperinsulinemia 
affects tissue perfusion only modestly (Utriainen et al., 1995) and that 
experimental improvement of tissue perfusion does not result in attenuation 
of skeletal muscle insulin resistance in patients with essential hypertension 
(Natah et al., 2000). 
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Alternatively, insulin resistance could raise blood pressure either by 
preventing the vasodilatory effects of the hormone or, via the attendant 
hyperinsulinemia, by upregulating the sympathetic and the antinatnuretic 
tone. The vascular effects of insulin are complex because they involve at least 
three mechanisms: hyperpolarization, nitric oxide-cyclic GMP, and 6-
adrenergic stimulation-cyclic AMP. This pleiomorphic effect of insulin has 
been confirmed in vitro: in smooth muscle cells, insulin induces an increase in 
cAMP and cGMP that is receptor mediated and, for cGMP only, partly nitric 
oxide dependent (Trovati et al., 1995). At pharmacologic concentrations, 
insulin stimulates nitric oxide synthesis in human endothelial cells; this 
effect depends on the number of insulin receptors, their tyrosine kinase 
activity, and, downstream to the receptor, Pl3-kinase and Akt signaling 
(Zeng et al., 2000). Insulin's effect on the endothelium is not limited to the 
stimulation of nitric oxide synthesis. In rat mesenteric arteries, insulin 
vasodilatation is a transient phenomenon caused by a parallel slow-onset 
stimulation of endothelin synthesis (Misurski et al., 2001). The vascular net 
effect of insulin results from the combination of the two opposite vasoactive 
stimuli. Elegant experiments in vitro and in humans have shown recently 
that concurrent endothelin production masks the vasodilatory effect of low 
physiologic hyperinsulinemia (Verma et a l , 2001). This could be the 
mechanism underlying the reduced vascular effect of insulin in insulin-
resistant rats (Miller et al., 2002), which has an increased responsiveness to 
endothelin (Juul et al., 1996). The two effects have not only different time 
course but also different dose-response characteristics and may be 
differentially active depending on the associated conditions. 
At physiologic concentrations, insulin enhances peripheral sympathetic 
outflow and directly desensitizes the sino-atrial node to the baroreflex control 
of heart rate (Muscelli et al., 1998). Mounting evidence also indicates that 
insulin, by trespassing (by transcytosis) the blood-brain barrier in the 
periventricular area, binds to neurons in the arcuate and paraventricular 
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nuclei, which then send inhibitory impulses to the vagus and excitatory 
impulses to the sympathetic nuclei (Davis et al., 1995). Overall, even in the 
absence of hypoglycemia, the cardiovascular system responds to acute insulin 
administration with a moderate, specific stress reaction. Of note is that the 
pattern of hemodynamic responses to euglycaemic hyperinsulinemia is 
maintained in obesity, an insulin-resistant state with a high-output, low-
resistance hemodynamic pattern (Ferrannini, 1992). Similarly, physiologic 
hyperinsulinemia directly restrains renal sodium excretion by acting on the 
distal portions of the nephron (deFronzo et al., 1975). This action is preserved 
in individuals with insulin resistance of glucose metabolism (Muscelli et al., 
1996) in whom chronic hyperinsulinemia might cause a rightward shift of the 
pressure-natriuresis curve (as documented in experimental animals 
(Fujiwara et al., 1999) and obese subjects (Rocchini et al., 1989). 
MEDICAL TREATMENTS IN METABOLIC SYNDROME 
There remains a need for medical intervention because about 50 percent of 
people with the metabolic syndrome do not reach targets without drugs. 
Furthermore, many people do not want to change their lifestyle or are unable 
to exercise. Therefore, drugs should be analyzed for their safety as well as 
effectiveness for prevention of the metabolic syndrome and associated 
cardiovascular diseases. 
Medical treatment of diabetes in patients with the metabolic 
syndrome 
So far drug intervention studies in pre-diabetes have been performed only in 
people with impaired glucose tolerance (IGT). No data from controlled 
prospective studies are available for subjects with impaired fasting plasma 
glucose (IFG). In subjects with IGT about one-third are suffering from the 
metabolic syndrome. In the US Diabetes Prevention Program (DPP) 
metformin (l-(diaminomethylidene)-3, 3-dimethyl-guanidine) was compared 
with placebo and lifestyle modification. It is remarkable that metformin also 
reduced body weight by ~lKg and had a beneficial effect on blood lipids but 
not on the blood pressure (deFronzo and Goodman, 1995). 
Acarbose, an inhibitor of a-glucosidases of small intestine, delays the 
release of glucose from complex carbohydrates and thus reduces postprandial 
glucose excursion. The efficacy of treatment of postprandial hyperglycemia 
with acarbose in subjects with IGT was tested in a multi-national study. Such 
a treatment not only reduced conversion to diabetes by 36 percent but also 
reduced the incidence of newly diagnosed hypertension by 34 percent 
(Chiasson et al., 2003). Furthermore, a significant reduction in the 
triglycerides and excess weight was also observed. Interestingly, the 
therapeutic effect of acarbose on IGT and traits of the metabolic syndrome 
were associated with a significantly lower incidence of major cardiovascular 
events. Thus, both hypoglycemic drugs (acarbose and metformin) had 
beneficial effects in people with IGT and the metabolic syndrome. 
The beneficial effects of metformin on parameters of the metabolic 
syndrome in clinical diabetes were confirmed by the UK Prospective Study 
Group (1998a). Metformin was the only drug in this mega-trial that 
significantly reduced cardiovascular events. It is still an open question why 
metformin, despite the fact that it achieved no stronger reduction in Hbalc 
than glibenclamide and insulin in the other arms of the group, was superior 
with respect to CVD. One explanation could be that it had therapeutic effects 
on overweight whereas the patients in the sulphonylurea and insulin groups 
gained weight. 
Analysis of studies in type 2 diabetes with at-least one-year duration 
revealed, that acarbose improved several components of the metabolic 
syndrome: overweight, hypertension and hypertriglyceridemia. This was 
associated with a reduction of the incidence of myocardial infarction by 65 
percent (Hanefeld et al., 2004). 
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The glitazones (pioglitazone, rosiglitazone) are insulin sensitizers that 
have additional beneficial effects on dyslipidemia and hypertension 
(Campbell, 2000; Raji et al., 2003). This is mainly due to a reduction of free 
fatty acids derived from intra-abdominal adipose tissue (Carey et al., 2002). 
Via activation of the nuclear receptor family P P A R Y (peroxisome proliferator-
activated receptors-y), they are involved in glucose and lipid metabolism. 
Thus, they act on two major pathogenetic factors of the metabolic syndrome: 
insulin resistance and intra-abdominal obesity. Pioglitazone also activates 
PPARa. Their strong effect on insulin resistance has stirred great interest in 
their potential benefit in prevention of the metabolic syndrome and CVD. For 
pioglitazone, and less pronounced for rosiglitazone, a decrease in 
triglycerides, an increase in HDL-cholesterol and a reduction in the small 
dense LDL subfraction have been described. However, a minor increase in 
LDL-cholesterol occurs in patients with type 2 diabetes if glitazones 
treatment is introduced (Campbell, 2000). This is due to the increase in large 
buoyant LDL particles, which are considered to be less atherogenic (Freed et 
al., 2002). Furthermore, a reduction of blood pressure in patients with type 2 
diabetes and hypertension has been described (Grossman, 2003). 
A major effect of glitazones is on the free fatty acid (FFA) release from 
intra-abdominal fat. The FFA flux from intra-abdominal fat depots is an 
important determinant of hepatic insulin resistance and contributes to the 
development of non-alcoholic fatty liver disease (NFLD). Earlier clinical trials 
have shown that glitazones reduce steatosis hepatis (Promrat et al., 2004). 
A reduction of the newly diagnosed diabetes was observed in some 
studies with ACE inhibitors and angiotensin-II-receptor antagonists (ARA) 
(Yusuf et al., 2001; Lindholm et al., 2002) and in a study with the statin 
pravastatin (Freeman et al., 2001). New studies are under way to test the 
potentials of combination therapy (rosiglitazone/ramipril and nateglinide/ 
valsartan) in subjects with IGT and IFG in the prevention of diabetes and 
cardiovascular complications. The surrogate markers so far available suggest 
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that glitazones should be effective in preventing CVD in clinical diabetes 
(Haffner et a l , 2002). 
In conclusion, oral hypoglycemics such as metformin, acarbose and 
insulin sensitizers are the drugs of first choice in subjects with pre-diabetes 
and type 2 diabetes that suffer from the metabolic syndrome. Furthermore, 
compounds used to treat conventional cardiovascular risk factors that 
improve insulin sensitivity and/or inhibit low-grade inflammation may be 
effective treatments for the metaboHc syndrome. 
Medical treatment of hypertension in patients with the metabolic 
syndrome 
Recently four classes of antihypertensive drugs are commonly used as 
monotherapy or - in the majority of cases - in combination: angiotensin 
converting enzyme (ACE) inhibitors/angiotensin-II-receptor antagonists 
(ARA), beta-blockers, calcium channel blockers and diuretics. Besides the 
lowering of blood pressure, certain antihypertensives may have different 
pleiotropic effects on the pathophysiology of the metabolic syndrome: 
ACE inhibitors such as Ramipril and ARAs like Losartan potassium have 
been shown to improve insulin resistance in many but not all studies. 
Accordingly, a reduction of newly diagnosed diabetes was reported in large 
prospective trials, with prevention of coronary heart disease as a primary 
outcome (Lindholm et al., 2002; Mann et al., 2003). Furthermore, ACE 
inhibitors/ARA reduces albumin excretion in diabetic patients with 
microalbumineria (Sica and Bakris, 2002; Mann et al., 2003). They have only 
marginal effects on lipids. 
Beta-blockers, even the 6i-selective drugs, increase triglycerides, lower 
HDL-cholesterol and worsen insulin sensitivity. There are consistent data 
from prospective studies showing that they precipitate the onset of diabetes 
(Jacob et a l , 1998). The use of atenolol, a 6i-selective beta-blocker, by the UK 
Prospective Diabetes Group (1998b) was associated with significantly higher 
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levels of Hbalc and weight gain, respectively, compared with the ACE 
inhibitor captopril. 
Calcium channel blockers obviously have no significant effect on the 
diseases and pathophysiology of the metabolic syndrome. Diuretics such as 
hydrochlorothiazide and torasemide increase triglycerides and decrease HDL-
cholesterol (Ferrari et al., 1991). 
In patients with the metabolic syndrome without CVD, ACE 
inhibitors/ARA should therefore be the drugs of first choice, followed by 
calcium channel blockers. This is particularly relevant for young obese people 
with dyslipidaemia and/or pre-diabetes. In the majority of cases treated with 
ACE inhibitors/ARA, low doses of diuretics will be needed in the long term to 
achieve near-normal blood pressure levels. However, for patients with CVD 
and the metabolic syndrome the introduction of selective beta-blockers is of 
benefit, as shown by evidence-based prospective studies. 
OXIDATIVE STRESS 
Oxidative stress is the term used to describe the condition of oxidative 
damage resulting when the critical balance between free radical generation 
and antioxidant defenses is unfavorable (Sies, 1991). Free radicals are 
reactive chemical species that contain one or more unpaired electrons. In vivo 
examples are hydrogen peroxide (H2O2), hypochlorous acid (HOCl), 
superoxide radical ('02"), hydroxyl radical ("OH), nitric oxide ("NO) and 
nitrogen dioxide (•NO2"); collectively described as reactive oxygen species 
(ROS). If not quenched by an antioxidant, these compounds will react with 
the nearest fat, protein, carbohydrate, RNA, or DNA molecule, altering its 
structure and function. Such interactions may also generate additional free 
radical centers, especially in polyunsaturated fatty acids. The nuclear DNA 
in every human cell receives an estimated 10,000 oxidative "hits" per day 
(Ames et al., 1993), indicating that cells are under constant bombardment 
from ROS. The antioxidant defense system includes enzymes such as 
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superoxide dismutase, glutathione peroxidase, and catalase; iron- and copper-
binding extracellular proteins (such as albumin, transferrin, lactoferrin, 
hepatoglobin, and ceruloplasmin); antioxidants, such as vitamin C, vitamin 
E, quinones, glutathione, uric acid, bilirubin, and the carotenoids (Krmsky, 
1992); and endogenous and exogenous polyphenolic compounds such as the 
flavonoids and lignans contained in fruits, vegetables, and legumes (Ratty 
and Das, 1988). Short term oxidative stress may occur in tissues injured by 
trauma, infection, heat radiation, hyperoxia, toxins, and excessive exercise 
(Halliwell et al., 1992). Alternatively, long term oxidative stress has been 
linked to CVD because oxidized low-density lipoproteins (LDLs) appear to be 
a prerequisite for foam cell formation and atherogenesis (Abby et al., 1993). 
Of the five criteria of metabolic syndrome defined in NCEP/ATP 
III (Alexander et al., 2003), four (and notably hypertriglyceridemia, 
hypertension, hyperglycemia, and abdominal obesity) are independently 
characterized by elevated systemic oxidative stress (Bae et al., 2001; 
Redon et al., 2003; Oberley, 1988; Keaney et al., 2003). Furthermore, 
hypertriglyceridemia, hypertension, and obesity are each associated with 
increased production of superoxide anion via the nicotinamide adenosine 
diphosphate oxidase pathway (Hiramatsu and Arimori, 1988; Zalba et al., 
2001; Brasier et al., 2002). In addition, hyperglycemia leads to increased 
formation of oxygen free radicals as a consequence of protein glycation and 
glucose autoxidation (Mezzetti et al., 2000). Initially, insuHn resistance is 
compensated by hyperinsulinemia, through which a normal glucose tolerance 
is preserved. 
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Deterioration to impaired glucose tolerance occur when insulin 
resistance increases further and/or the compensatory insulin secretory 
response decreases. An increase in insulin, free fatty acid (FFA) and/or 
glucose levels can raise ROS production and oxidative stress, as well as 
activate stress-sensitive pathways (Evans et al., 2003). This, in turn, can 
worsen both insulin action and secretion, thereby accelerating the 
progression to overt type 2 diabetes. Impaired glucose tolerance, i.e. 
postprandial hyperglycemia with fasting glucose in the normal range, is a 
risk factor for increased cardiovascular mortality (Ceriello, 2003a) and many 
studies show that postprandial h5T)erglycemia is associated with oxidative 
stress generation (Ceriello, 2003a). Repeated exposure to hyperglycemia and 
increased levels of FFA can lead to P-cell dysfunction that may become 
irreversible over time (Poitout and Robertson, 2002). In its initial stages, this 
damage is characterized by reversible defective insulin gene expression 
(Bruce et al., 2003). Glucose and lipid toxicity induce the gradual, time-
dependent establishment of irreversible damage to cellular components of 
insulin production and therefore to insulin content and secretion (Prato, 
2003). Oxidative stress is convincingly the mediator of such damage (Evans 
et al., 2003) as represented in Fig I (FI). 
ANTIOXIDANTS AND METABOLIC SYNDROME 
An antioxidant has been defined as "any substance that , when present at low 
concentrations compared to those of an oxidizable substrate (such as proteins, 
lipids, carbohydrates and nucleic acids), significantly delays or prevents 
oxidation of that substrate" (Halliwell, 1996). The definition proposed by the 
Panel on Dietary Antioxidants and Related Compounds of the Food and 
Nutrition Board is that "a dietary antioxidant is a substance in foods that 
significantly decreases the adverse effects of reactive oxygen species, reactive 
nitrogen species, or both on normal physiological function in humans" (Food 
and Nutrition Board, 1989). 
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When he proposed syndrome X, Reaven (Reaven, 1988) placed insuhn 
resistance squarely at the heart of the syndrome, and considerable evidence 
exists to suggest that oxidative stress can contribute to insulin resistance 
(Evans et al., 2005). Thus, it may be instructive to examine some of the 
evidences about the possible benefits of antioxidants on insulin sensitivity. In 
a study of 1665 adults in the United States, serum concentrations of insulin 
were inversely associated with alpha-carotene, beta-carotene, lycopene, beta-
cryptoxanthin, and lutein/zeaxanthin (Ford et al., 1999). In a study of 36 
participants, those who were insulin resistant, determined with an insulin 
suppression test, had lower concentrations of alphacarotene, beta-carotene, 
lutein, alpha-tocopherol, and delta-tocopherol, but not beta-cryptoxanthin, 
zeaxanthin, lycopene, and gamma tocopherol, than patients without insulin 
resistance (Facchini et al., 2000). Among 182 participants of the Botnia study 
(Ylonen et al., 2003), plasma concentrations of beta-carotene were inversely 
associated with insulin resistance in men. 
Unfortunately, little is known about how intakes of specific 
antioxidants may differ between people with and without metabolic 
syndrome. Among 8808 participants of the Third National Health and 
Nutrition Examination Survey (1988-1994) (Ford et al., 2003) in the United 
States, the use of vitamin or mineral supplements was not significantly 
different between participants with or without metabolic syndrome. 
Compared with participants who did not have metabolic syndrome, the 
intake of vitamin A was significantly lower among participants with the 
metabolic syndrome whereas the intake of vitamin C and E and carotenes 
was similar. In addition, participants with metabolic syndrome consumed 
fruits and vegetables less frequently than participants without this 
syndrome. 
Several small studies suggested that vitamin E supplementation 
affects insulin action but not secretion (Paolisso et al., 1993; Paolisso et al., 
1994). In 11 patients with type 2 diabetes melHtus, the use of 600 mg/day of 
24 
vitamin E for 3 months resulted in a reduction in the number of insuhn 
receptors (Skrha et al., 1999). In a study of 80 overweight participants, 
vitamin E supplementation (800 lU/day for 3 months follov^^ed by 1200 lU/day 
for 3 months) improved insulin sensitivity during the first 3 months 
(Manning et al., 2004). Finally, in a randomized clinical trial, insulin 
sensitivity among 28 offspring of people with type 2 diabetes mellitus did not 
improve from using 800 lU/day of vitamin E for 12 weeks (McSorley et al., 
2005). The effect of vitamin C supplementation on insulin parameters has 
also been studied. In a clinical trial in which participants were given 2 
gm/day of vitamin C, insulin concentrations were decreased at 0.5 per hour 
but elevated at 2 hours during an oral glucose tolerance test (Johnston and 
Yen, 1994). In another trial of 40 patients with type 2 diabetes mellitus, the 
use of 0.5 gm/day of vitamin C resulted in decreased concentrations of insulin 
(Paolisso et al., 1995). In a study of 109 Japanese patients with type 2 
diabetes mellitus, vitamin C supplementation (800 mg/d for 4 weeks) did not 
improve insulin resistance (Chen et al., 2006). 
A number of cross-sectional studies have examined the associations 
between dietary patterns and metabolic syndrome or its components. 
Particularly germane to this work are studies that have examined the 
associations between dietary patterns characterized by increased antioxidant 
intake such as in a Mediterranean-style diet. This diet, in addition to 
"regular physical activity," emphasizes "abundant plant foods, fresh fruit as 
the typical daily dessert, olive oil as the principal source of fat, dairy products 
(principally cheese and yoghurt), and fish and poultry consumed in low to 
moderate amounts, zero to four eggs consumed weekly, red meat consumed in 
low amounts, and wine consumed in low to moderate amounts". Total fat in 
this diet is 25% to 35% of calories, with saturated fat at 8% or less of calories 
(Willett et a l , 1995). The diet is often cited as beneficial for being low in 
saturated fat and high in monounsaturated fat and dietary fiber. 
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In a cross-sectional study of 2282 Greek men and women, participants 
who adopted a Mediterranean-style diet were less likely to have the 
metabolic syndrome than participants who did not (Panagiotakos et al., 
2004). A few studies have suggested that a Mediterranean-style diet might 
favorably influence outcomes or physiologic abnormalities. Among Greek 
patients with an acute coronary syndrome who had metabolic syndrome, the 
adoption of a Mediterranean-style diet was associated with a 23% reduction 
in coronary risk (Pitsavos et al., 2003). In a randomized clinical trial of 180 
Italian patients with metabolic syndrome, those who received the 
intervention that included the adoption of a Mediterranean-style diet showed 
favorable improvements in endothelial dysfunction and inflammatory 
markers (Esposito et al., 2004). 
Several studies have suggested that the prevalence of metabolic 
syndrome differs by level of alcohol intake. Beverages such as wine are 
known to contain various antioxidants such as flavonoids. The studies 
examining dietary patterns or alcohol consumption were unable or did not 
isolate any possible effect of specific antioxidant intake on the study 
outcomes. However, Very few data are available about the associations 
between physiologic measurements of antioxidants, such as circulating 
concentrations, and metabolic syndrome from either cross-sectional studies or 
prospective studies. In addition, no studies have reported on the prospective 
associations between physiologic measurements of antioxidants and 
complications attributable to metabolic syndrome. No randomized clinical 
trials have been conducted among people with metabolic syndrome to test the 
effects of antioxidant supplementation on oxidative stress, antioxidant 
status, or other health outcomes. 
VITAMIN C AS AN ANTIOXIDANT 
Vitamin C is an important water-soluble antioxidant in biological fluids (Frei 
et al., 1990). Vitamin C readily scavenges reactive oxygen and nitrogen 
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species, such as superoxide, and hydroperoxyl radicals, aqueous peroxyl 
radicals, singlet oxygen, ozone, peroxynitrite, nitrogen dioxide, nitroxide 
radicals, and hypochlorous acid (Halliwell, 1996), thereby effectively 
protecting other substrates from oxidative damage. Although vitamin C also 
reacts rapidly with hydroxyl radicals, it is nevertheless unable to 
preferentially scavenge this radical over other substrates (Niki and Noguchi, 
1997). The reason for this is that hydroxyl radicals are extremely reactive 
and will combine indiscriminately with any substrate in their immediate 
environment at a diffusion-limited rate. 
Two major properties of vitamin C make it an ideal antioxidant. First 
is the low one-electron reduction potentials of both ascorbate (282 mV) and 
its one-electron oxidation product, the ascorbyl radical (2174 mV), which is 
derived from the ene-diol functional group in the molecule (Halliwell, 1996). 
These low reduction potentials enable ascorbate and the ascorbyl radical to 
react with and reduce basically all physiologically relevant radicals and 
oxidants. For this reason, vitamin C has been said to be "at the bottom of the 
pecking order" and "to act as the terminal water-soluble small molecule 
antioxidant" in biological systems (Buettner, 1993). The second major 
property that makes vitamin C such an effective antioxidant is the stability 
and low reactivity of the ascorbyl radical formed when ascorbate scavenges a 
reactive oxygen or nitrogen species (Equationl). The ascorbyl radical readily 
dismutates to form ascorbate and dehydroascorbic acid (Equation 1 and 2), or 
is reduced back to ascorbate by an NADH-dependent semidehydroascorbate 
reductase (Wells and Jung, 1997). The 2-electron oxidation product of 
ascorbate, dehydroascorbic acid, can itself be reduced back to ascorbate by 
the glutathione-dependent enzyme, glutathione dehydroascorbate 
oxidoreductase [glutathione dehydrogenase (ascorbate), or glutaredoxin], or 
the NADPH-dependent selenoenzyme thioredoxin reductase (Wells and Jung, 
1997). Alternatively, dehydroascorbic acid is rapidly and irreversibly 
hydrolyzed to 2, 3- diketogulonic acid (DKG) (Equation 3) (Halliwell, 1996). 
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A H - « A - ' ^ A (Eq. 1) 
A - + A - ^ A H - + A (Eq. 2) 
A -> DKG -^ oxalate, threonate, etc (Eq. 3) 
Equation 1 shows the reversible 1- and 2-electron oxidation of ascorbate (AH) 
to the ascorbyl radical (A") and dehydroascorbic acid (A), whereas 
equation 2 shows the dismutation of the ascorbyl radical to form ascorbate 
and dehydroascorbic acid. Equation 3 represents the hydrolysis of 
dehydroascorbic acid to DKG, which then decomposes to oxalate, threonate, 
and many other products. Vitamin C has been recognized and accepted by the 
US Food and Drug Administration (FDA) as one of 4 dietary antioxidants, the 
other 3 being vitamin E, the vitamin A precursor b-carotene, and selenium, 
an essential component of the antioxidant enzymes glutathione peroxidase 
and thioredoxin reductase. 
VITAMIN E AS AN ANTIOXIDANT 
Vitamin E is the generic term used to describe a group of at least eight 
compounds that exhibit the biological activity of a-, 6-, y-- and 8-tocopherol 
and a-, 6-, y-. and 8-tocotrienol. a-Tocopherol is the most active form of 
vitamin E, according to results from early animal growth assays (Food and 
Nutrition Board, 1989). In terms of antioxidant activity, results from more 
recent in vitro comparisons indicate that a-tocopherol is superior to y-
tocopherol as it usually exhibits less than 30% of the antioxidant activity of 
the a-tocopherol (Sies et al., 1993). 
In plasma, vitamin E circulates in association with lipoproteins, mostly 
found in the LDL fraction under steady state conditions (Traber et al., 1993). 
In fact, a-tocopherol is the predominant antioxidant found in association with 
LDL; it is reported to be present at a molar ratio 6:1 (a-tocopherol to LDL) in 
well-nourished persons (Esterbauer et a l , 1991). Recent epidemiologic 
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studies indicate that supplemental vitamin E consumption is inversely 
associated v^ith the development of coronary artery disease in both men 
(Rimm et al., 1993) and women (Stampfer et al., 1993). Since oxidized LDL is 
implicated in the development and progression of atherosclerosis (Witztum 
and Steinberg, 1991) and a-tocopherol is known to limit LDL oxidation 
(Dieber-Rotheneder et al., 1991), it is attractive to speculate that the 
beneficial effects of a-tocopherol on coronary artery disease result from 
antioxidant protection of LDL. However, the effects of a-tocopherol on animal 
models of atherosclerosis are inconsistent (Verlangieri and Bush, 1992) 
despite continued protection of LDL against oxidation ex vivo (Keaney et al., 
1994). Clearly then, the beneficial effects of a-tocopherol are not explained 
completely by its antioxidant protection of the LDL particle alone, a-
tocopherol is incorporated into vascular tissue (Keaney et al., 1993) and may 
have important physiologic effects that are not directly related to the 
protection of LDL against oxidation in vivo. For example, a-tocopherol has 
been shown to influence leukocyte adhesion to endothelial cells (Faruqi et al., 
1994), monocytes transmigration (Navab et al., 1991), and oxidant-mediated 
cytotoxicity (Hennig et al., 1987). Moreover, a-tocopherol is known to inhibit 
protein kinase C in vascular smooth muscle cells (Boscoboinik et a l , 1991) 
and protein kinase C activation has been implicated in vascular disease due 
to diabetes (Tesfamariam et al., 1991) as well as oxidized-LDL (Ohgushi et 
al., 1993). Thus, these alternative effects of a-tocopherol have the potential to 
influence processes that are known to impair endothelium-dependent arterial 
relaxation. 
Diabetic subjects and experimental animal models exhibit high 
oxidative stress due to persistent and chronic hyperglycemia, thereby 
depleting the activity of the antioxidant defense system and promoting the 
generation of free radicals (Hong et a l , 2004). Vitamin E has been shown to 
decrease lipid peroxidation, inhibit platelet adhesion, aggregation, and 
smooth muscle cell proliferation, to exert its anti-inflammatory effect on 
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monocytes and to improve endothelial function (Harris et al., 2002). Animal 
studies have shown that vitamin E protects development of cholesterol-
induced atherosclerosis by inhibiting protein kinase C activity in smooth 
muscle cells in vivo (Kartal et al., 2003). However, in spite of these evidences, 
the effect of a-tocopherol on blood pressure is controversial (Newaz and 
Nawal, 1998). Manifestations of vitamin E deficiency are exacerbated by 
deficiency of selenium (a necessary cofactor for glutathione peroxidase). This 
may be prevented by feeding other antioxidants (Farrell and Roberts, 1994). 
In cells, most of the vitamin E is situated in the membranes, adjacent to 
unsaturated fatty acids that are vulnerable to free-radical attack. Vitamin E 
is a potent chain-breaking antioxidant, scavenging oxygen radicals and 
terminating free-radical chain reactions (Burton and Traber, 1990). A 
number of studies have also suggested its role in prevention of cardiovascular 
diseases, cancer and Parkinson's disease as well (Hodis et al., 1995; Knekt, 
1993; Stampfer et al., 1993). 
30 

MATERIALS 
Alloxan monohydrate 
Apo-B estimation kit 
Bovine serum albumin 
Calcium chloride 
CRP estimation kit 
Cupric chloride 
Dimethylsulphoxide 
Ethidium bromide 
Ethylenediaminetetraacetic acid 
Folin's reagent 
Glucose estimation kit 
HDL estimation kit 
Heparin sodium salt 
Histopaque 1077 
Hydrogen peroxide 
Low melting point agarose 
Magnesium chloride 
Nitrogen gas cylinder 
Phenylacetate 
Phosphate buffer saline 
Phosphotungstic acid 
Pyrogallol 
Sodium chloride 
Sodium hydroxide 
Sulfuric acid 
Tetramethoxypropane 
TGs estimation kit 
Thiobarbituric acid 
TNF-a estimation kit 
Total cholesterol estimation kit 
Triton X-100 
Vitamin C (Ascorbic acid) 
Vitamin E (a-tocopherol) 
Titan Biotech., India 
Giesse Diagnostics snc , Italy 
Sigma Chemical Co., USA 
SRL, India 
Calbiotech Inc., USA 
SRL, India 
Sigma Chemical Co., USA 
Sigma Chemical Co., USA 
Qualigens Fine Chemicals, India 
BDH, India 
Ranbaxy Diagnostic Div., India 
Ranbaxy Diagnostic Div., India 
SRL, India 
Sigma Chemical Co., USA 
SRL, India 
Sigma Chemical Co., USA 
Qualigens Fine Chemicals, India 
Sigma Chemical Co., USA 
SRL, India 
SRL, India 
SRL, India 
SRL, India 
Qualigens Fine Chemicals, India 
BDH, India 
BDH, India 
SRL, India 
Ranbaxy Diagnostic Div., India 
Sigma Chemical Co., USA 
Immunotech SAS, France 
Ranbaxy Diagnostic Div., India 
BDH, India 
Central Drug House, India 
Titan Biotech., India 
# All other chemicals were commercial products of analytical grade. 
SUBJECTS 
CHAPTER 1: 
A total of 120 subjects were recruited on a consecutive basis for a screening 
program to check the prevalence of metabolic syndrome at the J.N. Medical 
College, A.M.U. Aligarh. Men and women aged 30-75 yrs participated in 
this study. All the volunteers, unaware of their health status and not 
observing any medication schedule for either diabetes or hypertension, were 
randomly selected and divided into three categories: Control subjects (those 
having normal FBG and BP), diabetic subjects (those having FBG level >110 
mg/dl with normal BP), and hypertensive subjects (those having BP >130/80 
mmHg with normal FBG). Demographic information and clinical history 
was obtained after getting informal consent of all the subjects. A measuring 
tape was used to measure the waist circumference of all volunteers at the 
high point of iliac crest and at normal minimal respiration. Blood pressure 
determination was made using a periodically calibrated mercury 
sphygmomanometer and measurements were performed after a 10-min rest. 
Two measurements were taken: the interval between the first and second 
was at least 20 min. The value used was the arithmetic mean of both 
determinations. Fasting blood specimens were obtained from each subject to 
determine the levels of FBG and serum was isolated for determination of 
total cholesterol (TC), TGs, HDL, CRP, TNF-a, apo-B levels, and all other 
parameters of metabolic syndrome (discussed in 'methods'). 
CHAPTER 2(A): 
This study was based on 128 subjects who came for their regular check-up 
at J.N. Medical College, A.M.U. Ahgarh. Men and women aged 30-75 yrs 
participated in this study. All the subjects were divided into four categories: 
Control subjects (those having normal FBG), diabetic subjects (those having 
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FBG >110 mg/dl and observing no medication; newly detected diabetes, 
including both type-1 and type-2 diabetes), diabetic subjects receiving 
metformin monotherapy (500 mg, orally administered once daily), and 
diabetic subjects receiving insulin monotherapy (mixture of intermediate 
and short acting insulin, with a dosage of 10 I.U. injected sub-cutaneously, 
twice a day). The diabetic subjects receiving either of the two 
monotherapies, as already prescribed by their physicians were on the 
regular treatment for past 5 months and not receiving any other medication 
for hyperglycemia. Demographic information and clinical history was 
obtained after getting informal consent of all the subjects. A measuring tape 
was used to measure the waist circumference of all volunteers at the high 
point of iliac crest and at normal minimal respiration. Fasting blood 
specimens were obtained from each subject to determine the levels of FBG 
and serum was isolated for determination of TGs, HDL, CRP, TNF-a, apo-B 
levels and all other parameters of metabolic syndrome (discussed in 
'methods'). 
CHAPTER 2(B): 
This study was based on 99 subjects who came for their regular check-up at 
J.N. Medical College, A.M.U. Aligarh. Men and women aged 30-75 yrs 
participated in this study. All the subjects were divided into four categories: 
Control subjects (those having normal BP), hypertensive subjects (those 
having BP >130/80 mmHg and observing no medication; newly detected 
hypertension), hypertensive subjects receiving ramipril monotherapy (5 mg, 
orally administered once daily), and hypertensive subjects receiving losartan 
monotherapy (50 mg, orally administered once daily). The hypertensive 
subjects receiving either of the two monotherapies, as already prescribed by 
their physicians, were on the regular treatment for past 5 months and not 
receiving any other medication for hypertension. Demographic information 
and clinical history was obtained after getting informal consent of all the 
subjects. A measuring tape was used to measure the waist circumference of 
all volunteers at the high point of iliac crest and at normal minimal 
respiration. Blood pressure determination was made using a periodically 
calibrated mercury sphygmomanometer and measurements were performed 
after a 10-min rest. Two measurements were taken: the interval between the 
first and second was at least 20 min. The value used was the arithmetic mean 
of both determinations. Fasting blood specimens were obtained and serum 
was isolated from each sample for determination of TGs, HDL, CRP, TNF-a, 
apo-B levels and all other parameters of metabolic syndrome (discussed in 
'methods'). 
CHAPTER 3: 
Male albino rabbits weighing between 1.0 and 1.5 kg were used and 
maintained on commercial diet and water ad libitum. They were 
acclimatized to the laboratory conditions (for 2 weeks) before carrying out 
any experimental work and kept under the controlled conditions of 
temperature (37±2oC), and 12 hrs light/dark cycle throughout the 
experiment. The Experimental Ethical Committee for Animal Research 
approved the protocols used in this study. 
Induction of diabetes 
Diabetes was induced by administering intravenous injection of 5% solution 
of alloxan monohydrate (80 mg/kg body weight), dissolved in cold normal 
saline, to overnight fasted rabbits through their marginal ear vein. Fasting 
blood glucose (FBG) was checked regularly up to the development of stable 
hyperglycemia after three weeks of alloxan administration. The diabetic 
state was confirmed when FBG concentration exceeded 200 mg/dl. 
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Animal treatment 
A total of 12 rabbits were distributed into four experimental groups of three 
rabbits per group: non-diabetic (control, Gl); diabetic (G2); diabetic 
supplemented with 150 mg/kg body weight of vitamin C (ascorbic acid), 
dissolved in water (G3) (Sokoloff et al., 1967) and diabetic supplemented with 
1000 I.U./kg chow of vitamin E (a-tocopherol), dissolved in olive oil (G4) 
(Keaney et al., 1996), administered daily as an oral supplementation via 
gavage for a period of two weeks. The control group however, received olive 
oil only, so as to rule out the effects of olive oil alone. Thereafter, 5 ml fasting 
blood was collected from each animal by piercing the marginal ear vein to 
determine their FBG and serum was isolated from each sample for the 
determination of TGs, HDL, CRP, TNF-a, apo-B levels and all other 
parameters of metabolic syndrome (discussed in 'methods'). 
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METHODS 
Estimation of Total Cholesterol (TC) 
Total cholesterol in the serum was determined by the cholesterol-esterase-
oxidase-peroxidase method (Richmond, 1992). The assay was based on an 
enzyme-coupled reaction that detects both free cholesterol and choiesteryl 
esters in serum. Choiesteryl esters in the sample were first hydrolyzed by 
cholesterol esterase into cholesterol, which was then oxidized by cholesterol 
oxidase to yield hydrogen peroxide and the corresponding ketone product. 
Hydrogen peroxide was then detected by using ADHP (lO-acetyl-3,7-
dihydroxyphenoxazine), a highly sensitive and stable probe for hydrogen 
peroxide. In the presence of horseradish peroxidase, ADHP reacts with 
hydrogen peroxide with a 1:1 stoichiometry to produce highly fluorescent 
resorufin. 
The assay procedure was followed as per the directives of Ranbaxy 
Diagnostic Div., India. Typically, 50 |il of cholesterol standards as well as 
serum samples were added first of all, in the wells of a microtiter plate. 
Thereafter 50 nl of the assay cocktail was added to each well. This assay 
cocktail was prepared immediately before the start of experiment and 
included 4.745 ml of assay buffer (0.1 M potassium phosphate pH 7.4, 
containing 50 mM sodium chloride and 5 mM cholic acid), 150 ^1 of 
cholesterol detector (ADPH), 50 i^ l of horseradish peroxidase, 50 ^1 of 
cholesterol oxidase, and 5 |iil of cholesterol esterase. This was followed by a 
further incubation for 30 min at room temperature in dark and the 
fluorescence was recorded using excitation wavelengths of 565-580 nm and 
emission wavelengths of 585-595 nm. 
36 
Estimation of Triglycerides (TGs) 
Triglycerides levels in the serum were estimated by modified enzymatic 
method (Trinder, 1969) using color reaction to produce a fast, linear, end 
point reaction (Fossati and Prencipe, 1982; McGowan et a l , 1983). In this 
assay, triglycerides were first hydrolyzed by lipoprotein lipase to glycerol and 
free fatty acids. Glycerol was then phosphorylated by ATP with the help of 
glycerol kinase forming glycerol-1-phosphate. Glycerol-1-phosphate was then 
oxidized by glycerol phosphate oxidase to dihydroxyacetone phosphate and 
hydrogen peroxide. Peroxidase catalyzes the coupling of hydrogen peroxide 
with 4-aminoantipyrine and sodium N-ethyl-N-(3-sulfopropyl) m-anisidine 
(ESPA) to produce a quinoneimine dye that showed an absorbance maximum 
at 540 nm. 
The assay procedure was performed as per the directives of Ranbaxy 
Diagnostic Div., India. To begin with, 10 ^1 each of triglyceride standards as 
well as serum samples were added to the wells of a microtiter plate. The 
reaction was initiated subsequently by the addition of 150 ^1 of diluted 
enzyme buffer, a solution of triglyceride enzyme mixture in 15 ml of 50 mM 
sodium phosphate buffer (pH 7.2). This was followed by incubation at room 
temperature for 15 min and the absorbance was read at 540 nm. The increase 
in absorbance at this wavelength was directly proportional to triglyceride 
concentration of the sample. 
Estimation of High density lipoprotein (HDL) 
HDL quantification is based on the polyethylene glycol (PEG-6000) 
precipitation method in which HDL concentrations are determined using 
cholesterol esterase/cholesterol dehydrogenase reagent (Viikari, 1976). In this 
reaction, NAD was reduced to NADH. The optical density of thus formed 
NADH at 340 nm was directly proportionate to the concentration of HDL in 
the sample. 
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The assay procedure was performed as per the directives of Ranbaxy 
Diagnostics Div., India. The serum samples were first mixed with 
precipitation reagent (20 ^l each) and allowed to centrifuge at 9,500 rpm for 5 
min. The supernatant thus obtained (HDL) was diluted with the assay buffer 
in a ratio of 1:4. Thereafter, 50 i^l each of standards and HDL were pipetted 
into the wells of a microtiter plate. This was followed by addition of working 
reagent (60 ^1) in each well to initiate the reaction. The working reagent was 
prepared by mixing 50 )xl assay buffer, 18 |xl NAD solution, and 1 ^l enzyme 
mix, (as provided with the kit). The whole reaction set-up was then incubated 
for 30 min at room temperature and the absorbance was recorded at 340 nm. 
Estimation of Low density lipoprotein (LDL) 
LDL concentration was calculated using the Friedewald formula (Friedewald 
et al., 1972) as follows: 
LDL = [Total cholesterol - {Triglycerides/5 + High density lipoprotein}] 
The concentrations of previously estimated TC, TGs and HDL were used for 
this calculation. 
Estimation of CRP 
Estimation of CRP is based on the principle of a solid phase enzyme-
linked immunosorbent assay (ELISA). Assay procedure was followed as per 
the directives of the kit provided by Calbiotech Inc., USA and the details are 
given below: 
The assay system utilizes a unique monoclonal antibody directed 
against a distinct antigenic determinant on the CRP molecule. This mouse 
monoclonal anti-CRP antibody was used for solid phase immobilization (on 
the microtiter wells). A goat anti-CRP antibody was present in the antibody-
enzyme (horseradish peroxidase) conjugate solution. The serum samples as 
well as calibrators (CRP standards), 25 |al each, were allowed to react 
simultaneously with the two antibodies (100 |j.l), resulting in the CRP 
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molecules being sandwiched between the solid phase and enzyme-lmked 
antibodies. After 15 min incubation at room temperature, the wells were 
washed with 300 pd of wash buffer, a solution of buffered saline in distilled 
water, to remove unbound-labeled antibodies. Thereafter, 100 [i\ of working 
substrate solution, containing tetramethylbenzidine and hydrogen peroxide 
was added and incubated for 15 min, resulting in the development of blue 
color. The reaction was stopped with the addition of Hydrochloric acid (50 ^1), 
that changed the color to yellow. The concentration of CRP was directly 
proportional to the color intensity of the test sample. Absorbance was 
measured spectrophotometrically at 450 nm. 
Estimation of TNF-a 
Estimation of TNF-a is also based on the principle of ELISA. Assay procedure 
was followed as per the directives of the kit provided by Immunotech SAS, 
France and the details are given below: 
At first, 100 \i\ of conjugate containing the first monoclonal antibody 
anti-TNF-Q in presence of the second anti-TNF-a monoclonal antibody linked 
with alkaline phosphatase was added to the wells of a microtiter plate. 
Serum samples as well as the calibrators (TNF-a standards), 100 l^i each, 
were then allowed to react simultaneously with the conjugate following 
incubation for 2 hours at room temperature. After incubation, the wells were 
washed carefully with the wash solution diluted in distilled water. The bound 
enzymatic activity was then detected by addition of 200 fil of substrate 
dissolved in diethanolamine-HCl buffer which was further incubated in dark 
for 45 min. The reaction was stopped with the addition of 50 \i\ stop solution 
containing sodium hydroxide. The color intensity was read at 405 nm, and 
was proportional to the TNF-a concentration in the sample or calibrator. 
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Estimation of apo-B 
Turbidimetric test was used for the measurement of apo-B in serum. 
The assay procedure was followed as per the directives of the kit provided by 
Giesse Diagnostics snc , Italy and the details are given below: 
A goat serum anti-apo-B antibody was first diluted in the Tris buffer in 
a ratio of 1:41 to make the working reagent. At the same time, serum 
samples as well as calibrators (apo-B standards) were also diluted with saline 
solution in a ratio of 1:15. Thereafter, I ml of working reagent and 100 pi of 
diluted serum sample or calibrator were pipetted into cuvette and incubated 
for 10 min at room temperature. The blanks devoid of samples were also 
worked out in the same manner and absorbance was read on a 
spectrophotometer with a 340 nm filter. 
Determination ofFBG 
The most widely used method for the determination of blood glucose was 
proposed by Trinder in 1969. In this reaction, glucose oxidase reacts with 
glucose to form gluconic acid and hydrogen peroxide. The hydrogen peroxide 
is further splitted by peroxidase and reacts with 4-aminoantipyrine and 
phenol to produce a colored complex. The intensity of the coloration, read at 
505 nm, is proportional to the concentration of glucose in the sample. 
The assay procedure was followed as per the directives of Ranbaxy 
Diagnostic Div., India. Briefly, 10 |il of the fasting blood samples were mixed 
with 1 ml of working solution (containing 6.7 U/ml of glucose oxidase, 6.2 
U/ml of horseradish peroxidase, 0.2 mM of 4-aminoantipyrine, 8 mM of 
phosphate buffer and 86 mM of phenol). The blank and standard solutions 
were also prepared simultaneously by adding 10 ^1 of distilled water and 10 
^1 of standard glucose (100 mg/dl) to the 1 ml of working solution. All the 
tubes were mixed well and incubated at room temperature for 30 min. Blank 
solution was used to set the spectrophotometer and absorbance was read at 
505 nm. 
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Estimation ofMDA 
MDA in serum samples was determined fluorimetrically by thiobarbituric 
acid reaction (TBA). 0.2 ml of serum was taken in a stoppered centrifuge 
tube, made up to 1 ml with 0.9% sodium chloride solution, treated with 4 ml 
of N/12 sulfuric acid and shaken gently. 0.5 ml of 10% phosphotungstic acid 
was then added and mixed well followed by centrifugation at 3000 rpm for 10 
min. The supernatant thus obtained, was discarded and the sediment was 
treated with 2 ml of N/12 sulfuric acid and 0.3 ml of 10% phosphotungstic 
acid followed by centrifugation again for 10 min. Hence obtained supernatant 
was further discarded and to the sediment, 4 ml of distilled water and 1 ml of 
TBA reagent were added. Thereafter, 4 ml of distilled water and 4 ml of 0.5 
nmol/1 of tetramethoxypropane were taken as blank and standards 
respectively and 1 ml of TBA reagent was added to both the tubes. All the 
tubes were then incubated at 95°C in a boiling water bath for 60 min. At the 
end of this, the tubes were removed, cooled and treated with 5 ml of n-
butanol. Tubes were mixed vigorously and centrifuged at 3000 rpm for 15 
min. The upper n-butanol layer was then taken for fluorimetric measurement 
at 553 nm emission and 515 nm excitation. TBA reacting substance was 
expressed in terms of MDA as nmol/ml of serum (Kunio, 1984). 
Lowry method for protein estimation 
The Lowry method for determination of protein concentration is one of the 
most venerable and widely-used protein assays. It was first described by 
Lowry and coworkers in 1951. The method is based on both the biuret 
reaction, in which the peptide bonds of proteins react with copper under 
alkaline conditions to produce Cu+, which reacts with the Folin's reagent, and 
the Folin-Ciocalteau reaction, which is poorly understood but in essence 
phosphomolybdotungstate is reduced to heteropolymolybdenum blue by the 
copper-catalyzed oxidation of aromatic amino acids. 
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Briefly, 0.5 ml serum was mixed with 5 ml of freshly prepared copper 
reagent. To this solution, 0.5 ml of Folin's reagent was added after 10 min. 
This resulted in the development of blue color, which is partly due to the 
tyrosine and tryptophan content of protein. The intensity of the color 
produced was directly proportional to the concentration of protein in the 
serum sample which was measured spectrophotometrically at 660 nm using 
BSA as a standard. 
Assay of SOD activity 
The assay method was based on monitoring the inhibition of auto-oxidation of 
pyrogallol by SOD (Marklund and Marklund, 1974). The assay medium in a 
final volume of 3 ml consisted of 50 ^1 sample (serum) and 2.85 ml of 0.05 M 
tris-succinate buffer, pH 8.2. After incubation at 25°C for 20 min, the reaction 
was initiated by the addition of 8 nM pyrogallol. The change in absorbance 
was recorded spectrophotometrically at 420 nm for 3 min. Blanks devoid of 
sample were worked up in the same manner and run simultaneously. One 
enzyme unit is defined as the amount of enzyme required to cause 50% 
inhibition of the rate of pyrogallol auto-oxidation. Enzyme activity was 
expressed as units per mg of protein. 
Estimation ofcatalase 
The assay principle is summarized in the reaction scheme below: 
catalase 
2H2O2 • 2H2O + O2 
Absorbance at 240 nm No absorbance at 240 nm 
Catalase activity was measured by following the decrease in absorbance at 
240 nm due to decomposition of hydrogen peroxide (H2O2) (Aebi, 1984). The 
reaction was allowed to proceed in 0.05 M phosphate buffer (pH 7.0) 
containing 1 ml of 30 mM H2O2 and 50 |.il ml sample. One enzyme unit is 
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defined as the amount of enzyme decomposing 1 jiM H2O2 per min at 25°C. 
Enzyme activity was expressed as units per mg of protein/min. 
Small dense LDL-C Assay 
The details and validation of this experiment have been described elsewhere 
(Hirano et al,, 2003). In brief, the precipitation reagent (0.1 ml) containing 
150 U/ml of heparin sodium salt and 90 mM magnesium chloride was added 
to 0.1 ml of serum sample and the samples were incubated for 10 mm at 
37 °C after mixing. Each sample was placed in an ice-bath and allowed to 
stand for 15 min after which the precipitates were collected by 
centrifugation at 15000 rpm for 15 min at 4 ^C. The precipitates were 
always packed tightly at the bottom of the tube and the supernatant was 
clear. This heparin-Mg2+ supernatant contain sdLDL cholesterol with no 
influence of other lipoproteins (Hirano et al., 2004). Nitrogen gas was 
bubbled through the supernatant collected in separate tubes, which were 
then closed tightly with parafilm and kept at 4 ^C in dark to protect it from 
oxidative modification. 
Oxidation of small dense LDL 
The procedure for oxidation of small dense LDL was adapted from the 
method described by Esterbauer et al. (1989) for LDL oxidation. 10 ^1 of 
supernatant containing sdLDL, collected above, oxygenated PBS and 32 pi 
of 1 mM cupric chloride was added to a 2 ml quartz cuvette and the 
oxidation reaction products, the conjugated dienes, were monitored (Ashton 
et al., 2000) continuously at 37 °C on a UV spectrophotometer at 234 nm. 
Assessment of oxidative damage (Lipid peroxidation) 
Lipid peroxides in the oxidized lipoproteins were determined by mixing 0.1 
ml of the medium containing the modified lipoproteins with 1.0 ml of iodine-
color reagent, incubating the mixture for 30 min at room temperature in the 
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dark, and reading the absorbance at 365 nm. The concentration of hpid 
peroxides was calculated (el-Saadani et a l , 1989) using a molar absorption 
coefficient of 2.46x10'* Micm-i. In principle, this assay makes use of the 
oxidative capacity of lipid peroxides to convert iodide to iodine, which can be 
measured photometrically at 365 nm. Concentrations of lipid peroxides as 
low as 1 nmol/ml could be measured by this procedure. 
Measurement of arylesterase activity of PON-1 using phenylacetate 
as a substrate 
Initial rates of hydrolysis were determined spectrophotometrically at 270 
nm in a power wave 200 microtiter scanning spectrophotometer. The assays 
were performed in a final volume of 250 ^1 containing 1 mM phenylacetate 
and 2 mM calcium chloride dissolved in 20 mM Tris-HCl buffer, pH 8.0 in 
the presence of 0.1 i^l of serum. The extinction coefficient at 270 nm for the 
reaction was 1307 mol/l/cm. One unit of arylesterase activity is equal to 1 
^imol of phenylacetate hydrolyzed per min (de Geest et al., 2000). 
DNA damage determination by alkaline comet assay 
One ml of venous blood sample served for DNA damage assessment using 
alkaline comet assay. Lymphocyte isolation for the comet assay was 
performed using the Histopaque 1077. 1ml of heparinised blood was 
carefully layered over 1 ml histopaque and centrifuged for 35 min at 500 x g 
and 25°C. The interface band containing lymphocyte were washed with 
phosphate buffered saline (PBS) and then collected by 15 min centrifugation 
at 400 X g. The resulting pellets were resuspended in PBS to obtain 
approximately 20,000 cells in 10 [il. 
Comet assay was performed according to Singh et al. (1988) with the 
slight modifications. Essentially, 100 |ul of 0.5% normal melting agarose was 
pipetted onto frosted microscope slides and allowed to solidify under a 
coverslip, which was then carefully removed. Approximately, 20,000 cells 
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(10 ^1) were suspended in 75 |il low melting agarose gel (LMPA); the cell 
suspension was rapidly pipetted onto the first agarose layer, and gently 
spread by placing a coverslip on top. This was allowed to solidify on an ice 
tray for 5 min. After removal of the cover slip, the slide was immersed in 
freshly prepared lysing solution (2.5 M sodium chloride, 100 mM EDTA, and 
10 mM Tris, with 1% Triton X-100, and 10% DMSO) prepared just before 
use and incubated overnight at 4°C. The slides were removed from the 
lysing solution, drained, and placed in a horizontal gel electrophoresis tank. 
The tank was filled with fresh, cold electrophoresis solution (1 mM EDTA 
and 300mM NaOH) to a level approximately 0.25 cm above the slides. The 
slides were left in the solution for 20 min to allow the unwinding of the DNA 
and expression of alkali-labile damage before electrophoresis. 
Electrophoresis was conducted at 4 °C for 30 min using 25 V and a 
current of 300 mA. Following electrophoresis, the slides were washed thrice 
in Tris buffer (0.4 M, pH 7.5) to neutralize the excess alkali. Finally the 
slides were stained with 75 ^1 ethidium bromide (20 fig/ml) and covered with 
a coverslip. The slides were then placed in a humidified chamber to prevent 
drying of the gel and analyzed the same day. Slides were scored using an 
image analysis programme (Komet 5.5, Kinetic Imaging, Liverpool, UK) 
attached to an Olympus (Cx41) fluorescent microscope and an integrated 
camera (equipped with a 540-560 nm excitation and 590 nm barrier filter). 
Comets were scored at lOOx magnijBcation. Images from 50 cells (25 from 
each replicate slide) were analyzed. The parameter taken to assess 
lymphocyte DNA damage was tail length (migration of DNA from the 
nucleus, [imeters) and was automatically generated by Komet 5.5 image 
analysis programme. 
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Statistical analysis 
Results were expressed as mean ± S.D. for all continuous variables. The 
qualitative data were expressed in percentages. Differences between the 
control, diabetic, hypertensive, and metformin/insulin/ramipril/losartan 
treated groups as well as antioxidant supplemented groups were assessed 
using ANOVA followed by student's t-test. Associations between DNA 
damage and parameters of metabolic syndrome along with the parameters 
of NCEP/ATP III were evaluated by Pearson's correlation test. All tests 
were two-tailed and p-value less than 0.05 were considered to be 
statistically significant. All the analysis was performed with sigma 
statistical software, Sigmastat 3.5 and Origin 6.1. 
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The metabolic syndrome is a combination of several factors which may 
share a common aetiology and each of which is a risk factor contributing to 
CVD. In the past few years the concept of metabolic syndrome has been a 
permanent topic of debate, particularly concerning its pathogenesis and 
clinical usefulness, and today still no consensus has been reached (Grundy, 
2006). This is partially reflected by the use of several definitions, based on 
different diagnostic criteria, among them the definition proposed by the 
WHO, NCEP/ATP III, and that of EGIR are all the rage (Alberti and 
Zimmet, 1998). The various definitions have been shown to identify 
different individuals hindering comparisons between different studies and 
different populations. The NCEP/ATP III definition has however been found 
to be the most straightforward to implement because the five criteria 
(abdominal adiposity, hypertension, hypertriglyceridemia, low HDL, and 
hyperglycemia) were clearly defined. Although not included in the 
diagnostic criteria, an increase in the secretion of apoB-containing 
lipoproteins and pro-inflammatory cytokines may also contribute to the 
increased incidence of diabetes and CVD (Eckel, 2007). It has also been 
reported previously that the metabolic syndrome is well characterized by 
the presence of smaller, denser lipoprotein particles that increase their 
susceptibility to oxidative modification and a diminished serum 
paraoxonase (PON-1) activity that is a major determinant of the antioxidant 
capacity of HDL. These may be contributory factors to the increased 
presence and severity of coronary diseases in such patients (Garin et al., 
2005). In general, the greater the number of metabolic syndrome 
components, the greater is the risk for these outcomes. 
The newly detected diabetic and hypertensive subjects were 
consequently chosen for this study, to identify their risk of developing 
metabolic syndrome by estimating the parameters proposed by NCEP/ATP 
III along with the other risk markers. 
47 
1.1: Anthropometric observations 
As earlier reports have proposed the involvement of elevated blood 
glucose and increased blood pressure in metabolic syndrome (Grundy et al., 
2004), both diabetic and hypertensive subjects were included in the present 
work. Table.1.1 represents the anthropometric characteristics of control (C), 
diabetic (D) and hypertensive subjects (HT). It clearly depicts the elevated 
levels of fasting blood glucose (FBG) and blood pressure (BP) along with the 
records of age, family history and waist circumference of all subjects. 
Several reports have suggested that prevalence of metabolic 
syndrome is associated with age. In the third National Health and Nutrition 
Examination Survey (NHANES III) performed in the USA, the prevalence 
of metabolic syndrome increased from 6.7% among participants of 20-29 
years of age to 43.5% for 60-69 year-olds and was 42.0% for participants of 
70 years or older (Alexander et al., 2003). Similar pat tern was observed in 
this study as well. Our observations (table. 1.1) illustrate that most of the 
diabetic and hypertensive subjects were from the age group of 50-59 years. 
The effect of generalized obesity is also extremely important so much 
so that, in populations where obesity is more common in women than in 
men, the prevalence of metabolic syndrome is likely to be higher in women 
than in men. This trend can be observed in Indian, Iranian and Turkish 
populations (Onat et al., 2002; Azizi et al., 2003; Gupta et al., 2003; 
Ramachandran et al., 2003; Ozsahin et al., 2004). However, the pattern 
observed in the present study was in-a-way opposite as it showed higher 
waist circumference of men as compared to women. Besides, table.1.1 also 
suggests that the waist circumference of both hypertensive and diabetic 
subjects is always greater than that of control subjects. 
The available data describing the role of genetic factors in 
determining the prevalence of metabolic syndrome are limited and many 
findings have yet to be replicated in other populations (Corella and Ordovas, 
2004). The data from this study suggests, subjects having a family history of 
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either diabetes or hypertension are at a higher risk of developing the same 
disease and hence metaboHc syndrome (table. 1.1). 
1.2: Lipid profile 
The dyslipidemia typically found in subjects with the metabolic syndrome 
includes an elevated concentration of plasma TGs, a fraction of LDL in 
which the particles are smaller and denser than normal, and a low 
concentration of HDL cholesterol (Alberti and Zimmet, 1998). Fig. 1.2 depicts 
the concentration of total cholesterol in all the participants of this study. It 
perceives that the average cholesterol of diabetic subjects (D) was maximum 
followed by hypertensive (HT) and control subjects (C). This result was 
consistent to the previous reports that have suggested an alteration in 
cholesterol metabolism during insulin deficiency (Young et al., 1988). It is 
known that in type 2 diabetic subjects, cholesterol absorption efficiency is 
low (Simonen et al., 2002), whereas the synthesis of cholesterol is high 
(Abrams et al., 1982). This could be a primary factor in modifying 
cholesterol metabolism (Young et al., 1988). 
The figure also demonstrates the concentration of TGs in all study 
groups. Mean TGs were highest in hypertensive subjects (HT), followed by 
diabetic subjects (D) and lowest in control subjects (C). A meta-analysis of 
17 prospective, population-based studies found that an increase in plasma 
triglyceride of 1 mM, or 89 mg/dl, was associated with an increased risk of 
CVD (Hokanson and Austin, 1996). The Physician's Health Study found 
that the relative risk of myocardial infarction increased with increasing 
postprandial triglyceride concentrations (Stampfer et al., 1996). A study by 
Jeppesen et al. (1998) has suggested that high plasma triglycerides were 
associated with an increased risk of ischemic heart disease. Evidence also 
exists that a combined measurement of plasma triglyceride and HDL, 
provides a strong index of risk of CVD (Gaziano et a l , 1997). Eventually, 
measurement of HDL was also performed in this study and is demonstrated 
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in the same figure. No significant variation in HDL levels was observed 
among the three categories. Moreover, the values observed for diabetic (D) 
and hypertensive subjects (HT) were almost always similar. In addition, the 
LDL levels among control, diabetic, and hypertensive subjects are also 
illustrated and it is deduced that the concentration of LDL was highest in 
hypertensive subjects (HT), followed by diabetic (D) and control subjects (C). 
1.3: sdLDL oxidation 
A lipoprotein profile characterized by the predominance of small, dense LDL 
particles is one of the key elements of atherogenic dyslipidemia in metabolic 
syndrome (Krauss and Siri, 2004). In vitro studies have suggested that 
sdLDL particles confer increased atherosclerotic risk due to their increased 
susceptibility to oxidation (Chait et al., 1993). It was discovered that a 
combination of heparin and magnesium precipitate a part of LDL which 
remained in the supernatant. This fraction was identified as sdLDL and 
found very similar to the one isolated by ultracentrifugation. The 
supernatant obtained thus, was used as a source of sdLDL in the present 
study. It was oxidized in-vitro using cupric chloride (details given in 
'methods') and the kinetics was observed in terms of peak time. The results 
presented in fig. 1.3 indicate the earliest peak of oxidation of sdLDL among 
hypertensive subjects (HT) followed by diabetic (D) and control subjects (C). 
Thus, suggesting hypertension as a major risk to atherogenesis and 
metabolic syndrome. This result was in agreement with the previous reports 
that have found an inverse relationship between the lag time of in vitro 
LDL oxidation and the severity and progression of coronary atherosclerosis 
(Regnstrom et al., 1992) suggesting the enhanced susceptibility to oxidation 
may underlie the excess vascular disease observed in patients with diabetes. 
This is also consistent with the studies showing that the mean lag time of 
sdLDL oxidation is lower in patients with diabetes than in controls 
(Dimitriadis et al., 1995; Yoshida et al., 1997). 
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Parameters 
Males (n) 
Females (n) 
FBG 
(mg/dl) 
BP (mm Hg) 
(Sys) 
(Dia) 
Age prevalence 
(Yrs) 
WC (cm) 
Males 
Females 
Family history 
Positive 
Negative 
C (n=67) 
39 
28 
98 ±1.3 
113 ± 1.5 
65.3 ± 1.3 
30-39 
86 ±1.5 
75 ±1.6 
12% 
88% 
D (n=37) 
28 
9 
172 ±1.8 
115 ±2 .1 
65.8 ±2 .0 
50-59 
105 ±1.6 
95 ±1 .6 
4 0 % 
6 0 % 
HT (n=16) 
9 
7 
108 ±2.1 
131 ±2.2 
79.8 ±2.5 
50-59 
104 ± 1.9 
93 ±2.4 
56% 
4 4 % 
Table.1.1: Anthropometric observations in diabetic and hypertensive 
subjects. 
The blood glucose level was determined by glucose oxidase method proposed 
by Trinder (1969). The diabetic state was confirmed when FBG concentration 
exceeded 120 mg/dl. The blood pressure (BP) and waist circumference (WC) 
for each subject was measured by the standard techniques (as described in 
'methods'). Results are expressed as mean ± S.D. or percentage, wherever 
applicable. 
C Control group 
D Diabetic group 
HT Hypertensive group 
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Fig.1.2: Lipid profile of diabetic and hypertensive subjects. 
The concentration of serum TC, TGs, and HDL was measured by an 
enzymatic colorimetric test using commercial kits from Ranbaxy Diagnostic 
Div., India. LDL concentration was calculated using the Friedewald formula. 
Results are expressed as mean ± S.D. 
C Control group 
D Diabetic group 
HT Hypertensive group 
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Fig.1.3: sdLDL oxidation time of diabetic and hypertensive subjects. 
The procedure for oxidation of small dense LDL was adapted from the 
method described by Esterbauer et al (1989). 10 ^1 of supernatant containing 
sdLDL, oxygenated PBS and 32 |il of 1 mM CuCb was added to a 2 ml quartz 
cuvette and the oxidation reaction products, the conjugated dienes, were 
monitored at 234 nm. Results are expressed as mean ± S.D. 
C Control group 
D Diabetic group 
HT Hypertensive group 
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1.4: PON-1 activity 
PON-l is an HDL-associated enzyme that has been identified as an 
important determinant of the capacity of HDL to prevent oxidative 
modification to LDL. Aviram et al. (1998) showed that the esterolytic 
activity of PON-1 in serum HDL correlated inversely with the susceptibility 
of HDL to oxidation. The activity of this enzyme has also been reported to be 
decreased in cardiovascular diseases (Navab^ et al., 1997 and McElveen et 
al., 1986) and in diabetes mellitus (Mackness et al., 1998 and Sakai et al., 
1998). A few scientists have observed reduced levels of serum PON-1 in the 
patients with metabolic syndrome (Garin et al., 2005). In light of these 
observations, serum PON-1 levels were measured in this study and the 
results obtained were quite similar. Fig. 1.4 shows that the PON-1 activity 
was significantly reduced in case of hypertensive (HT) and diabetic subjects 
(D). However, no such diminution was seen in the control subjects (C) 
without diabetes or hypertension. This supports the notion that qualitative 
changes to the LDL and HDL profiles in metabohc syndrome is accompanied 
by a reduction in the capacity of one of the main antioxidant activities 
associated with HDL (Garin et al., 2005). This could be a contributory factor 
to the increased incidence and severity of CVD observed in metabolic 
syndrome affected populations. 
1.5: CRP levels 
Recently several studies have drawn attention to the finding of elevated 
levels of CRP, a sensitive marker of inflammation, in subjects of metabolic 
syndrome or in association with its components (Haverkate et al., 1997; 
Koenig et a l , 1999; Mendall et al., 1996). Elevated levels of CRP were also 
found in type 2 diabetic patients with features of metabolic syndrome 
(Pickup et al., 1997). Similar results were obtained following the estimation 
of serum CRP levels of the subjects involved in this study. 
54 
Fig. 1.5 represents the CRP levels in control, diabetiot and hypertensive 
I N , : 
subjects. It is clearly depicted that CRP levels of botft diabetjc (D) iancj 
\% >• ' i* 
hypertensive subjects (HT) were greater than that of cofetrol subjects (Q). 
"* ' ,'' 
The importance of this finding stems from the evidence,^^at ele-v^tio^ in 
CRP level is associated w i^th an increased risk of metabolic syndrome and 
cardiovascular events (Florez et al., 2006). These results strongly suggest 
that CRP levels might provide an additional measure for identifying 
subjects for these co-morbidities and who therefore, would benefit from 
preventive interventions. 
1.6: TNF-a levels 
Metabolic syndrome accompanies nearly all patients who become obese, yet 
the relationship between adiposity and insulin sensitivity is not clear. A 
possible aetiology for insulin resistance in obesity is the production of the 
cytokine, TN"F-a. Recent human studies have demonstrated elevated TNF-a 
expression in the adipose tissue of obese subjects, and its decreased 
expression following weight loss (Hotamisligil et al., 1995 and Kern et al., 
1995). Nonetheless, the present study reveals higher levels of TNF-a at the 
onset of diabetes and hypertension (fig.1.6). It is clearly depicted that TNF-a 
levels were always greater in case of hypertensive subjects (HT), followed by 
the diabetic (D) and control subjects (C). Previously reported elevation in 
the waist circumference of both diabetic and hypertensive subjects might 
provide a coherent explanation for such a change in TNF-a levels. These 
results are consistent to the earlier reports demonstrating a strong 
relationship between TNF-a and metabolic syndrome (Bertin et al., 2000). 
These findings strongly recommend the estimation of TNF-a in prediction of 
metabolic syndrome. 
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Fig.1.4: PON-1 activity of diabetic and hypertensive subjects. 
The assays were performed in a final volume of 250 ^1 containing 1 mM 
phenylacetate and 2 mM CaCk in 20 mM Tris-HCl buffer, pH 8.0 in the 
presence of 0.1 ^l of serum and was read at 270 nm. Results are expressed as 
mean± S.D. 
C Control group 
D Diabetic group 
HT Hypertensive group 
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Fig.1.5: CRP levels of diabetic and hypertensive subjects. 
The concentration of serum CRP was measured by an enzymatic colorimetric 
test using a commercial kit from Calbiotech Inc., USA. Results are expressed 
as mean ± S.D. 
C Control group 
D Diabetic group 
HT H5T)ertensive group 
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Fig. 1.6: TNF-a levels of diabetic and hypertensive subjects. 
The concentration of serum TNF-a was measured by an enzymatic 
colorimetric test using a commercial kit from Immunotech SAS, France. 
Results are expressed as mean ± S.D. 
C Control group 
D Diabetic group 
HT Hypertensive group 
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1.7: Apo-B levels 
Apo-B is the primary apolipoprotein of low density lipoproteins (LDL), 
which is responsible for carrying cholesterol to tissues (Chumakova et al., 
2005). It has recently been found to be associated with metabolic syndrome 
and a few studies have also revealed the association of Apo-B levels of 
diabetic persons with metabolic syndrome (Relimpio et al., 2002; Onat et al., 
2007). In another study, including 77 non-diabetic postmenopausal 
overweight and obese women, apo-B was found to be the primary predictor 
when compared with various inflammatory markers Qike IL-6, CRP, TNF-a 
and others) among a variety of risk parameters such as adiposity, blood 
pressure, insulin resistance, TGs, etc (Faraj et al., 2006). It was suggested 
that high apo-B would be associated with increased risk of developing 
coronary heart disease and diabetes. These findings stimulated the 
verification of apo-B levels in the diabetic and hypertensive subjects 
included in present study. This was done to predict the risk of metabolic 
syndrome. Results presented in fig. 1.7 perpetuate that the apo-B levels were 
high in both diabetic (D) and hypertensive subjects (HT). The control 
subjects (C) having neither diabetes nor hypertension, showed a noticeably 
low level for apo-B. This result further adds to the hypothesis that apo-B 
probably has a potential role in the development of metabolic syndrome. 
1.8: Correlation between NCEP/ATP III parameters and 
observed parameters of metabolic syndrome 
The NCEP/ATP III guidelines to propose metabolic syndrome state that a 
person must have three of the following five abnormalities: abdominal 
adiposity, hypertension, hypertriglyceridemia, low high-density lipoprotein 
(HDL) cholesterol, and hyperglycemia. Eventually, the prevalence of 
metabolic syndrome in diabetic and hypertensive subjects included in this 
study was also estimated on the basis of same criteria. In addition, the role 
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of sdLDL oxidation and serum paraoxonase (PON-1) activity in prediction of 
metabolic syndrome has also been recognized recently (Nishtha et al., 
2008a). Hence, it may be assumed that there exist some relationship 
between the parameters incorporated in NCEP/ATP III guidelines and the 
other parameters being evaluated in this study. Fig. 1.8 represents a 
correlation between the NCEP/ATP III components and the other observed 
factors namely CRP, TNF-a and apo-B levels together with sdLDL oxidation 
time and PON-1 activity measured in each group. It was witnessed that a 
significantly positive correlation was found between the levels of CRP, 
TNF-a, apo-B and NCEP/ATP III parameters. This implies elevation in all 
these parameters as metabolic syndrome progresses. On the other hand, a 
significantly negative correlation was deduced between sdLDL oxidation 
time as well as PON-1 activity with respect to NCEP/ATP III parameters. 
This reveals the existence of an inverse relationship of these parameters to 
metabolic syndrome. Thus, explains their declination as metabolic syndrome 
progresses. 
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Fig. 1.7; Apo-B levels of diabetic and hypertensive subjects. 
The concentration of serum Apo-B was measured by an enzymatic 
colorimetric test using a commercial kit from Giesse Diagnostics snc, Italy. 
Results are expressed as mean ± S.D. 
C Control group 
D Diabetic group 
HT Hypertensive group 
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Fig. 1.8: Correlation between NCEP/ATP III parameters and observed 
parameters of metabolic syndrome in diabetic and hypertensive 
subjects. 
Pearson's correlation analysis was used for determination of relationship 
between NCEP/ATP III parameters and observed parameters of diabetic and 
hypertensive subjects. The correlation coefficient (r) of indicated parameters 
was plotted against the following parameters to get a positive or negative 
relationship. 
1 sdLDL oxidation time 
2 PON-1 activity 
3 CRP concentration 
4 TNF-a concentration 
5 Apo-B concentration 
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Metformin {(l-(diaminomethylidene)-3,3-dimethylguanidine) is an 
inexpensive compound with documented glucose-lowering effect in both obese 
and non-obese subjects having type 2 diabetes (Consoli et al 2004; Donnelly 
et al 2006). The reduction of glycemic levels upon supplementation with 
metformin is done primarily by inhibiting hepatic glucose output (Leverve et 
al 2003). The beneficial effects of metformin on parameters of the metabolic 
syndrome in clinical diabetes were confirmed by the UK Prospective Study 
Group (UKPDS, 1998a) and it was the only drug in this mega-trial that 
significantly reduced cardiovascular events. 
Insulin analogs have also been developed by modifying the amino acid 
sequence of the insulin molecule. Insulin is available in rapid, short, 
intermediate, and long-acting types that may be injected separately or mixed 
in the same syringe. Rapid-acting insulin analogs (insulin lispro and insulin 
aspart) are available, and other analogs are in development. Regular is short-
acting insulin. Intermediate-acting insulins include lente and NPH. 
Ultralente and insulin glargine are long-acting insulins. Insulin preparations 
with a predetermined proportion of intermediate-acting insulin mixed with 
short or rapid-acting insulin (for example, 70% NPH/30% regular, 50% 
NPH/50% regular, and 75% NPH/25% insulin Hspro) are also available 
(American Diabetes Association, 2002). 
The present study investigates whether a monotherapy with 
metformin or insulin (mixture of intermediate and short acting insulin) has 
any beneficial role or not in metabolic syndrome and DNA damage. The 
parameters being analyzed herein follow the guidelines of NCEP/ATP III and 
include the determination of fasting blood glucose, HDL, and triglyceride 
levels in all the subjects involved. In addition to this, sdLDL oxidation time, 
serum paraoxonase (PON-1) activity, concentration of inflammatory markers 
(CRP and TNF-a) as well as apo-B and lipid peroxides levels were calculated 
as earlier reports from this laboratory have published their role in metabolic 
syndrome (Nishtha et a l , 2008b). Previous studies have also demonstrated 
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an association between increased DNA damage and diabetes (Collins et a l , 
1998). In light of these observations, the extent of DNA damage in diabetic 
subjects as well as the effect of metformin or insulin monotherapy against 
this damage was also monitored. 
2A.1: Anthropometric observations 
Improved glycemic control in diabetes has, to date, not shown any significant 
reduction in CVD. In fact, cardiovascular events increased in the Veterans 
Affairs Cooperative Study on Glycemic ControJ and Complications in Type 11 
Diabetes (VACSDM), and the decrease in cardiovascular events in the United. 
Kingdom Prospective Diabetes Study (UKPDS) was not statistically 
significant. In contrast, insulin given acutely as an intravenous infusion has 
shown a favorable effect on several risk factors of CVD (Chaudhuri et al., 
2004). 
In an effort to identify the effect of glycemic control in reducing 
metabolic syndrome, a detailed analysis was performed on diabetic subjects 
receiving metformin monotherapy (500 mg, orally administered once daily), 
and diabetic subjects receiving insulin monotherapy (10 I.U. injected sub-
cutaneously, twice a day). Diabetic subjects receiving either of the two 
monotherapies, as already prescribed by their physicians were on the regular 
treatment for past 5 months and not receiving any other medication for 
h5T3erglycemia. Measurement of all the components of metabolic syndrome, 
established in previous section was also performed in this study. Non-diabetic 
controls (C) as well as the diabetic subjects who were not receiving any 
hypoglycemic drug (D+ND) were also chosen in addition to the metformin or 
insulin supplemented subjects and their anthropometric observations are 
listed in table.2A.1. It is depicted that the diabetic subjects dependent on 
insulin (D+I) were from a comparatively elder age group. Waist 
circumference of all the categories remained almost same except the control 
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group (C), where it was found to be significantly low. However, a major 
difference was noticed in the blood glucose levels of all subjects. It is 
witnessed from the table that FBG levels reduced significantly in insulin 
treated subjects followed by metformin treated subjects among the diabetic 
population. This is coherent to the previous reports suggesting reduction in 
blood glucose in overweight diabetic subjects upon administration of 
metformin as well as insulin (Bailey and Turner, 1966; Inzucchi et al., 1998; 
Phillips et al., 2003). 
2A.2: HDL levels 
Previous studies of diabetes treatment were limited to the glycemic control 
only. Modern therapies however also imply the role played by blood lipids in 
the progression of diabetes (deFronzo and Goodman, 1995; Campbell, 2000). 
In the present study, HDL levels of all subjects were measured to judge their 
relevance to metabolic syndrome. Fig.2A.2 represents an insignificant 
variation in HDL levels of the four categories. Diabetic subjects receiving 
insulin or metformin monotherapy (D+I, D+M) however, reported slightly 
elevated amounts of HDL. Thus indicating a plausible role of insulin as well 
as oral hypoglycemics in improvement of lipid profile, which is a major 
decisive factor of metabolic syndrome. This result is consistent to the findings 
of Fonseca et al. (2006) highlighting increased HDL levels upon insulin and 
metformin administration. 
2A.3: TGs levels 
The metabolic syndrome is frequently associated with low HDL and 
hypertriglyceridemia (Steiner, 2004). Poorly controlled diabetes causes 
h3^ertriglyceridemia and therefore, drug treatment should be effective not 
only for the lipid disorder but also, in the best case, to improve insulin 
resistance and glucose tolerance (Meyers and Kashyap, 2004). It was 
65 
observed that the metformin treated group (D+M) demonstrated remarkably 
decreased concentration of TGs (fig.2A.3) followed by the levels in insulin 
treated group (D+I), and no drug group (D+ND). Thus, suggesting the role of 
oral hypoglycemics in reducing TGs levels and bringing it near normal levels 
as shown in the control group (C). This effect of metformin adds up to the 
reason why oral hypoglycemics are the drugs of first choice in diabetic 
subjects who also suffer from metabolic syndrome. 
2A.4: Lipid peroxidation 
It has recently been reported from this laboratory that concentration of lipid 
peroxides in oxidized sdLDL is an important marker of metabolic syndrome 
and oxidative stress (Nishtha et al., 2008b). Thus, the sdLDL was isolated, 
oxidized by cupric chloride and lipid peroxides were measured in the present 
study groups. Fig.2A.4 shows the lowest concentration of lipid peroxides in 
metformin treated group (D+M). The diabetic group amid insulin 
administration (D+I) also witnessed a noticeable reduction when compared to 
the group receiving no drug at all (D+ND). This suggests that the maximum 
lipid peroxidation occurred in diabetic group receiving no treatment and the 
lowest in non-diabetic control (C) group. This result also indicates that the 
production of lipid peroxides is increased upon initiation of diabetes which is 
abridged by the supplementation of either oral hypoglycemics or insulin. 
Similar studies involving both metformin and insulin as therapeutic targets 
for diabetes have also reported decreased lipid peroxidation (Fonseca et al., 
2006). Thus, the result generates a necessity for the provision of adequate 
basal insulin or in other words, proper glycemic control to lower the lipid 
peroxidation and presumably, oxidative stress leading to metabolic 
syndrome. 
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Parameters 
Males (n) 
Females (n) 
Age (Yrs) 
WC (cm) 
FBG (mg/dl) 
C 
(n=28) 
12 
16 
36 ±3 .1 
79 ±1 .8 
96 ±1 .5 
D + ND 
(n=30) 
25 
5 
46 ±8 .1 
102 ±1 .3 
170 ±2.3 
D + I 
(n=35) 
28 
7 
52 ±9 .3 
110 ±2 .3 
120 ±1.7 
D + M 
(n=35) 
20 
15 
48 ±8.7 
105 ±2.8 
136 ±1.5 
Table.2A.l: Anthropometric observations in untreated diabetic 
subjects, and diabetic subjects treated with insulin or metformin 
monotherapy. 
The blood glucose level was determined by glucose oxidase method proposed 
by Trinder (1969). The diabetic state was confirmed when FBG concentration 
exceeded 120 mg/dl. The waist circumference (WC) for each subject was 
measured by the usual procedures as described in 'methods'. Results are 
expressed as mean ± S.D. 
C Control 
D + ND Diabetic + No Drug 
D + I Diabetic + Insulin 
D + M Diabetic + Metformin 
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Fig.2A.2: HDL levels of untreated diabetic subjects, and diabetic 
subjects treated with insulin or metformin monotherapy. 
The concentration of serum HDL was measured by an enzymatic colorimetric 
test using a commercial kit from Ranbaxy Diagnostic Div., India. Results are 
expressed as mean ± S.D. 
C Control 
D + ND Diabetic + No Drug 
D + I Diabetic + Insulin 
D + M Diabetic + Metformin 
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Fig.2A.3: TGs levels of untreated diabetic subjects, and diabetic 
subjects treated with insulin or metformin monotherapy. 
The concentration of serum TGs was measured by an enzymatic colorimetric 
test using a commercial kit from Ranbaxy Diagnostic Div., India. Results are 
expressed as mean ± S.D. 
C Control 
D + ND Diabetic + No Drug 
D + 1 Diabetic + Insulin 
D + M Diabetic + Metformin 
69 
2A.4: Lipid peroxidation in untreated diabetic subjects, and diabetic 
subjects treated with insulin or metformin monotherapy. 
Lipid peroxides in the oxidized lipoproteins were determined by mixing 
0.1 ml of the medium containing the modified lipoproteins with 1.0 ml of 
iodine-color reagent, incubating the mixture for 30 min at room temperature 
in the dark, and reading the absorbance at 365 nm. Results are expressed as 
meaniS .D. 
C Control 
D + ND Diabetic + No Drug 
D + I Diabetic + Insulin 
D + M Diabetic + Metformin 
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2A.5: PON-1 activity 
Previous results from the same study have revealed insignificantly elevated 
concentration of HDL in diabetic subjects after insulin or metformin 
monotherapy. As serum paraoxonase (PON-1) is an HDL-associated enzyme 
that protects both HDL and LDL from oxidation, a curiosity was raised to 
determine the content of this enzyme also. The results obtained after 
performing PON-1 assay in all the four categories came out to be analogous 
to what was expected. Fig.2A.5 reveals the rise in activity of this enzyme in 
case of diabetic subjects treated with metformin (D+M) followed by those 
receiving insulin (D+I). The PON-1 activity of diabetic subjects receiving no 
medication (D+ND) showed significantly low-levels whereas; the non-diabetic 
control group (C) showed the highest levels of enzyme activity. These results 
were comprehensible to the earlier proposed hypothesis stating that 
metformin possess antioxidant properties and significantly lowers insulin 
resistance (Faure et al., 1999). 
2A.6: CRP and TNF-a levels 
Both CRP and TNF-a are the markers of inflammation that have been 
associated with diabetes, metabolic syndrome and CVD (Tracy et al., 1997). 
There are different views among scientists, regarding the effect of oral 
hypoglycemics as well as insulin analogues on the CRP levels of diabetic 
patients. Yudkin et al. (1999) hypothesized the association of high CRP levels 
and oxidative stress. Further, Dandona et al. (2002) established the anti-
inflammatory properties of intravenous insulin. The results explained in 
fig.2A.6(a) indicate high CRP levels in the diabetic subjects receiving no drug 
(D+ND) as compared to the non-diabetic control subjects (C). However, an 
insignificant reduction in CRP levels was also noticed in diabetic subjects 
after insulin or metformin monotherapy (D+I, D+M). 
The implication of TNF-a in the pathogenesis of metabolic syndrome 
has been attributed to the over-expression of TNF-a gene in the adipose 
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tissue of obese humans (Hotamisligil et al., 1995; Kern et a l , 1995) and 
rodents (Hotamisligil, 1993; Hotamisligil et al., 1996). Moreover, certain 
studies have also reported an association of increased TNF-a with insulin 
resistance (Hotamisligil, 1993; Ruan and Lodish, 2003). Thus, the increment 
in the levels of TNF-a in diabetic subjects (D+ND) as displayed in fig.2A.6(b), 
may account for the development of metabolic syndrome. Despite this risk, a 
slender, non-significant attenuation of TNF-a levels was also observed after 
administration of insulin or metformin alone (D+I, D+M). 
2A.7: Oxidation ofsdLDL andApo-B levels 
Circulating levels of apolipoproteins reflect the number of, rather than the 
cholesterol concentration of, lipoprotein particles. Specifically, the level of 
apo-B reflects the number of triglyceride-rich VLDL particles and the number 
of LDL particles. It thus gives more credence to the number of sdLDL 
particles than the more regular measurement of LDL cholesterol (Lind et al., 
2006). Assessment of qualitative changes in sdLDL is therefore more 
significant in metabolic syndrome because of its ability to get oxidized easily 
(Scheffer et al., 2003). Such an important role of Apo-B and sdLDL in 
determination of metabolic syndrome has provided grounds for their 
estimation in the present study. Therefore, the time taken for oxidation of 
sdLDL, isolated from different groups was monitored. Surprisingly, it was 
found that oxidation of sdLDL from diabetic subjects (D+ND) completed in 
minimum time when compared to the one observed for non-diabetic control 
subjects (C) and diabetic subjects treated with metformin (D+M) or insulin 
(D+I) [fig.2A.7(a)]. Increase in the time required for oxidation of sdLDL in 
diabetic subjects receiving metformin depicts qualitative changes in sdLDL 
particles of these subjects, and thus reducing their chances of developing 
atherosclerosis and metabolic syndrome. 
Similarly, fig.2A.7(b) reveals the effect of metformin or insulin 
supplementation on the apo-B levels of diabetic subjects. It is quite 
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remarkable that apo-B levels significantly decreased when diabetic subjects 
were treated with metformin (D+M). A lesser reduction was also observed in 
the insulin treated subjects (D+I) as compared to those receiving no drug 
(D+ND). Induction of these changes in sdLDL and apo-B by metformin 
administration may be one of the mechanisms of the anti-atherogenic effect of 
such oral hypoglycemics. 
2 A.8: Oxidative stress marker MDA 
There is growing evidence that excess generation of highly reactive free 
radicals, largely due to hyperglycemia, causes oxidative stress, which further 
exacerbates the development and progression of diabetes and its 
complications (Johansen et al., 2005). Also it has been reported that 
uncontrolled hyperglycemia was associated with elevated levels of 
malondialdehyde (MDA), an important marker of oxidative stress, which may 
get reduced with the supplementation of numerous antioxidant compounds 
(Vega-Lopez et al., 2004). Therefore it was of interest to measure MDA levels 
in serum of the diabetic subjects receiving either metformin or insulin 
monotherapy. Fig.2A.8 demonstrates elevated MDA levels in the diabetic 
group receiving no treatment (D+ND) denoting increased oxidative stress. On 
the other hand, metformin and insulin treated groups (D+M, D+1) showed 
remarkably decreased MDA levels; metformin revealing enhanced 
antioxidant effect as compared to that of insulin. Hence, it may be affirmed 
that in diabetic condition, free radicals are elevated and metformin or insulin 
treatment attenuated these changes. 
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Fig.2A.5: PON-1 activity of untreated diabetic subjects, and diabetic 
subjects treated with insulin or metformin monotherapy. 
The assays were performed in a final volume of 250 yd containing 1 mM 
phenylacetate and 2 mM CaCh in 20 mM Tris-HCl buffer, pH 8.0 in the 
presence of 0.1 nl of serum and was read at 270 nm. Results are expressed as 
mean ± S.D. 
C Control 
D + ND Diabetic + No Drug 
D + I Diabetic + Insulin 
D + M Diabetic + Metformin 
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Fig.2A.6(a): CRP levels of untreated diabetic subjects, and diabetic 
subjects treated with insulin or metformin monotherapy. 
The concentration of serum CRP was measured by an enzymatic colorimetric 
test using a commercial kit from Calbiotech Inc., USA. Results are expressed 
as mean± S.D. 
C Control 
D + ND Diabetic + No Drug 
D + I Diabetic + Insulin 
D + M Diabetic + Metformin 
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Fig.2A.6(b): TNF-a levels of untreated diabetic subjects, and diabetic 
subjects treated with insulin or metformin monotherapy. 
The concentration of serum TNF-a was measured by an enzymatic 
colorimetric test using a commercial kit from Immunotech SAS, France. 
Results are expressed as mean ± S.D. 
C Control 
D + ND Diabetic + No Drug 
D + I Diabetic + Insulin 
D + M Diabetic + Metformin 
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Fig.2A.7(a): sdLDL oxidation time of untreated diabetic subjects, and 
diabetic subjects t reated with insulin or metformin monotherapy. 
The procedure for oxidation of small dense LDL was adapted from the 
method described by Esterbauer et al. (1989). 10 ^1 of supernatant containing 
sdLDL, oxygenated PBS and 32 ^1 of 1 mM CuCl2 was added to a 2 ml quartz 
cuvette and the oxidation reaction products, the conjugated dienes, were 
monitored at 234 nm. Results are expressed as mean ± S.D. 
C Control 
D + ND Diabetic + No Drug 
D + I Diabetic + Insulin 
D + M Diabetic + Metformin 
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Fig.2A.7(b): Apo-B levels of untreated diabetic subjects, and diabetic 
subjects treated with insulin or metformin monotherapy. 
The concentration of serum Apo-B was measured by an enzymatic 
colorimetric test using a commercial kit from Giesse Diagnostics snc, Italy. 
Results are expressed as mean ± S.D. 
C Control 
D + ND Diabetic + No Drug 
D + I Diabetic + Insulin 
D + M Diabetic + Metformin 
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Fig. 2A.8: MDA levels of untreated diabetic subjects, and diabetic 
subjects treated with insulin or metformin monotherapy. 
MDA in serum was determined fluorimetrically by thiobarbituric acid 
reaction (TBA) as described in 'methods'. TBA reacting substance was 
expressed in terms of MDA as nmol/ml of serum and was measured at 
553 nm emission and 515 nm excitation wavelength. Results are expressed as 
mean ± S.D. 
C Control 
D + ND Diabetic + No Drug 
D + I Diabetic + Insulin 
D + M Diabetic + Metformin 
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2A.9: SOD and Catalase activity 
Maritim and colleagues recently reviewed in detail that diabetes has multiple 
effects on the protein levels and activity of the antioxidant enzymes such as 
superoxide dismutase (SOD) and catalase, which further augment oxidative 
stress by causing a suppressed defense response (Maritim et al., 2003). SOD 
immediately converts superoxide radical to hydrogen peroxide, which is then 
detoxified to water either by catalase in the lysosomes or by glutathione 
peroxidase in the mitochondria. A plethora of studies have been performed to 
determine the activity of these enzymes upon induction of diabetes and after 
supplementation with metformin or insulin (Ramanathan et al., 1999; 
Pavlovic et al., 2000; Kocic et al., 2007). All these studies have emphasized 
the role of these hypoglycemics in ameliorating oxidative stress and implicate 
that such a treatment significantly increased the level of antioxidant 
enzymes and reduced the amount of lipid peroxidation. The results indicated 
in fig.2A.9(a,b) also witnessed similar outcomes and elucidate that the 
enzyme activity of SOD as well as catalase was highest in the non-diabetic 
control group (C) and decreased significantly in diabetic subjects receiving no 
treatment (D+ND). It is interesting to note that though both metformin and 
insulin monotherapy succeeded in augmentation of SOD and catalase 
activity, the results of treatment with metformin (D+M) showed much 
significant values as compared to that of treatment with insulin (D+I). This 
investigation suggests that the application of metformin monotherapy in 
diabetic subjects improves the antioxidative enzyme status considerably and 
thus adds to an important preventive measure for oxidative stress. 
2A.10: DMA damage 
Insulin dependent diabetes mellitus is associated with increased oxidative 
stress in vivo and under conditions of oxidative stress; damage to cellular 
biomolecules (lipids, proteins, carbohydrates, and DNA) can occur (Hannon-
Fletcher et a l , 2000). Such damage in the DNA of diabetic subjects can be 
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measured by a technique known as comet assay. The comet assay, can 
potentially measure DNA lesions in any organ or tissue even in the absence 
of mitotic activity. Cells are examined using fluorescent microscope. Cells 
look like comets with a bright fluorescent head and tail, the length and 
intensity of which are related to the number of strand breaks (Dobrzynska, 
2005). 
Traditionally, peripheral blood lymphocytes have been preferred 
because they are regarded as sentinel cells being early warning signals for 
adverse health effects (Tice et al., 2000). The assay involves treatment of 
small number of cells layered on glass slides and sandwiched between layers 
of agarose. Furthermore, agarose embedded cells are lysed to generate a 
nucleoid body composed of nuclear DNA stripped of some attached protein 
and its histones. These nucleoid bodies are then subjected to limited 
electrophoresis that cause the damaged DNA to migrate away from the 
undamaged DNA forming a "comet", in which the 'head' of the comet is the 
undamaged DNA and the 'tail' the damaged DNA. Therefore, the more 
damaged a cell's DNA is, the greater the amount of DNA in the tail (often 
measured as olive tail movement, OTM or tail length) (Almeida et al., 2006). 
The size of the comet and the distribution of fluorescence within it are 
correlated quantitatively with the frequency of DNA breaks (Fairbairn et al., 
1995). 
Several studies have shown increases in the level of DNA damage in 
subjects with poor glycemic control (Collins et al., 1998 and Lorenzi et al., 
1987), and no significant changes in subjects with good glycemic control 
(Anderson et al., 1998). To verify the extent of DNA damage in untreated 
diabetic subjects and those receiving a hypoglycemic treatment, fresh 
lymphocytes were isolated from the blood samples of each subject and the 
procedures of comet assay were followed. Interestingly, this study also 
presented similar results when DNA damage was assessed for non-diabetic 
control subjects (C), diabetic subjects receiving no medication (D+ND), and 
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diabetic subjects treated with oral metformin (D+M) or sub-cutaneously 
supplied insulin (D+I). Fig.2A.10 represents the extent of DNA damage in all 
the above stated categories and witnesses no significant alteration in tail-
length of subjects from any of the three diabetic groups. DNA damage in the 
non-diabetic control subjects (C) was however lesser than any other category 
stated. This result implies that supplementation of oral hypoglycemics or 
even insulin does not provide any significant protection to the DNA damage. 
2A.11: Correlation between NCEP/ATP III parameters and 
observed parameters 
Present study engrosses the determination of glycemic control and its effect 
on metabolic syndrome. The NCEP/ATP III components (abdominal 
adiposity, hypertension, hypertriglyceridemia, low HDL, and hyperglycemia) 
as well as the parameters observed in present study (CRP, TNF-a and apo-B 
levels together with sdLDL oxidation time, lipid peroxidation, and PON-1 
activity) have been shown to be involved in metabolic syndrome in the earlier 
chapter. Several reports have also revealed an increased DNA damage in 
diabetes (Collins et al., 1998; Lorenzi et al., 1987; Anderson et al., 1998). In 
an effort to establish a relationship between these factors and NCEP/ATP III 
parameters in diabetic subjects with the administration of insulin or 
metformin, Pearson's correlation analysis was performed. The plotted values 
of correlation coefficient (r) in fig.2A.ll reveal a negative correlation between 
(i) the values of PON-1 activity and the levels of TGs and FBG, (ii) lipid 
peroxidation and HDL, (iii) CRP and HDL, (iv) sdLDL oxidation time and 
levels of TGs and FBG, (v) TNF-a and HDL, (vi) apo-B and HDL, (vii) DNA 
damage and HDL. Thus it adds to an important observation depicting the 
reduction in lipid peroxidation, and levels of CRP, apo-B and TNF-a together 
with the DNA damage upon elevation in HDL concentration followed by 
insulin or metformin administration. Similarly, the decrease in TGs and FBG 
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concentration as a result of the treatment with these hypoglycemics was 
found to be responsible for increased PON-1 activity and the time required 
for oxidation of sdLDL. This implies that regulation of FBG, TGs and HDL 
levels after treatment with hypoglycemics, may play a crucial role in 
preventing the development of metabolic syndrome and other risk factors 
associated with it. 
83 
Fig.2A.9(a): SOD activity of untreated diabetic subjects, and diabetic 
subjects treated with insulin or metformin monotherapy. 
The assay medium in a final volume of 3 ml consisted of 50 )xl sample 
(serum) and 0.05 M tris-succinate buffer, pH 8.2 (2.85 ml). After incubation 
at 25°C for 20 min, the reaction was initiated by the addition of 8 nM 
pyrogallol. The change in absorbance was recorded spectrophotometrically 
at 420 nm for 3 min. One enzyme unit (E.U.) is defined as the amount of 
enzyme required to cause 50% inhibition of the rate of pyrogallol auto-
oxidation. Results are expressed as mean ± S.D. 
C Control 
D + ND Diabetic + No Drug 
D + I Diabetic + Insulin 
D + M Diabetic + Metformin 
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Fig.2A.9(b): Catalase activity of untreated diabetic subjects, and 
diabetic subjects treated with insulin or metformin monotherapy. 
Catalase activity was measured by following the decrease in absorbance at 
240 nm due to decomposition of hydrogen peroxide (H2O2). The reaction was 
allowed to proceed in 0.05 M phosphate buflfer (pH 7.0) containing 1 ml 
H2O2 (30 mM) and 50 \il sample. One enzyme unit (E.U.) is defined as the 
amount of enzyme decomposing 1 pM H2O2 per min at 25°C. Results are 
expressed as mean ± S.D. 
C Control 
D + ND Diabetic + No Drug 
D + I Diabetic + Insulin 
D + M Diabetic + Metformin 
85 
Fig.2A.10: DNA damage in untreated diabetic subjects, and diabetic 
subjects treated with insulin or metformin monotherapy. 
DNA breakage in the lymphocytes isolated from each subject was measured 
by comet assay proposed by Singh et al. (1988) as described in 'methods'. 
Comet tail length (^meters) was observed and plotted against each group. 
Results are expressed as mean ± S.D. 
C Control 
D + ND Diabetic + No Drug 
D + 1 Diabetic + Insulin 
D + M Diabetic + Metformin 
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Fig.2A.ll: Correlation between NCEP/ATP III parameters and 
observed parameters with insulin or metformin monotherapy. 
Pearson's correlation analysis was used for determination of relationship 
between the components of NCEP/ATP III and the parameters observed in 
diabetic subjects with the administration of insulin or metformin. The 
correlation coefficient (r) of indicated parameters was plotted against the 
following parameters to obtain a positive or negative relationship. 
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PON-1 activity 
Lipid peroxidation 
CRP concentration 
sdLDL oxidation time 
TNF-a concentration 
Apo-B concentration 
DNA damage 
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Angiotensin II [formed from angiotensin I in a reaction catalyzed by 
angiotensin converting enzyme (ACE, kininase II)] is a potent 
vasoconstrictor, the primary vasoactive hormone of the rennin-angiotensin 
system and an important component in the pathophysiology of hypertension. 
It also stimulates aldosterone secretion by the adrenal cortex. Losartan and 
its principal active metabolite block the vasoconstrictor and aldosterone-
secreting effects of angiotensin II by selectively blocking the binding of 
angiotensin II to the angiotensin I receptor found in many tissues (vascular 
smooth muscle, adrenal gland) and thus called as Angiotensin receptor 
blocker (ARB) or Angiotensin receptor antagonist (ARA) (Vitale et al., 2005). 
Ramipril, on the other hand inhibit ACE in human subjects and 
animals. Inhibition of ACE results in decreased plasma angiotensin II which 
leads to decreased vasopressor activity and a decreased aldosterone secretion. 
Although ACE inhibitors are clinically effective, their use has been hampered 
by adverse effects such as temporary and reversible decline in glomerular 
filtration rate (GFR), angioedema and cough; which are thought to be caused 
due to inhibition of aldosterone synthesis and release (Pitt et al., 1997 and 
Garvas, 1999). Moreover, with prolonged use, the effectiveness of ACE 
inhibitors may be attenuated by generation of angiotensin II through non-
ACE pathways or by up regulation of angiotensin I because of stimulation of 
rennin secretion. Several clinical trials (Anderson et al., 2000; Stigant et al., 
2000; Brenner et a l , 2001; Lewis et al., 2001) have however, established that 
these limitations of ACE inhibitors may be circumvented by use of the newer 
ARA. 
To find evidence regarding the involvement of ACE inhibitors and 
ARAs in prevention of hypertension and thereby metabolic syndrome, all the 
parameters of metabolic syndrome were analyzed once again; though in 
context with antihypertensive monotherapy this time. 
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2B.1: Anthropometric observations 
Table.2B.1 demonstrates the anthropometric characteristics of all the study 
subjects chosen for this section. A total of 99 subjects were selected, out of 
which 79 were the newly diagnosed hypertensive subjects, and the remaining 
20 were normotensive controls (C). The hypertensive population was further 
sub-divided into three categories: those receiving no medication (HT+ND) at 
all, those receiving ramipril (HT+R) (5 mg orally administered, once in a day) 
as a monotherapy, and finally those receiving losartan (HT+L) (50 mg orally 
administered, once in a day) as a monotherapy prescribed by their 
physicians, for past 5 months. The groups receiving losartan (HT+L) and 
ramipril (HT+R) as a monotherapy comprised of elder subjects, compared to 
those belonging to the no drug (HT+ND) as well as control group (C). No 
significant difference was observed in waist circumference of the three 
hypertensive groups. Thus it can safely be said that neither ramipril, nor 
losartan play any remarkable role in the improvement of waist circumference 
or bringing it to near normal levels as displayed by control group (C). 
Observed reduction in systolic and diastolic blood pressure as a result of 
ramipril and losartan monotherapy, are also indicative of the role of these 
anti-hypertensive drugs in ameliorating metabolic syndrome. 
2B.2: HDL levels 
Besides the lowering of blood pressure, certain anti-hypertensives may have 
different pleiotropic effects on the pathophysiology of metabolic syndrome 
(Brenner et al., 2001). Accordingly, serum HDL concentration was measured 
for all the subjects involved. Fig.2B.2 put across no major variation in HDL 
levels of any of the group and thus suggests no significant role of ARA and 
ACE inhibitors in altering the lipid profile of hypertensive subjects. This 
result is in concordance with the previous reports suggesting only marginal 
effects of these drugs on lipid profile (Sica and Bakris, 2002). 
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2B.3: TGs levels 
Akin to the alteration in HDL, increment of TGs levels is also an important 
indication of metabolic syndrome. As conceived in the former result, that 
showed no remarkable change in HDL even after ramipril or losartan 
monotherapy, the present result (fig.2B.3) also depicts that none of the anti-
hypertensives have any beneficial effect over dyslipidemia. It is clearly 
evident that the TGs levels of non-treated (HT+ND), ramipril treated 
(HT+R), as well as the losartan treated group (HT+L) was almost the same 
but higher than that observed for the control group (C). Thus, it greatly 
emphasizes the need for some combination therapy, where drugs specifically 
capable of reducing lipid disorder should be used in addition to these ARA or 
ACE inhibitors in order to obtain a preventive measure for metabolic 
syndrome. 
2B.4: Lipid peroxidation 
Hypertension is a risk factor for atherogenesis (Kannel and Sorlie, 1975). The 
increased risk of CVD in hypertensive subjects correlates with blood pressure 
and may be linked to other factors including oxidative modification and 
accumulation of lipids in the vascular wall (AUemann and Weidmann, 1995). 
The effect of both ramipril and losartan was thereby observed against the 
concentration of lipid peroxides in the oxidized sdLDL of each subject 
involved in this study. Fig.2B.4 demonstrates the lowest lipid peroxidation in 
normotensive control subjects (C) and highest in the h5TDertensive subjects 
with no medication (HT+ND). However, it is clearly depicted that both 
ramipril (HT+R) and losartan (HT+L) monotherapy succeeded in reducing 
the amount of lipid peroxidation in hypertensive category. Thus, suggesting 
an important contribution of these anti-h3T)ertensives towards suppression of 
oxidative stress, a major culprit of metabolic syndrome. 
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Parameters 
Males (n) 
Females (n) 
Age (Yrs) 
WC (cm) 
BP (mm Hg) 
(Sys) 
(Dia) 
C 
(n=20) 
9 
11 
33 ±2 .1 
86 ±1 .3 
126 ±1 .3 
75 ±1.2 
HT + ND 
(n=19) 
10 
9 
39 ±3.6 
98 ±2.3 
131 ±2 .3 
78.8 ±1.5 
HT + R 
(n=28) 
13 
15 
42 ±2 .8 
96 ± 3 . 1 
115 ± 2 . 1 
68.3 ±2 .0 
HT + L 
(n=32) 
19 
13 
44 ±3.2 
95 ±3.2 
117 ±2.6 
71 ± 1.6 
Table.2B.l: Anthropometric observations in untreated hypertensive 
subjects, and hypertensive subjects treated with ramipril or losartan 
monotherapy. 
The waist circumference (WC) and blood pressure (BP) for each subject was 
measured by the usual procedures as described in 'methods'. Results are 
expressed as mean ± S.D. 
C Control 
HT + ND Hypertensive + No Drug 
HT + R Hypertensive + Ramipril 
HT + L Hypertensive + Losartan 
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Fig.2B.2: HDL levels of untreated hypertensive subjects, and 
hypertensive subjects treated with ramipril or losartan 
monotherapy. 
The concentration of serum HDL was measured by an enzymatic colorimetric 
test using a commercial kit from Ranbaxy Diagnostic Div., India. Results are 
expressed as mean ± S.D. 
C 
HT + ND 
HT + R 
HT + L 
Control 
Hypertensive + No Drug 
Hypertensive + Ramipril 
H5T)ertensive + Losartan 
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Fig.2B.3: TGs levels of untreated hypertensive subjects, and 
hypertensive subjects treated with ramipril or losartan 
monotherapy. 
The concentration of serum TGs was measured by an enzymatic colorimetric 
test using a commercial kit from Ranbaxy Diagnostic Div., India. Results are 
expressed as mean ± S.D. 
C Control 
HT + ND Hypertensive + No Drug 
HT + R Hypertensive + Ramipril 
HT + L Hypertensive + Losartan 
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Fig.2B.4: Lipid peroxidation in untreated hypertensive subjects, and 
hypertensive subjects treated with ramipril or losartan 
monotherapy. 
Lipid peroxides in the oxidized hpoproteins were determined by mixing 
0.1 ml of the medium containing the modified Hpoproteins with 1.0 ml of 
iodine-color reagent, incubating the mixture for 30 min at room temperature 
in the dark, and reading the absorbance at 365 nm. Results are expressed as 
mean ± S.D. 
C Control 
HT + ND Hypertensive + No Drug 
HT + R Hypertensive + Ramipril 
HT + L Hypertensive + Losartan 
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2B.5: PON-1 activity 
The activity as well as concentration of PON-1 has been reported to be 
decreased in CVD (Navab et al., 1997) and diabetes (Sakai et al., 1998), The 
results published from this laboratory have also proposed a diminished 
PON-1 activity in hypertension (Nishtha et al., 2008a). Following the same 
guideline, PON-1 activity of hypertensive subjects dependent upon ramipril 
or losartan was also measured. Surprisingly, the enzyme activity was found 
to be low in hypertensive subjects receiving no treatment (HT+ND) as 
compared to those receiving ramipril (HT+R) or losartan (HT+L) 
monotherapy (Fig.2B.5). Control group (C), however displayed the highest 
enzyme activity. This result is indicative of a plausible role of ARA and ACE 
inhibitors in maintaining the antioxidant status by upregulating the levels of 
PON-1. Thus, suggesting reduction in oxidative stress and the risk of 
metabolic syndrome. 
2B.6: CRP and TNF-a levels 
Rapidly evolving work now demonstrates that CRP has several direct effects 
at the level of the vessel wall (Pasceri et al., 2001). These observations along 
with basic research into the inflammatory mechanism of both diabetes and 
vascular dysfunction provide strong evidence that insulin resistance and 
atherosclerosis share a common inflammatory basis. Based on these 
evidences, CRP levels were evaluated in the normotensive as well as 
hypertensive subjects receiving either ramipril or losartan. This was 
performed in an attempt to verify the role of these drugs against 
inflammation, critically developing into metabolic syndrome. Fig.2B.6(a) 
represents a rise in CRP levels of hypertensive subjects receiving no 
treatment (HT+ND) while a significant drop in hypertensive subjects when 
treated with losartan (HT+L) and ramipril (HT+R). Nonetheless, the 
normotensive control group (C) revealed the lowest concentration of CRP. 
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Based on the evidences that elevated levels of another pro-
inflammatory cytokine, TNF-a, also contribute substantially to metabolic 
syndrome (Devaraj et al., 2004), this research was further extended for the 
estimation of this component too. Fig.2B.6(b) witnesses a significant 
reduction in TNF-a levels of the losartan treated group (HT+L) as compared 
to that of no drug (HT+ND) and ramipril treated group (HT+R). The later 
ones, however showed almost similar values. The control group (C) showed an 
obvious lowest concentration of TNF-a. These results throw light on the 
pleiotropic effects of these drugs on the pathophysiology of metabolic 
syndrome. 
2B.7: Apo-B levels and oxidation ofsdLDL 
Clinical assessment of the apo-B containing lipoproteins has fostered the 
investigations for measurement of standard lipids and their use as indices of 
atherogenic lipoprotein abnormalities of the metabolic syndrome (Austin et 
al., 1990). Consequently, apo-B levels were evaluated in all the subjects 
involved in this study and illustrated in fig.2B.7(a). The group containing 
normotensive control subjects (C) showed lowest concentration of apo-B; 
while no significant variation was depicted in the apo-B content of 
hypertensive subjects receiving no drug (HT+ND) and those receiving 
ramipril or losartan (HT+R, HT+L) as a monotherapy. 
Similarly, fig.2B.7(b) represents the time taken for oxidation of sdLDL 
isolated from all the four categories. It is clearly indicated that the sdLDL 
isolated from all hypertensive subjects got oxidized in lesser duration of time 
as compared to that of normotensive control subjects (C). An almost equal 
amount of time was however noticed when rest of the three hypertensive 
groups (HT+ND, HT+R, HT+L) were compared to each other. Thus 
suggesting that ramipril and losartan are unable to reduce apo-B levels or 
more specifically, to create any qualitative changes in the lipoprotein profile 
of hypertensive subjects. 
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Fig.2B.5: PON-1 activity of untreated hypertensive subjects, and 
hypertensive subjects treated with ramipril or losartan 
monotherapy. 
The assays were performed in a final volume of 250 jil containing 1 mM 
phenylacetate and 2 mM CaCh in 20 mM Tris-HCl buffer, pH 8.0 in the 
presence of 0.1 \i\ of serum and was read at 270 nm. Results are expressed as 
m e a n i S.D. 
C 
HT + ND 
HT + R 
HT + L 
Control 
Hypertensive + No Drug 
HjT)ertensive + Ramipril 
Hypertensive + Losartan 
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Fig. 2B.6(a): CRP levels of untreated hypertensive subjects, and 
hypertensive subjects treated with ramipril or losartan 
monotherapy. 
The concentration of serum CRP was measured by an enzymatic colorimetric 
test using a commercial kit from Calbiotech Inc., USA. Results are expressed 
as mean ± S.D. 
C 
HT + ND 
HT + R 
H T + L 
Control 
HjTjertensive + No Drug 
Hypertensive + Ramipril 
Hypertensive + Losartan 
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Fig.2B.6(b): TNF-a levels of untreated hypertensive subjects, and 
hypertensive subjects treated with ramipril or losartan 
monotherapy. 
The concentration of serum TNF-a was measured by an enzymatic 
colorimetric test using a commercial kit from Immunotech SAS, France. 
Results are expressed as mean ± S.D. 
C Control 
HT + ND Hypertensive + No Drug 
HT + R Hypertensive + Ramipril 
HT + L Hypertensive + Losartan 
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Fig.2B.7(a): Apo-B levels of untreated hypertensive subjects, and 
hypertensive subjects treated with ramipril or losartan 
monotherapy. 
The concentration of serum Apo-B was measured by an enzymatic 
colorimetric test using a commercial kit from Giesse Diagnostics snc, Italy. 
Results are expressed as mean ± S.D. 
C 
HT + ND 
HT + R 
HT + L 
Control 
Hypertensive + No Drug 
Hypertensive + Ramipril 
Hypertensive + Losartan 
100 
100 
90 
0) 
HT+ ND HT+ R HT+L 
Fig.2B.7(b): sdLDL oxidation time of untreated hypertensive 
subjects, and hypertensive subjects treated with ramipril or losartan 
monotherapy. 
The procedure for oxidation of small dense LDL was adapted from the 
method described by Esterbauer et al. (1989). 10 [d of supernatant containing 
sdLDL, oxygenated PBS and 32 ^1 of 1 mM CuCk was added to a 2 ml quartz 
cuvette and the oxidation reaction products, the conjugated dienes, were 
monitored at 234 nm. Results are expressed as mean ± S.D. 
C Control 
HT + ND Hypertensive + No Drug 
HT + R Hypertensive + Ramipril 
HT + L Hypertensive + Losartan 
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2B.8: Oxidative stress marker MDA 
Increased vascular oxidative stress could be involved in the pathogenesis of 
hypertension (Miyajima et al., 2007), a major risk factor for cardiovascular 
disease mortality. Also it has been reported that in essential hypertension 
ROS may increase due to a diminution of the activity of antioxidant enzymes 
(Pedro-Botet et al., 2000). To explore any protective role offered by ACE 
inhibitors or ARAs against oxidative stress, this study evaluated the levels of 
MDA, the oxidative stress damage index in hypertensive subjects. Fig.2B.8 
demonstrates highly elevated MDA levels in the group of hypertensive 
subjects receiving no drug at all (HT+ND) as compared to the 
normotensive subjects (C). However, the treatment with ramipril alone 
(HT+R), significantly reduced the MDA levels. A relatively lesser amount of 
decrease was also noticed in the losartan treated group (HT+L). These 
findings are consistent to the previous reports suggesting reduction in 
oxidative stress and improvement in the endothelial function in hypertensive 
patients following ramipril and losartan monotherapy (Beatriz et al., 2007; 
Barath et al., 2006). 
2B.9: SOD and Catalase activity 
The occurrence of oxidative stress may arise from a primary decrease in the 
antioxidant defense system or from an elevation of ROS concentration. This 
derangement leads to oxidative damage to the structure of biomolecules, 
likely involving the antioxidant enzymes, thus contributing to the oxidative 
stress found in hypertensive subjects, but not in normotensive subjects 
(Rodrigo et al., 2007). As a consequence of decreased activity of antioxidant 
enzymes SOD and catalase, a reduction in the endothelium dependent 
vasodialation of the vascular smooth muscle cells of hypertensive subjects 
could be expected (Lassegue and Griendling, 2004). The treatment with anti-
hypertensives such as ramipril or losartan may however provide a protection 
from these damaging consequences. Therefore the assays were performed for 
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determination of SOD as well as catalase activity in the hypertensive 
subjects receiving no drug and those receiving ramipril or losartan as a 
monotherapy. Fig.2B.9(a,b) reveal reduced activity of both SOD and catalase 
in the hypertensive group receiving no treatment (HT+ND) suggesting high 
oxidative stress. The treatment with ramipril (HT+R) and losartan (HT+L) 
however successfully replenished the antioxidant enzyme activities in the 
hypertensive subjects. Interestingly, the effect of ramipril therapy was more 
pronounced than that of losartan therapy, suggesting its greater antioxidant 
capacity. Similar protective effects of ramipril and losartan against 
hypertension have been reported earlier (Khattab et al., 2004; Barath et al., 
2006) and this study also put forward an important role of ramipril in 
ameliorating oxidative stress. 
2B.10: DNA damage 
Earlier studies have shown an association between hypertension and the 
oxidation of LDL, and particularly the fact that its susceptibility to oxidation 
is greater in patients with essential hypertension than in normotensive 
subjects (Pierdomenico et al., 1998). It is suggested that oxidative 
modification of LDL could promote and accelerate the development of 
atherosclerosis (Witztum, 1994). Some studies have demonstrated the 
presence of DNA damage and DNA adducts in the atherosclerotic lesions and 
tissues (Binkova et al., 2002 and Martinet et al., 2002). The result presented 
in fig.2B.10 is consistent to the above reports, as a significant DNA damage 
was observed in hypertensive patients of all the three categories (HT+ND, 
HT+R, HT+L) as compared to the control group (C). However, the three 
groups of hypertensive subjects showed an almost equal extent of DNA 
damage; suggesting no beneficial role of ramipril or losartan against DNA 
damage, a major factor of metabolic syndrome. 
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2B.11: Correlation between NCEP/ATP III parameters and 
observed parameters 
Present work focuses the effect of anti-hypertensive drugs on metabolic 
syndrome. The NCEP/ATP III components (HDL, TGs, and BP) as well as the 
parameters observed (CRP, TNF-a and apo-B levels together with sdLDL 
oxidation time, lipid peroxidation, PON-1 activity, and extent of DNA 
damage), have been employed to ascertain the potential of metabolic 
syndrome in hypertensive and normotensive subjects chosen for this study. 
However, to find a relationship between these factors and NCEP/ATP III 
parameters in hypertensive subjects with the administration of ramipril or 
losartan therapy, Pearson's correlation analysis was performed. The plotted 
values of correlation coefficient (r) in fig.2B.ll reveal a negative correlation 
between (i) the values of PON-1 activity and the levels of TGs together with 
diastolic BP, (ii) lipid peroxidation and HDL, (iii) CRP and HDL, (iv) sdLDL 
oxidation time and HDL (v) TNF-a and TGs, (vi) apo-B and HDL (vii) DNA 
damage and HDL. Thus it may be suggested that reduction in BP and TGs 
levels upon ramipril or losartan monotherapy instigate the elevation of PON-
1 activity in hypertensive subjects. Also the increased HDL concentration 
may facilitate the decrease in lipid peroxidation, levels of CRP and apo-B 
along with the amendment of DNA damage as well as the time taken by 
sdLDL for oxidation. Changes in the TNF-a level however, was shown to be 
related with the reduction of TGs levels. This implies that improvement in 
BP, TGs as well as HDL levels on account of ramipril or losartan 
monotherapy play a pivotal role in regulation of several other metabolic 
syndrome parameters in hypertensive subjects. 
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Fig.2B.8: MDA levels of untreated hypertensive subjects, and 
hypertensive subjects treated with ramipril or losartan 
monotherapy. 
MDA in serum was determined fluorimetrically by thiobarbitunc acid 
reaction (TBA) as described in 'methods'. TBA reacting substance was 
expressed in terms of MDA as nmol/ml of serum and was measured at 
553 nm emission and 515 nm excitation wavelength. Results are expressed as 
mean ± S.D. 
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Fig.2B.9(a): SOD activity of untreated hypertensive subjects, and 
hypertensive subjects treated with ramipril or losartan 
monotherapy. 
The assay medium in a final volume of 3 ml consisted of 50 ^1 sample (serum) 
and 0.05 M tris-succinate buffer, pH 8.2 (2.85 ml). After incubation at 25°C 
for 20 min, the reaction was initiated by the addition of 8 nM pyrogallol. The 
change in absorbance was recorded spectrophotometrically at 420 nm for 3 
min. One enzyme unit is defined as the amount of enzyme required to cause 
50% inhibition of the rate of pyrogallol auto-oxidation. Results are expressed 
as mean± S.D. 
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Fig.2B.9(b): Catalase activity of untreated hypertensive subjects, and 
hypertensive subjects treated with ramipril or losartan 
monotherapy. 
Catalase activity was measured by following the decrease in absorbance at 
240 nm due to decomposition of hydrogen peroxide (H2O2). The reaction was 
allowed to proceed in 0.05 M phosphate buffer (pH 7.0) containing 1 ml H2O2 
(30 mM) and 50 nl sample. One enzyme unit is defined as the amount of 
enzyme decomposing 1 pM H2O2 per min at 25°C. Results are expressed as 
mean± S.D. 
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Fig.2B.10; DNA damage in untreated hypertensive subjects, and 
hypertensive subjects treated with ramipril or losartan 
monotherapy. 
DNA breakage in the lymphocytes isolated from each subject was measured 
by comet assay proposed by Singh et al. (1988) as described in 'methods'. 
Comet tail length (^imeters) was observed and plotted against each group. 
Results are expressed as mean ± S.D. 
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Fig.2B.ll: Correlation between NCEP/ATP III parameters and 
observed parameters with ramipril or losartan monotherapy. 
Pearson's correlation analysis was used for determination of relationship 
between the components of NCEP/ATP III and the parameters observed in 
hypertensive subjects with the administration of ramipril or losartan 
therapy. The correlation coefficient (r) of indicated parameters was plotted 
against the following parameters to obtain a positive or negative relationship. 
1 PON-1 activity 
2 Lipid peroxidation 
3 CRP concentration 
4 sdLDL oxidation time 
5 TNF-a concentration 
6 Apo-B concentration 
7 DNA damage 
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Hitherto, it has been recognized that diabetic subjects exhibit high oxidative 
stress due to persistent and chronic hyperglycemia, thereby depleting the 
activity of antioxidative defense system and promoting the generation of free 
radicals. To this end, it has become clear that ameliorating oxidative stress 
through treatment with antioxidants might be an effective strategy for 
reducing diabetic complications that may also lead to metabolic syndrome. 
There are evidences suggesting that antioxidants, such as a-tocopherol 
(vitamin E), have potential benefits with respect to CVD. Alpha-tocopherol 
has been shown to decrease lipid peroxidation, inhibit platelet adhesion, 
aggregation and smooth muscle cell proliferation, to exert anti-inflammatory 
effect on monocytes and to improve endothelial function (Harris et al., 2002). 
Animal studies have shown that vitamin E protects development of 
cholesterol-induced atherosclerosis by inhibiting protein kinase C activity in 
smooth muscle cells in vivo (Kartal et al., 2003). 
Ascorbic acid (vitamin C) is the main water-soluble antioxidant in 
human plasma (Frei et al., 1990). Earlier it was reported that long-range, 
heavy dose ascorbic acid therapy tends to normalize considerably, but not 
completely, the disturbances in certain blood fat metabolism factors, such as 
total cholesterol, triglycerides and lipoprotein lipase (LPL) activity (Sokoloff 
et al., 1967). Several studies have demonstrated that ascorbic acid improves 
endothelial-dependent vasodilatation in hypertension and diabetes. It has 
been proposed that such effects may be due to scavenging of superoxide 
anions and its reactive oxygen intermediates (Ting et al., 1996). 
Earlier the role of metformin and insulin was verified against diabetes 
and metabolic syndrome, no significant improvement was observed though. 
This study therefore, is an attempt to investigate whether the 
supplementation of vitamin C or E in diabetic animals could be an 
alternative to prevent oxidative stress and metabolic syndrome or not. For 
this purpose, a total of 12 rabbits were distributed into four experimental 
groups of three rabbits per group: non-diabetic (control, Gl); alloxan-mduced 
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diabetic (G2); diabetic supplemented with 150 mg/kg body weight of vitamin 
C (G3) and diabetic supplemented with 1000 I.U./kg chow of vitamin E (G4), 
administered daily as an oral supplementation via gavage for a period of two 
weeks. Thereafter, 5 ml fasting blood was collected from each animal and 
serum was isolated to determine all the parameters of oxidative stress and 
metabolic syndrome. 
3.1: Elevated parameters of metabolic syndrome 
3.1(a): FBG levels 
It has been recognized previously that an increase in plasma glucose to above 
normal levels typically develops late in the course of metabolic syndrome 
(Genuth et al., 2003). This study therefore, employs the measurement of FBG 
in all the four animal groups involved. Fig.3.1(a) demonstrates, that the FBG 
level was highest for the diabetic group (G2) and lowest for the non-diabetic, 
control group (Gl). The groups supplemented with antioxidants, vitamin C 
and vitamin E (G3 and G4), however attained an intermediate level, with the 
lowest FBG level in G3, among treated groups. This is consistent with the 
previous findings suggesting that antioxidants have potential benefits with 
respect to CVD (Vieira and Vianna, 2005). 
3.1(h): TGs levels 
Altered metabolism of triglyceride-rich lipoproteins and their elevated levels 
in serum can contribute substantially to the risk of ischemic heart disease in 
patients with metabolic syndrome (Krauss and Siri, 2004). In light of these 
observations, serum TGs levels were also estimated in the present study. 
Fig.3.1(b) demonstrates that the concentration of TGs was highest in diabetic 
group (G2), signifying atherogenic dyslipidemia and a possibility for the 
development of metabolic syndrome. Further, the supplementations of 
vitamin C and Vitamin E (G3 and G4) to the diabetic rabbits lead to the 
reduction in their TGs levels. This finding is in agreement to the proposal 
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drawn by Vieira and Vianna (2005) that vitamin supplementation may be 
used as an alternate therapy to treat lipid disorder for diabetic subjects. 
3.1(c): Apo-B levels 
Following the elevation in TGs levels, a somewhat greater portion of apo-B is 
observed in VLDL. There is growing evidence that all apo-B containing 
lipoproteins are atherogenic and elevated apo-B levels cause atherogenic 
dyslipidemia (Grundy, 2004). Consequently, apo-B levels were determined for 
all groups involved in this study and illustrated in fig.3.1(c). It was observed 
that diabetic group (02) contained highest apo-B levels followed by vitamin E 
(G4) and vitamin C (G3) supplemented groups. The lowest apo-B levels 
attained by G3 suggest that vitamin C may play an important role in 
regulating metabolic syndrome and associated abnormalities. 
3.1(d): Lipid peroxidation 
Diabetes is known to be associated with increased oxidative stress in vivo 
(Zozulinska et al., 1996). The increased oxidative stress together with poor 
metabolic control enhances lipid peroxidation in diabetic subjects, which has 
been proposed to be related with aetiology of diabetic complications or 
metabolic syndrome (Armstrong and Al-Awadi, 1991). In the present study, 
concentration of lipid peroxides was determined in the oxidized sdLDL 
isolated from the serum of each animal, by the method proposed by el-
Saadani et al. (1989). Results obtained in fig.3.1(d) conceive that the animals 
belonging to diabetic group (G2) had the greatest amount of lipid peroxides; 
whereas those supplemented with antioxidants such as vitamin C or vitamin 
E (G3, 04) had lesser amounts of lipid peroxides in their serum. This result 
rationally explains that lipid peroxidation may occur due to depletion of 
endogenous antioxidants in sdLDL. Hence, the inverse relationship between 
plasma levels of dietary antioxidants and the risk of metabolic syndrome 
observed in several epidemiological studies can be clearly understood. 
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Fig.3.1(a): FBG levels of untreated diabetic rabbits, and diabetic 
rabbits supplemented with antioxidants. 
The FBG level was determined by glucose oxidase method proposed by 
Trinder (1969). The diabetic state was confirmed when FBG concentration 
exceeded 200 mg/dl. Results are expressed as mean ± S.D. 
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Fig.3.1(b): TGs levels of untreated diabetic rabbits, and diabetic 
rabbits supplemented with antioxidants. 
The concentration of serum TGs was measured by an enzymatic colorimetric 
test using a commercial kit from Ranbaxy Diagnostic Div., India. Results are 
expressed as mean ± S.D. 
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Fig.3.1(c): Apo-B levels of untreated diabetic rabbits, and diabetic 
rabbits supplemented with antioxidants. 
The concentration of serum Apo-B was measured by an 
colorimetric test using a commercial kit from Giesse Diagnostics 
Results are expressed as mean ± S.D. 
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Fig.3.1(d): Lipid peroxidation in untreated diabetic rabbits, and 
diabetic rabbits supplemented with antioxidants. 
Lipid peroxides in the oxidized Hpoproteins were determined by mixing 
0.1 ml of the medium containing the modified lipoproteins with 1.0 ml of 
iodine-color reagent, incubating the mixture for 30 min at room temperature 
in the dark, and reading the absorbance at 365 nm. Results are expressed as 
mean±S.D. 
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3.1(e): CRP levels 
Persons with metabolic syndrome commonly have high levels of CRP (Ridker 
et al., 2003). Evidence is growing that an elevation of serum CRP levels 
predicts the development of type 2 diabetes and occurrence of major CVD 
events (Pradhan et al., 2001). In order to validate the necessity of estimating 
this inflammatory marker as a component of metabolic syndrome, the serum 
CRP levels were measured. Fig.3.1(e) shows that maximum concentration of 
CRP was found in the diabetic group (G2), followed by vitamin E and C 
supplemented groups (G4, G3) and finally the non-diabetic, control group 
(Gl). The surprisingly reduced CRP concentration in the antioxidant 
supplemented groups indicates the role of these vitamins in warding off the 
complications associated with metabolic syndrome. Numerous studies have 
confirmed that CRP levels are elevated in patients with metabolic syndrome 
(Tracy, 1999; Rifai and Ridker, 2001; Jialal and Devaraj, 2003) but none, best 
to our knowledge, have yet reported the suppression of CRP levels after 
antioxidant supplementation. Nonetheless, Frohlich et al. (2000) have 
demonstrated the association between CRP and the features of metabolic 
syndrome in a population-based study. It was concluded that mean CRP 
levels increased steadily as the number of metabolic abnormalities increased. 
3.1(f): TNF-a levels 
TNF-a is another proinflammatory cytokine secreted by monocytes-
macrophages, endothelial cells, and to a large extent, by adipocytes. Several 
studies have shown that levels of TNF-a are an important regulator of insulin 
sensitivity (Hotamisligil, 1993) and that neutralization of TNF-a improves 
insulin sensitivity in fa/fa rats but not in obese humans with diabetes (Arner, 
2003 and Kern et al., 1995). The results avowed in fig.3.1(f) coherently states 
that TNF-a levels were raised in the group of diabetic rabbits (G2). The levels 
were reduced significantly, in the groups supplemented with vitamin C (G3) 
and vitamin E (G4). It may be thus assumed that treatment with vitamins or 
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antioxidants suppress the exacerbation in insulin resistance and other 
metabolic abnormalities that are probably caused by elevation of 
proinflammatory cytokines and other factors of metabolic syndrome. 
3.2: Declined parameters of metabolic syndrome 
3.2(a): HDL levels 
An inverse relationship between the levels of HDL and the risk of developing 
premature CVD has been a consistent finding in many prospective population 
studies. In several of these studies, the level of HDL has been the single most 
powerful lipid predictor of future CVD events (Assmann et al., 1998; 
Manninen et al., 1992; Stamler et al., 1986). The NCEP/ATP III criterion also 
puts forth the importance of decreased HDL concentration in diagnosing 
metabolic syndrome. Consequently, HDL concentration was determined in all 
the four groups participating in this study. Fig.3.2(a) shows that the diabetic 
group (G2) has lowest concentration of HDL followed by the vitamin E group 
(G4), vitamin C group (G3), and finally the control group (Gl). Thus, above 
result indicates the efficacy of vitamins in improving HDL profile; thereby 
supporting the h5T)othesis of Gordon et al (1989) which suggests that, for 
every 1 mg/dl (0.025 mM) increase in HDL-C, the CVD risk is reduced by 2% 
to 5%. 
3.2(b): PON-1 activity 
Paraoxonase-1 (PON-1) is an HDL-associated enzyme that possesses 
antioxidative properties. In addition, diabetes is characterized by increased 
oxidative stress and decreased PON-1 activity. The mean serum PON-1 
activity for Gl, G2, G3 and G4 is demonstrated in fig.3.2(b). The highest and 
the lowest enzyme activity corresponding to the control group Gl and 
diabetic group G2, strongly suggest the reduction of arylesterase activity of 
PON-1 during oxidative stress. However, a noticeable elevation in the 
enzyme activity of the groups supplemented with vitamin C and E (G3, G4) 
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indicates the protection offered by antioxidants, possibly through 
maintaining the balance of excess free radicals and antioxidant defenses. 
This result also highlights the significance of decreased oxidative stress and 
increased PON-1 activity in recuperating diabetes as well as metabolic 
syndrome. Rozenberg et al. (2008) have reported that increasing PON-1 
expression in mice could attenuate the development of diabetes, a 
phenomenon which could be attributed to the antioxidative properties of 
PON-1 and decreased oxidative stress. 
3.2(c): sdLDL oxidation 
Previous reports have established that not only quantitative but also 
qualitative changes to lipoprotein profiles contribute to the increased 
incidence of coronary diseases (Gardner et al., 1996). Another important 
contributor to increased coronary risk is oxidative stress (Chisolm and 
Steinberg, 2000). In addition, there may be a pathological link between these 
parameters as modified forms of low density lipoproteins such as sdLDL are 
more susceptible to oxidative stress (de Graff et al., 1991). Similarly, 
fig.3.2(c) demonstrates the average time required for the oxidation of sdLDL. 
It is clearly depicted that sdLDL of diabetic group (G2) got oxidized earliest 
as compared to other experimental groups. One means by which sdLDL could 
increase the risk of vascular diseases is their greater susceptibility to 
oxidation (de Graff et al., 1991). Diabetes is associated with increased 
oxidative stress (Ceriello, 2003b) and anti-oxidant protective mechanisms are 
suggested to be sub-optimal in diabetes and metabolic syndrome (Ford et al., 
2003). Eventually, the time required for oxidation of sdLDL in vitamin 
supplemented groups (G3 and G4) was more than tha t required by the 
diabetic group receiving no such supplementation. The sdLDL isolated from 
vitamin C supplemented group however, procured maximum time to get 
oxidized, conferring a better preventive measure for diabetes as well as 
metabolic syndrome. 
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Fig.3.1(e): CRP levels of untreated diabetic rabbits, and diabetic 
rabbits supplemented with antioxidants. 
The concentration of serum CRP was measured by an enzymatic colorimetric 
test using a commercial kit from Calbiotech Inc., USA. Results are expressed 
as mean ± S.D. 
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Fig.3.1(f): TNF-a levels of untreated diabetic rabbits, and diabetic 
rabbits supplemented with antioxidants. 
The concentration of serum TNF-a was measured by an enzymatic 
colorimetric test using a commercial kit from Immunotech SAS, France. 
Results are expressed as mean ± S.D. 
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Fig,3.2(a): HDL levels of untreated diabetic rabbits, and diabetic 
rabbits supplemented with antioxidants. 
The concentration of serum HDL was measured by an enzymatic colorimetric 
test using a commercial kit from Ranbaxy Diagnostic Div., India. Results are 
expressed as mean ± S.D. 
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Fig.3.2(b): PON-1 activity of untreated diabetic rabbits, and diabetic 
rabbits supplemented with antioxidants. 
The assays were performed in a final volume of 250 |il containing 1 mM 
phenylacetate and 2 mM CaCb in 20 mM Tris-HCl buffer, pH 8.0 in the 
presence of 0.1 i^l of serum and was read at 270 nm. Results are expressed as 
mean ± S.D. 
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Fig.3.2(c): sdLDL oxidation time of untreated diabetic rabbits, and 
diabetic rabbits supplemented with antioxidants. 
The procedure for oxidation of small dense LDL was adapted from the 
method described by Esterbauer et al. (1989). 10 ^1 of supernatant containing 
sdLDL, oxygenated PBS and 32 |u.l of 1 mM CuCb was added to a 2 ml quartz 
cuvette and the oxidation reaction products, the conjugated dienes, were 
monitored at 234 nm. Results are expressed as mean ± S.D. 
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3.3: Oxidative stress marker MDA 
In recent years it has been known that, the most important factor that 
increases the free radicals production in diabetes is the hyperglj'cemic status, 
which can induce damage such as lipid peroxidation. Present approaches to 
diabetic therapy involve mainly drugs enhancing insulin secretion or 
signaling as well as inhibitors of endogenous glucose production (Aguirre et 
al., 1998), while the role of antioxidants as agents important for restoring the 
redox balance of the organism is still underestimated. This study therefore 
focuses the role of vitamin C or E alone in suppressing oxidative stress and 
related anomalies in alloxan-induced diabetic rabbits. Fig.3.3 illustrates the 
highest MDA levels, in diabetic animals (G2). Besides, it was also shown that 
supplementation with vitamin C (G3) as well as vitamin E (G4) successfully 
reduced the MDA levels. Present results hence, signify the involvement of 
antioxidant therapy in ameliorating oxidative stress. 
3.4: SOD and Catalase activity 
Under normal circumstances, free radicals that are produced through 
biological processes and in response to exogenous stimuli are controlled by 
various enzymes and antioxidants in the body. SOD and catalase are 
paradigm of such enzymes and generate the antioxidant defense system 
(Cheryl et al., 1996). A group of researchers have previously reported that a 
single dose of alloxan produced a decrease in the liver and pancreatic SOD 
and catalase activities during the development of alloxan-induced diabetes 
(Hamden et al., 2008). Akin to these findings, our results represented in 
fig.3.4(a) and (b) also demonstrate changes in the activity of antioxidant 
enzymes SOD and catalase, when verified in the serum of diabetic rabbits 
after the supplementation of vitamin C or E. It is elucidated that the specific 
activity of both SOD and catalase drop off significantly with diabetes and 
raised concomitantly after vitamin therapy as seen in G2, G3 and G4. 
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Nonetheless, the extent of recovery was slightly greater in G3, the vitamin C 
supplemented group, as compared to G4, the vitamin E supplemented group; 
suggesting it to be more effectual against oxidative stress. 
3.5: DNA damage 
Increased blood glucose levels stimulate the production of ROS, which can 
cause damage to biological macromolecules such as proteins and DNA 
(Bonnefont-Rousselot, 2002). In the present study, DNA damage was 
observed in the lymphocytes of alloxan-induced diabetic rabbits with or 
without the supplementation of antioxidants. The damage (expressed as tail 
length, ^meters) was measured in all the four groups Gl, G2, G3 and G4 via 
comet assay (as described in 'methods'). The representative photographs 
displaying the images of comets obtained after DNA damage before and after 
the supplementation of vitamin C or E is shown in fig. 3.5(a). The 
corresponding tail length was also determined and represented in fig.3.5(b). 
Maximum DNA damage was observed in diabetic rabbits (G2) depicting the 
association of diabetes with increased oxidative stress. The antioxidants 
supplemented groups however experienced a lesser extent of DNA damage 
and it was observed that the reduction was more pronounced in vitamin C 
supplemented group (G3) as compared to the vitamin E supplemented group 
of diabetic rabbits. This result justifies the scavenging of free radicals by 
these vitamins and reduction of ROS, thereby ameliorating DNA damage in 
diabetes and metabolic syndrome. 
3.6: Correlation between DNA damage and metabolic 
syndrome 
A number of studies have reported the relation between DNA damage and 
diabetes (Hannon-Fletcher et al., 2000; Lima et al., 2007; Demirbag et al., 
2005). To determine the association of DNA damage with metabolic 
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syndrome, Pearson's correlation analysis was performed. The correlation 
coefficient (r) obtained is an easy indicator of the role of elevated as well as 
declined parameters of metabolic syndrome in carrying out DNA damage. 
Fig.3.6 represents the result obtained after the correlation analysis and 
indicates positive correlation coefficient for the elevated factors and negative 
correlation coefficient for the declined factors of metabolic syndrome. This is 
an indication of enhanced DNA damage with increase in CRP, TNF-a, lipid 
peroxides, TGs and apo-B levels together with an increment in blood glucose. 
However, the negatively correlated factors propose an inverse relationship 
and explain the association of DNA damage with a decline in PON-1 activity, 
HDL concentration and the time required for oxidation of sdLDL. It can thus, 
safely be said that DNA damage do also occur in metabolic syndrome. 
3.7: Correlation between NCEP/ATP III parameters and 
observed parameters with antioxidants 
Present study contemplates the prediction as well as prevention of metabolic 
syndrome and DNA damage in diabetic animals after antioxidant 
supplementation. Though NCEP/ATP III criteria were involved herein to 
determine metabolic syndrome, other parameters analyzed throughout the 
study, were also taken into consideration. These parameters incorporated the 
analysis of serum PON-1 activity, time required for oxidation of sdLDL, 
concentration of lipid peroxides together with CRP, apo-B and TNF-a levels 
in serum, along with the estimation of DNA damage. In an effort to reveal a 
relationship between these factors and NCEP/ATP III parameters (FBG, TGs 
and HDL) in the diabetic rabbits with supplementation of vitamin C or E, 
Pearson's correlation analysis was performed. The plotted values of 
correlation coefficient (r) in fig.3.7 reveal a negative correlation between 
(i) the values of PON-1 activity and the levels of TGs and FBG, (ii) lipid 
peroxidation and HDL, (iii) sdLDL oxidation time and levels of TGs and FBG, 
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(iv) CRP and HDL, (v) apo-B and HDL, (vi) TNF-a and HDL, (vii) DNA 
damage and HDL. Thus it adds to an important observation depicting tha t 
the reduction in lipid peroxidation, and levels of CRP, apo-B and TNF-a 
together with the DNA damage occur due to an elevation m HDL 
concentration; an outcome of antioxidant supplementation. Similarly, the 
decrease in TGs and FBG concentration as a result of vitamin C or E 
supplementation was found to be responsible for increased PON-1 activity 
and the time required for oxidation of sdLDL. This implies that FBG, TGs 
and HDL levels play a fundamental role in regulation of several other 
metabolic syndrome parameters. 
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Fig.3.3: MDA levels of untreated diabetic rabbits, and diabetic 
rabbits supplemented with antioxidants. 
MDA in serum was determined fluorimetrically by thiobarbituric acid 
reaction (TBA) as described in 'methods'. TBA reacting substance was 
expressed in terms of MDA as nmol/ml of serum and was measured at 
553 nm emission and 515 nm excitation wavelength. Results are expressed as 
mean± S.D. 
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Fig.3.4(a): SOD activity of untreated diabetic rabbits, and diabetic 
rabbits supplemented with antioxidants. 
The assay medium in a final volume of 3 ml consisted of 50 ^1 sample (serum) 
and 0.05 M tris-succinate buffer, pH 8.2 (2.85 ml). After incubation at 25oC 
for 20 min, the reaction was initiated by the addition of 8 nM pyrogallol. The 
change in absorbance was recorded spectrophotometrically at 420 nm for 
3 min. One enzyme unit (E.U.) is defined as the amount of enzyme required 
to cause 50% inhibition of the rate of pyrogallol auto-oxidation. Results are 
expressed as mean ± S.D. 
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Fig.3.4(b): Catalase activity of untreated diabetic rabbits, and 
diabetic rabbits supplemented with antioxidants. 
Catalase activity was measured by following the decrease in absorbance at 
240 nm due to decomposition of hydrogen peroxide (H2O2). The reaction was 
allowed to proceed in 0.05 M phosphate buffer (pH 7.0) containing 1 ml 
H2O2 (30 mM) and 50 ^1 sample. One enzyme unit (E.U.) is defined as the 
amount of enzyme decomposing 1 pM H2O2 per min at 25°C. Results are 
expressed as mean ± S.D. 
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Fig.3.5(a): DNA damage in untreated diabetic rabbits, and 
diabetic rabbits supplemented with antioxidants (representative 
photographs). 
DNA breakage in the lymphocytes isolated from each rabbit, as measured by 
comet assay proposed by Singh et al. (1988) (details of the method are 
described in 'methods'). 
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Fig.3.5(b): Extent of DNA damage in untreated diabetic rabbits, and 
diabetic rabbits supplemented with antioxidants. 
DNA breakage in the lymphocytes isolated from each rabbit was measured by 
comet assay proposed by Singh et al. (details of the method are described in 
'methods'). Comet tail length (^meters) was observed and plotted against 
each group. Results are expressed as mean ± S.D. 
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Fig.3.6: Correlation between DNA damage and parameters of 
metabolic syndrome as measured in diabetic rabbits. 
Pearson's correlation analysis was performed to determine the relationship 
between DNA damage and the observed parameters of metabolic syndrome. 
The plotted values of correlation coefficient (r) indicate the positive or 
negative relationship between DNA damage and following parameters: 
1 PON-1 activity 
2 Lipid peroxidation 
3 CRP concentration 
4 sdLDL oxidation time 
5 HDL concentration 
6 TGs concentration 
7 Fasting blood glucose levels 
8 TNF-a concentration 
9 Apo-B concentration 
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Fig.3.7: Correlation between NCEP/ATP III parameters and observed 
parameters with antioxidants. 
Pearson's correlation analysis was used for determination of relationship 
between the components of NCEP/ATP III and the parameters observed with 
vitamin supplementation. The correlation coefficient (r) of indicated 
parameters was plotted against the following parameters to obtain a positive 
or negative relationship. 
1 PON-1 activity 
2 Lipid peroxidation 
3 sdLDL oxidation time 
4 CRP concentration 
5 Apo-B concentration 
6 TNF-a concentration 
7 DNA damage 
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Metabolic syndrome, first described by Reaven in 1988, is characterized by a 
constellation of cardiovascular risk factors, including atherogenic 
dyslipidemia, abnormal glucose tolerance, hypertension, and visceral obesity, 
which are intimately associated with insulin resistance and 
hyperinsulinemia. Insulin resistance has been proposed to be the common 
denominator of the metabolic syndrome, but insulin resistance per se is not a 
compulsory element of the NCEP/ATP III definition used in the present 
study. Of the five criteria of metaboUc syndrome defined in NCEP/ATP III, 
four (and notably hypertriglyceridemia, hypertension, hyperglycemia, and 
abdominal obesity) are independently characterized by the presence of 
systemic oxidative stress (Redon et al., 2003; Keaney et al., 2003). 
Furthermore, hypertriglyceridemia, hypertension, and obesity each is also 
associated with increased production of superoxide anion via the 
nicotinamide adenosine diphosphate oxidase pathway (Brasier et al., 2002). 
In addition, hyperglycemia leads to the formation of oxygen free radicals that 
may promote protein glycation and glucose autoxidation (Mezzetti et al., 
2000). 
Understanding the prevalence of a condition is helpful in defining the 
public health burden of that condition. Meaningful prevalence estimates are 
difficult to develop without a suitable definition however, which in the case of 
metabolic syndrome continues to be debated. The NCEP/ATP III definition is 
perhaps the most straightforward to implement because the five criteria are 
clearly defined. The present study therefore implied the same definition and 
its parameters to define metabolic syndrome in diabetic as well as 
hypertensive population. Given the high prevalence of metabolic syndrome 
and the associated risk of diabetes and CVD, an understanding of all facets of 
this syndrome is critical. 
Earlier it has been established that increased plasma TGs and reduced 
HDL levels are the key features of metabolic syndrome. Although elevated 
LDL is not an integral characteristic, there is usually an increase in the 
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proportion of small, dense LDL particles. Together these abnormalities 
constitute the atherogenic dyslipidemia, as a component of metabolic 
syndrome (Krauss and Siri, 2004). Garin et al. (2005) have revealed 
significant, qualitative changes to lipoproteins in patients with this 
syndrome. Working on a similar ground, our results too have indicated 
qualitative changes in the lipid profile of diabetic and hypertensive subjects, 
thereby suggesting their risk for the development of metabolic syndrome. 
Moreover, the increase in waist circumference, FBG, as well as BP of the 
chosen population does satisfy the requirements of NCEP/ATP III to describe 
metabolic syndrome. These changes represent a net deterioration of the 
cardiovascular profile, which would contribute to an increased risk of 
coronary diseases and metabolic syndrome. 
Oxidation of LDL is a process of lipid peroxidation in which the 
polyunsaturated fatty acids of LDL are successively degraded to different 
products (Brookes et al., 2003). The increased oxidative susceptibility of 
LDL together with the abnormal lipid profile like elevated TGs and low 
HDL levels, leads to increased CVD risk (Devaraj and Jialal, 1998). It has 
been observed that patients with h5T)ertension have a significantly lower 
lipid peroxidation lag time as compared to normotensive subjects (Bracht et 
al., 1997). There is evidence of a genetic influence on the LDL subfraction 
pattern and possibly the atherogenic potential (Shimano et al., 1991). 
Previously it has been reported that the sub-fraction of LDL namely dense 
LDL, light LDL and very light LDL have different susceptibility for lipid 
peroxidation in vitro (Vasankari et al., 2001). The results of the present 
study therefore focus on the sub-fraction of LDL that is sdLDL as the 
literature points towards the sdLDL being particularly atherogenic (Vega 
and Grundy, 1996). Hypertensive patients have a preponderance of sdLDL 
particles, a phenomenon associated with atherogenic lipoprotein profile and 
a three-fold increased risk of CVD (Bracht et al., 1997). This may probably 
be due to the high susceptibility of sdLDL to oxidation. We have thus 
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demonstrated that the sdLDL of hypertensive subjects oxidized fastest as 
compared to that of diabetic and control subjects. 
A surprisingly delayed oxidation of sdLDL in diabetic subjects may 
sug-gest that very high concentration of glucose could have actually acted as 
an antioxidant. This is in accordance with the report presented by Karabina 
et al. (2005) where incubation of HDL with glucose as high as IM 
concentration, a quantity routinely used for generation of advanced 
glycation end products in vitro, lead to the preservation of the esterolytic 
activity of PON-1, an antioxidant enzyme associated with HDL. In contrast, 
when incubation of HDL was performed with physiologically normal (5 mM) 
or elevated glucose concentrations (up to 100 mM), there was a loss of 
esterolytic activity of PON-1. These data suggest that lower concentration of 
glucose may facilitate or sustain oxygen radical production whereas very 
high concentration might be self-quenching. There is precedence in 
literature for the "antioxidant" effects of glucose and other sugars (Chuyen, 
1998), as molar concentration of mannitol has long been used as a radical 
scavenger (England et al., 1986). The delayed peak of oxidation in diabetes, 
as observed in our study, however is not suggestive of reduced risk of CVD, 
as the lipid profile of diabetic subjects remains abnormal with serum 
cholesterol, LDL and TGs elevated similar to hypertensive subjects. This 
could only be suggestive of elevated glucose acting as antioxidant and 
probably leading to delayed oxidation of sdLDL in diabetes as compared to 
hypertension. 
HDL is known to potentially reduce oxidative modifications of LDL. 
The prevention of lipid peroxide formation during copper-induced LDL 
oxidation by HDL could be due to their enzyme content, such as PON-1. The 
exact mechanism by which PON-1 exerts its protective effect however, is not 
well established. It has been proposed that the antioxidant effect could be 
associated with the peroxidase-like activity of this enzyme. Thus, by 
hydrolyzing preformed lipid peroxides, PON-1 can delay the oxidation 
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induced by metal ions (Shih et al , 1998). Our results have shown a reduced 
PON-1 activity in hypertension as well as in diabetes being much reduced in 
hypertension. Thus, in hypertensive subjects, more qualitative changes 
occur to LDL which renders them more susceptible to oxidation; coupled to a 
reduction in the potential antioxidant activity of HDL. This is suggestive of 
hypertension being a higher risk for developing CVD compared to diabetes. 
Moreover, the TGs, LDL cholesterol as well as waist circumference in 
diabetic and hypertensive subjects remained elevated. Consequently, these 
are viewed as severe metabolic syndrome patients. 
A relation between apo-B concentration and metabolic syndrome has 
previously been described in type 2 diabetic subjects (Relimpio et al., 2002). 
It provides a good surrogate measure of increased LDL particle numbers in 
people with metabolic syndrome and insulin resistance (Williams et al., 
2003). The Framingham Heart Study established the best correlation 
between apo-B and small LDL particle number (Kathiresan et al., 2006). We 
have demonstrated that apo-B levels were increased in both diabetic and 
hypertensive subjects almost equally. This apo-B dysregulation may be 
caused by increased non-esterified fatty acid (NEFA) flux to the liver (Zhang 
et al., 2004) or by an altered cholesterol homeostasis (low cholesterol 
absorption and high cholesterol synthesis). The results discussed till now 
strongly suggest that along with qualitative, the quantitative aspects of 
cholesterol metabolism are equally important to assess the metabolic 
syndrome. 
Recent cohort studies have demonstrated that CRP independently 
represents additive prognostic values at all levels of metabolic syndrome 
(Ridker et al., 2004). These studies also suggested a consideration of adding 
CRP as one of the clinical criterion for the assessment of metabolic 
syndrome. We have shown that CRP levels were significantly increased up 
to an approximately similar extent, in both diabetic and hypertensive 
subjects. This finding is consistent to recent reports suggesting the 
]39 
association of high CRP levels with the presence of metabolic syndrome in 
population based studies (Frohlich at al., 2000; Festa et al., 2000). In a 
study of apparently healthy women to evaluate the relationship between 
CRP, metabolic syndrome, and incident CVD over an 8-year period of follow-
up (Wu et al., 2002), CRP levels more than 3 mg/1 at baseline added 
independent prognostic information of the metabolic syndrome at all levels 
of severity. Women with the metabolic syndrome showed a 4- and 2.6-fold 
increase in their risk for CVD depending on whether CRP levels were 
greater or less than 3 mg/1, when compared to those without the metabolic 
syndrome and having CRP levels lower than 3 mg/1. Similar augmented 
values of CRP were observed in the present study also where both diabetic 
as well as hypertensive population displayed CRP levels more than the 
control subjects; thereby suggesting them to be at a greater risk for the 
development of metabolic syndrome. It has been proposed earlier that in 
addition to being a marker of innate immunity, CRP also has several direct 
effects at the level of the vessel wall (Pasceri et a l , 2001). Thus it is 
conceived that CRP is pro-atherogenic in endothelial cells. These 
observations along with basic research into the inflammatory mechanisms 
of both diabetes and vascular dysfunction (Pradhan and Ridker, 2002), 
provide strong evidence that insulin resistance and atherosclerosis share a 
common inflammatory basis. 
The TNF-a gene locus seems to be involved in human insulin 
resistance-mediated hypertension (Pausova et al., 2000). Additional studies 
have suggested that TNF-a has an important role in the development of 
insuhn resistance, both in obesity, and in NIDDM. When a soluble TNF-a-
binding protein was infused into fa/fa rats, which have high levels of 
adipose tissue TNF-a, there was a 2-3 fold increase in insulin-stimulated 
glucose uptake, along with improved insulin receptor autophosphorylation 
in both adipose tissue and muscle (Hotamishgil et a l , 1994). We have 
therefore monitored the changes in TNF-a levels in diabetic as well as 
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hypertensive subjects. As anticipated, the TNF-a levels of both the 
categories were found to be elevated. The hypertensive group however, 
showed comparatively greater elevation. Thus, suggesting an important role 
of TNF-a in developing metabolic syndrome, putting hypertensive 
population at a major risk. Consistent to our findings, Grundy (2003) has 
also suggested a significant association between inflammation, hypertension 
and metabolic syndrome. TNF-a is involved in the pathophysiology of 
hypertension in the metabolic syndrome and has also been known to 
stimulate the production of endothelin-1 and angiotensinogen (Kahaleh and 
Fan, 1997). 
Hitherto, the measurement and observation of various components of 
metabolic syndrome in diabetic and hypertensive population has given an 
idea of the contribution of diabetes as well as hypertension to metabolic 
syndrome. In view of the requirement of an integrated approach for 
treatment of this cluster of diseases and its complications, medical 
treatments of traits of the metabolic syndrome should be scrutinized with 
respect to pleiotropic effects on hyperglycemia, hypertension, dyslipidemia, 
adipokines, and low-grade inflammation. Several studies have shown that 
• t reatments to improve insulin resistance or reduce low-grade sub-clinical 
inflammation also have beneficial effects on other components of the 
metabolic syndrome (Dagenais et al., 2001; Chiasson et al., 2003; Torgerson 
et al., 2004). 
So far drug intervention studies in pre-diabetes have been performed 
only in people with impaired glucose tolerance (IGT). No data from 
controlled prospective studies are available for subjects with impaired 
fasting blood glucose (FBG). In subjects with IGT, about one-third is 
suffering from the metabolic syndrome. In the US Diabetes Prevention 
Program (DPP), metformin was compared with placebo and hfestyle 
modifications. It is remarkable that administration of metformin in diabetic 
subjects reduced the relative risk of developing metabohc syndrome by 
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21.7 % as compared to 14.4 % reduction attained by diet and exercise 
(Zimmet et al., 2003). Metformin is the only anti-diabetic drug that has been 
proven to reduce cardiovascular complications of diabetes, as shown in a 
large study of overweight patients with diabetes (UKPDS 34, 1998a). The 
International Diabetes Federation (IDF) has suggested the use of metformin 
in all cases inadequately controlled by non-pharmacological treatments 
(IDF, 2005). Metformin is therefore, said to be recommended by most 
guidelines as the drug of choice for monotherapy in diabetic patients. 
Insulin is generally considered the most effective hypoglycemic 
treatment in type 2 diabetes (Nathan, 2007). In fact, unlike other 
medications, the therapeutic effect of insulin maintains a dose-response 
relationship in virtually any dose range; for this reason, it is conceivable 
that any degree of h3T)erglycemia can be corrected by insulin treatment, 
provided that adequate doses are administered. The UK Prospective 
Diabetes Study (UKPDS) have established that intensive therapy with 
insulin significantly reduced the diabetes related complications (UKPDS 33, 
1998b). 
An attempt was therefore made to observe the beneficial effects of 
metformin or insulin monotherapy against the diabetic complications 
leading to metabolic syndrome. It was manifested from our findings that in 
addition to an obvious reduction in the levels of FBG, TGs, and lipid 
peroxides, a significant increase in the serum PON-1 activity, sdLDL 
oxidation time as well as HDL levels was observed in the diabetic subjects 
receiving either metformin or insulin monotherapy. Nonetheless, the clear 
depiction of better control through metformin rather than insulin as 
observed in our study, is in agreement to the earlier reports validating the 
benefit to risk ratio for metformin was many fold greater than that for 
insulin in first fine type 2 diabetes (UKPDS 34, 1998a). 
Some researchers have indicated that metformin has anti-atherogenic 
effect (UKPDS 34, 1998a; Matsumoto et a l , 2004). As for the mechanisms of 
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anti-atherogenic effects of metformin, recent studies have revealed that 
metformin significantly lowers insulin resistance and do possess anti-
oxidant activity (Faure et al., 1999). A significant elevation in the serum 
PON-1 activity of diabetic subjects after metformin monotherapy, as 
observed in the present study, is also an indication of the antioxidant 
potential of metformin. Diabetic subjects treated with insulin monotherapy 
also showed comparable results however. Small-sized LDL particles are well 
known to be atherogenic (Austin et al., 1988) and normalization of LDL 
particle size is one of the probable anti-atherogenic changes. Induction of 
these changes by metformin or insulin administration may be one of the 
mechanisms of their anti-atherogenic effect. This cannot be directly 
suggested through our studies but there was a definite delay in sdLDL 
oxidation time after metformin as well as insulin monotherapy. Such a 
delay in oxidation could be due to either the lowering of sdLDL particle 
number or normalization of their size. Nonetheless, the quantification of 
sdLDL particles is necessary to confirm these findings. 
An increase in TGs-rich lipoproteins which is one of the 
characteristics of dyslipidemia caused by insulin resistance (Ginsberg et al., 
2005) is known to be related with the appearance of small-sized LDL 
(Reaven et al., 1993). In addition, the presence of increased small dense 
LDL particles may be related closely to the high predictive ability of 
cardiometabolic disorders and elevations in apo-B. It was also shown that 
high apo-B levels were more closely associated with central obesity, insulin 
resistance and inflammation (Sattar et al., 2004). Consistent to these 
findings, our results have also shown a significant decrease in the TGs and 
apo-B levels in diabetic subjects upon administration of metformin as well 
as insulin. A plausible explanation of these changes could be attributed to 
the reduction in hepatic gluconeogenesis, decreased absorption of glucose 
from the gastrointestinal tract, and increased insulin sensitivity upon 
metformin administration (Hundal et al., 2000). A recent study has shown 
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that metformin stimulates the hepatic enzyme AMP-activated protein 
kinase (AMPK), which plays an important role in the metabolism of fats and 
glucose (Zhou et al., 2001). AMPK stimulates both the catabolism of existing 
intracellular energy stores, such as TGs and an insulin-independent influx 
of extracellular energy sources, such as glucose (Hardie, 2003). On the other 
hand, the correction of abnormalities in the lipid profile after insulin 
administration may be the consequence of a balance maintained between 
lipid synthesis and breakdown, by insulin via acting as a strong anti-
lipolytic agent (Howard et al., 1984). Previous studies have also reported a 
decreasing effect of metformin on very low-density lipoprotein (VLDL) 
(HoUenbeck et al., 1991), but the mechanism of this effect by metformin was 
not fully understood. 
Increased inflammatory markers like TNF-a and CRP have been 
observed in patients with diabetes and hypertension, which are important 
pathobiological components of metabolic syndrome (Nishtha et a l , 2008b). 
The measurement of these inflammatory markers thus provides a treatment 
target for metabolic syndrome. We observed minor decrement in the values 
of TNF-a and CRP upon metformin or insulin monotherapy in diabetic 
subjects. Earlier reports have also demonstrated no significant effect of 
glycemic control on markers of inflammation (Fonseca et al., 2006). Our 
findings consistently failed to demonstrate any significant anti-
inflammatory properties of metformin or insulin. It is very well known that 
there exists a clear relationship between the number of metabolic disorders 
(dyslipidemia, obesity, insulin resistance, diabetes, and hypertension) and 
increasing CRP levels and the strongest association of high CRP levels have 
been observed with increasing central obesity and insulin resistance (Ford, 
2003). Since our results with metformin or insulin monotherapy provided no 
changes at all in the increased waist circumference of diabetic subjects, a 
plausible explanation to unaltered inflammatory markers may be given 
thus. 
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Previous in vitro and in vivo studies have demonstrated that 
metformin causes an improvement in antioxidant activities in various 
tissues and also acts to Kmit Hpid peroxidation (Kanigur-Sultuybek et al., 
1995; Tessier et al., 1999; Srividhya and Anuradha, 2002). Analogous to 
these findings, our results have also demonstrated significantly reduced 
concentration of lipid peroxides in diabetic subjects after metformin as well 
as insulin monotherapy. The previously reported modification in the 
lipoprotein profile with similar treatment may be accountable for this 
important outcome. There is a good evidence for the involvement of 
enhanced oxidative stress in the pathogenesis of CVD and diabetes (West, 
2000). 
Free radicals can damage the double bonds of polyunsaturated fatty 
acids in the cell membrane, leading to a chain of chemical reactions called 
lipid peroxidation, during which aldehydes are formed. The measurement of 
malondialdehyde (MDA) by the thiobarbituric acid test is an indirect way of 
quantifying oxidative stress. We therefore, determined the levels of MDA in 
untreated diabetic subjects and those treated with metformin or insulin 
monotherapy. A significant elevation in the MDA levels of untreated 
diabetic subjects was noticed and hence perpetuates the relationship 
between diabetes and oxidative stress. On the other hand, decreased MDA 
levels were obtained with metformin as well as insulin monotherapy 
suggesting an important role of both of these hypoglycemics against 
oxidative stress. Similar outcomes with insulin monotherapy have been 
previously proposed by Konodo et al., (2002), where insulin therapy 
repressed LDL oxidation in diabetic subjects, which probably has resulted in 
decreased MDA levels. Therefore insulin therapy should also be 
acknowledged for its anti-oxidant potential; though in our study metformin 
showed better anti-oxidant property. It can thus be concluded that 
treatment with metformin may ameliorate the imbalance between free 
radical-induced increase in lipid peroxidation and decreased antioxidant 
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defences, by reducing the MDA level and increasing the enzymatic activities 
of SOD and catalase. 
Bonnefont-Rousselot et al. (2003) also suggested that metformin could 
directly scavenge ROS or indirectly act by modulating the intracellular 
production of superoxide radicals. Thus, metformin may also help in 
protecting against free radical-induced-DNA damage. An opinion w a^s 
therefore laid to verify the effect of metformin or insulin monotherapy in 
protection, if any, on the DNA damage incurred by free radical production 
during diabetes or metabolic syndrome. Therefore, v^ e^ performed comet 
assay to investigate the DNA damage in peripheral blood lymphocytes 
obtained from diabetic subjects receiving either of the two monotherapies. 
Evidently, no significant changes were observed in the comet tail length 
obtained for diabetic as well as treated subjects. This result suggests that a 
suitable monotherapy with recommended doses of metformin or insulin in 
the newly detected diabetic subjects is unable to protect against DNA 
damage which may possibly be induced by oxidative stress. 
These results strongly suggest that although the monotherapy with 
metformin or insulin succeeded in subsidizing a many of the components of 
metabolic syndrome, several issues are still unanswered. It was noticed that 
despite of beneficial changes in lipoprotein profile, such a monotherapy was 
unable to recompense for increased inflammatory markers and the DNA 
damage incurred in diabetic population. However, the association between 
various components of metabolic syndrome observed in this study and the 
parameters laid by NCEP/ATP III provided opportunity to understand the 
changes noticed before and after treatment in diabetic subjects. Thus 
correlation analysis serves as an important tool to justify the aberrations of 
these metabolic parameters using TGs and HDL. Out of the parameters 
analyzed in this study, those depicting elevated levels could be related 
directly to increased TGs and where the levels of parameters investigated 
were lower than normal, a direct relation with decreased HDL content can 
146 
be suggested. These findings are in agreement with the observations of Zak 
at al (2007); where positive correlation was found between the numbers of 
metabohc syndrome components and concentration of glucose and total 
cholesterol (TC), TGs, LDL, VLDL, and apo-B. The closest relation was 
found between the concentration of TGs and apo-B. 
High blood pressure is a classical feature of the metabolic syndrome. 
It has been reported that the metabolic syndrome is present in up to one 
third of hypertensive patients (Schillaci et al., 2004). Blood pressure levels 
are strongly associated with visceral obesity and insulin resistance 
(Ferrannini et al., 1997), which are the main pathophysiologic features 
underlying the metabolic syndrome. It has been mentioned earlier that the 
components of metabolic syndrome are treated individually, there being no 
current treatment that can target all features. Some classes of 
antihypertensive drugs, notably calcium channel blockers, angiotensin-
converting enzyme (ACE) inhibitors and angiotensin II receptor antagonists 
(ARAs), have been shown to reduce the occurrence of newly onset diabetes, 
particularly when compared with diuretics and 6-blockers (Sierra and 
Ruilope, 2003). It may therefore, be assumed that besides the lowering of 
blood pressure, certain antihypertensives may have different pleiotropic 
effects on the pathophysiology of the metabolic syndrome. ACE inhibitors 
and ARAs have also been shown to improve insulin resistance in many but 
not all studies (Kennedy et al., 2001). Furthermore, a reduction in excretion 
of albumin in the diabetic patients with microalbuminuria has also been 
observed upon administration of these drugs but their effect on lipid profile 
has been found to be insignificant (Sica and Bakris, 2002, Mann et al., 
2003). In patients with the metabolic syndrome, ACE inhibitors or ARAs 
should therefore be the drugs of first choice. 
In light of these observations, we chose ramipril and losartan, the 
well-known prototypes of ACE inhibitor and ARA, to verify whether they 
may or may not treat all the components of metabolic syndrome in 
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hypertensive subjects. Ramipril is one of the most frequently used ACE 
inhibitors in the treatment of hypertension in adults (Kaplan et al., 1993). 
Earlier studies on children with chronic kidney diseases associated with 
hypertension also put forward the efficacy of ramipril (Seeman et a l , 2004). 
However, the newly introduced ARA (losartan) has been reported by some 
scientists to be more effective anti-hypertensive therapy because 
it leaves no option for regeneration of AT-II through non-ACE pathways 
(McConnaughcy et al., 1999). 
Our results have demonstrated a significant elevation in PON-1 
activity together with a reduction in lipid peroxidation as well as levels of 
inflammatory markers in hypertensive subjects treated with either ramipril 
or losartan as a once-daily anti-hypertensive agent. Surprisingly, the 
effectiveness of ramipril was found greater than that of losartan while 
analyzing each of the above reported parameters. ACE inhibitor ramipril 
has indisputably demonstrated reduced cardiovascular events in a broad 
range of high-risk patients who participated in the HOPE trial (Kennedy et 
al., 2001). Ramipril should therefore be a first choice antihypertensive agent 
in an individual with hypertension associated with metabolic syndrome. 
This may also be evident from the previous reports suggesting that ramipril 
can reduce cardiovascular morbidity and mortality by slowing the 
progression of atherosclerotic plaque formation, preserving endothelial 
function and reducing plaque activation independently of effects on blood 
pressure and lipid levels (Kennedy et al., 2001). 
Visceral adipose tissue produces and secretes a number of 
adipocytokines, such as leptin, tumor necrosis factor-a (TNF-a), interleukin-6 
(IL-6), angiotensinogen, and non-esterified fatty acids (NEFA), which induce 
hypertension (Katagiri et al., 2007). Thus abnormalities in inflammatory 
mediators have also been reported to be implicated with development of 
hypertension. A positive relationship between increased serum levels of CRP 
and the risk for development of hypertension was observed in participants of 
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the Women's Health Study (Sesso et al., 2003). In addition, serum TNF-a 
concentration has been reported to be positively correlated with systolic blood 
pressure and insulin resistance in humans (Zinman et al., 1999), and 
increased TNF-a secretion has been observed in monocytes from hypertensive 
patients (Dorffel et al., 1999). Hence, it is proposed that reduction of these 
inflammatory markers as a result of ramipril or losartan monotherapy in the 
hypertensive subjects could help to explore better prevention measures for 
metabolic syndrome. 
After the seminal observations by Welborn et al (1966) and Modan et 
al (1985), an impressive amount of information was collected in support of the 
notion that essential hj^jertension is a condition characterized by multiple 
metabolic disturbances. It was observed that over-weight, IGT, 
hjT)erinsulinemia, low serum HDL, and high TGs levels were more frequently 
found in patients with essential hypertension than in normotensive subjects, 
regardless of age, gender, and ethnic background. As a result of epidemiologic 
analysis, and clinical investigations conducted by many research groups 
(Reaven, 1988; Ferrannini et al., 1991; Haffner et al., 1988), a blood pressure-
centered point of view gradually has shifted in favor of a broader, more 
metabolic-oriented perspective. We therefore, also analyzed the variation, if 
any, occurred in serum HDL, TGs, and apo-B content of hypertensive subjects 
after ramipril or losartan monotherapy. The results obtained however, 
demonstrated only slight improvement. Correspondingly, no significant 
alteration was observed even in the oxidation time of sdLDL after any of the 
above drug treatments performed in h5T)ertensive subjects. Consequently, the 
studies till this point suggest that though ACE inhibitors and ARAs have a 
significant role in lowering of blood pressure and inflammatory markers, the 
improvement of lipoprotein profile still remains a question. This is 
particularly important in patients with concomitant hypertension and 
dyslipidemia, because this group is at high risk for metabolic syndrome, and 
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in order to substantially reduce this risk, both BP and lipoprotein profile 
control must be achieved. 
In rats metabolic syndrome could be induced by chronic consumption of 
high fat and high refmed sugar (Barnard et al., 1998). Hypertension is 
therefore known to be associated with oxidative stress (Roberts et al., 2005), 
avid nitric oxide (NO) inactivation, and down-regulation of NO synthase 
(NOS) isoforms and endothelial NOS activator (Roberts et al., 2005). This 
suggests that oxidative stress and endothelial dysfunction may be strongly 
associated with development of hypertension in the metabolic syndrome. 
Recent evidences also propose that oxidative stress, which is elevated in the 
metabolic syndrome (Furukawa et al., 2004), is associated with sodium 
retention and salt sensitivity (Sarafidis and Bakris, 2007). It has also been 
suggested that formation of free radicals is increased in hypertensive 
subjects. Akin to these findings, our results have also demonstrated the 
involvement of oxidative stress in hypertension. The elevated MDA levels 
together with the decreased activity of antioxidant enzymes such as SOD and 
catalase in hypertensive subjects disturbs the critical balance between free 
radical generation and antioxidant defenses and hence causes oxidative 
stress. Surprisingly, the level of this oxidative stress marker was found to get 
reduced after ramipril or losartan monotherapy. A significant elevation in the 
activity of SOD and catalase was also observed in the hypertensive subjects 
being treated with these drugs. Nonetheless, much improved results were 
obtained with ramipril monotherapy suggesting it to possess better 
antioxidant potential compared to losartan. These results might provide an 
explanation for recovery of certain parameters following ramipril and 
losartan monotherapy. 
Some studies have reported that DNA damage in subjects with 
hypertension was not significant as compared to the subjects without 
hypertension (Negishi et al , 2001). Our results, on the contrary, have shown 
an unambiguous and extended tail length of DNA belonging to hypertensive 
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subjects when compared to that of normotensive control subjects. Besides, it 
was also witnessed that neither ramipril nor losartan monotherapy could 
prevent the DNA damage up to any conspicuous level; as evidenced by almost 
similar tail-lengths of treated or non-treated subjects. 
If one clinical axiom can be drawn from this available data, it is that 
the management of components of metabolic syndrome risk factors in 
isolation will not adequately reduce the risk of metabolic syndrome events. It 
therefore, greatly emphasized the need for development of some combination 
therapy or 'pol5^iir which may have a broad spectrum of actions for treating 
the low-grade inflammation, lipoprotein abnormalities and hence the 
complications associated with metabolic syndrome; keeping the role of 
"oxidative stress" as central. 
Oxidative stress, an imbalance between prooxidant and antioxidant 
factors, in favor of prooxidants and thereby potentiating oxidative damage, 
may play a role in the pathophysiology of diabetes and CVD (Rao, 2002). 
Consequently, the question of whether antioxidants could have a beneficial 
effect on reducing the risk of these conditions, especially CVD, has been 
intensively investigated, but the results remain inconclusive (Asplund, 2002). 
If antioxidants play a protective role in the pathophysiology of diabetes and 
cardiovascular disease, understanding the physiological status of antioxidant 
concentrations among people at high risk for developing these conditions, 
such as people with the metabolic syndrome, is of interest. 
The abnormal glucose metabolism in diabetes is also attributed to 
oxidative stress due to several factors. Hyperglycemia leads to the over-
production of free radicals and the nonenzymatic glycation of proteins which 
exert deleterious effects on pancreas and liver. This hyperglycemia is 
accompanied with the increase in marked oxidative impact as evidenced by 
the significant increase in lipid peroxidation together with a decrease in the 
activity of antioxidant enzymes, such as SOD and catalase. Although 
quenching of free radical species, which is the principal mechanisms of action 
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of antioxidants, other mechanisms that affect the pathophysiology of diabetes 
and cardiovascular disease may be operating as well (Visioli, 2001). The 
effects of vitamins C and E have received a great deal of interest. Through 
effects on oxidation of LDL cholesterol, leukocyte adhesion, and endothelial 
function, vitamins C and E may slow atherosclerosis (Carr et al., 2000). 
These vitamins were also found to be positively associated with paraoxonase 
activity (Jarvik et a l , 2002). 
We have recently reported that the PON-1 activity together with 
oxidation time of sdLDL and concentration of HDL were significantly reduced 
while total TGs and CRP levels were elevated in metabolic syndrome patients 
(Nishtha et al., 2008b). It was also observed that the treatment of all of these 
anomalous parameters of metabolic syndrome was not possible by either the 
monotherapy for hj^Derglycemia using metformin or insulin or the 
monotherapy for hypertension using ramipril or losartan. It was therefore 
predicted that the best possible key to find a cure for metabolic syndrome 
could be the treatment of each of the associated complication or parameter. 
Our results with vitamin C and E demonstrated a significant improvement in 
each of the component of metabolic syndrome, being considered throughout 
the study. 
Previous reports have suggested that increased DNA damage verified 
in the alloxan-induced diabetic animals was due to a significant disturbance 
in the antioxidant defense system (Damascene et al., 2002). Our results have 
also indicated increased DNA damage in diabetic group, reinforcing the 
association of diabetes with oxidative stress. The damage was partially 
recovered when they were supplemented with vitamin C and the result 
obtained indicates that the protection could be acquired by maintaining the 
balance of excess free radicals and reduced antioxidant defenses. Vitamin E 
supplemented group however showed an insignificant reduction in the DNA 
damage. This is analogous to the earlier reports suggesting a rather 
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increased DNA damage after vitamin E supplementation in diabetic human. 
subjects (Winterbone et al., 2007). 
It has also been reported previously that both Vitamin C and E, the 
well-known scavengers of free radicals do facilitate the reduction in ROS 
production or help in promoting the antioxidant defense system (Parthiban 
et al., 1995). The amendment of abnormal metabolic syndrome parameters 
in antioxidant supplemented groups also implies the beneficial role of these 
vitamins against metabolic syndrome. Nevertheless, the extent of protection 
offered by vitamin C was higher than that with vitamin E. This may be 
attributed to the reason that vitamin E (tocopherol) is oxidized to 
tocopheroxyl radical upon reaction with a free radical and thus may itself 
act as a pro-oxidant sometimes (Bowry et al., 1995; Neuzil et al., 1997). 
Vitamin C on the other hand, serves as a co-antioxidant and regenerates 
tocopherol (Bowry et al., 1995; Packer, 1997) which is the active and reduced 
form of tocopheroxyl radical. This is a potentially important function 
because in vitro experiments have shown that tocopherol may lead to 
increased production of free radicals in the absence of vitamin C (Neuzil et 
al., 1997). However, the in vivo relevance of the interaction between vitamin 
C and vitamin E is unclear. 
The precise mechanism for such a beneficial effect of these 
antioxidants, over the metabolic abnormalities that are directly linked to 
oxidative stress may be the scavenging of superoxide anions and its reactive 
oxygen intermediates (Ting et al., 1996). The concomitant decreased levels 
of MDA, as well as increased activities of SOD and catalase, rationally 
explain for the compensation in the complexities associated with metabolic 
syndrome upon antioxidant supplementation. It has long been postulated 
that supplementation with dietary antioxidants can alleviate the redox 
imbalance and thereby protect against the deteriorating effects of oxidative 
stress, progression of degenerative diseases, and aging (Pryor, 2000). 
Probably the anti-h5qDerglycemic or anti-hypertensive drugs do not possess 
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such specific ability of maintaining this redox imbalance and therefore are 
not sufficient enough to work against metabolic syndrome and its 
complications. 
This is a novel study in the field of metabolic syndrome where the 
role of antioxidants has been identified against DNA damage and other 
related abnormalities. With the help of these evidences, it can now safely be 
said that DNA damage increases with diabetes and oxidative stress which is 
partially recovered by dietary supplementation of vitamin C. The correlation 
of DNA damage with the parameters of metabolic syndrome firmly suggests 
the occurrence of DNA damage in metabolic syndrome also. In light of these 
observations, it is plausibly suggested that vitamin C may be prescribed to 
the patients suffering from diabetes and metabolic syndrome in order to 
minimize the complications raised by oxidative stress. Human studies are 
nonetheless needed to confirm these findings. 
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Summary 
Aim: The aim of this study is to compare the extent of small dense low-density 
lipoprotein (sdLDL) oxidation in diabetic and hypertensive patients and to investigate 
their correlation with Metabolic Syndrome as per NCEP ATP III criterion. 
Design and methods: In the present study, 120 human subjects, men and women were 
selected randomly from the age group of 30-75 yrs for the screening of Metabolic 
Syndrome. Family history and prevalence of diabetes and hypertension in different 
age groups were recorded. Their waist circumference was measured and lipid profile 
was also determined. The sdLDL was isolated and oxidized in vitro. Attention was 
focused on the peak oxidation time of sdLDL in vitro and estimation of serum 
paraoxonase (PON-1) activity of all volunteers. 
Results: Our results have indicated an overall increase in total cholesterol (TC), 
triglycerides (TGs), low-density lipoproteins (expressed as mg/dL) as well as mean 
waist circumference (expressed as cm) of the diabetic (242 ±10.1, 218 ±21.6, 
140 ±4.9, 105 ±1.6) and hypertensive subjects (220 ±6.4, 250 ±12.9, 150 ±5.6, 
104 ± 1.9) as compared to controls (182 ± 5.4,142 ± 8.9,112 ± 4.3, 86 ± 1.5). It was 
also found that most of the diabetic and hypertensive subjects were from the age 
group of 50-59 yrs. The results obtained after oxidation of sdLDL have shown an early 
peak of oxidation in hypertensives [peak value = 65.3 ± 5.6 s] followed by diabetics 
[peak value = 75.7 ± 3.8 s]. Antioxidant enzyme paraoxonase was also found to be 
compromised in hypertensives and in diabetics. 
Conclusion: The early peak of oxidation of sdLDL in hypertensives put them at a 
higher risk to CVD as compared to diabetics and abnormal lipid profile and increased 
waist circumference of diabetics and hypertensives suggest them to be potential 
patients of Metabolic Syndrome as per NCEP ATP III criterion. 
© 2007 Diabetes India. Published by Elsevier Ltd. All rights reserved. 
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Introduction 
The observation that certain risk factors accumulate 
in coronary patients is suggestive of a common origin 
and was the subject of quite early reports in clinical 
literature [1,2]. The concept has evolved through a 
number of synonyms [3] to its present status as the 
Metabolic Syndrome [4]. The strongest candidate 
for the common origin is insulin resistance [4,5]. A 
growing number of metabolic anomalies are linked 
to insulin resistance [3], the core components as 
excess weight, dyslipidemia and hypertension have 
recently been incorporated into guidelines by WHO 
[6] and National Cholesterol Education Programme 
Adult Treatment Panel III (NCEPATP III) [7] to provide 
a definition of the Syndrome which should aid clin-
ical studies. Insulin resistance (or Indications for 
abnormal glucose metabolism) Is the central feature 
of WHO definition whereas the NCEPATP III recom-
mendations do not require evidence of insulin resis-
tance. 
Patients with the Metabolic Syndrome have sig-
nificantly decreased low-density lipoprotein (LDL)-
cholesterol/apo-A1 ratio which is related to the 
formation of small, dense lipoprotein particles that 
has higher susceptibility to oxidative modifications 
[8]. Hypertensive patients may have a preponder-
ance of small dense LDL (sdLDL) particles; a phe-
nomenon associated v/lth an atherogenic 
lipoprotein profile and a 3-fold increased risk of 
cardiovascular diseases [9]. Additional risk factors 
that may be associated with the Syndrome include 
Type-ll diabetes, hyperurecemia, microalbumi-
nuria, and coagulation abnormalities that constitute 
a prothrombic diathesis [10]. Several studies have 
found an inverse relationship between the lag time 
of in vitro LDL oxidation and the severity and pro-
gression of coronary atherosclerosis [11], suggesting 
that enhanced susceptibility to oxidation may 
underlie the excess vascular disease observed in 
patients with diabetes. 
The Syndrome is also associated with reduced 
concentrations and activities of the antioxidant 
enzyme paraoxonase-1 [8]. Human serum paraoxo-
nase (PON-1), a 43 kDa protein catalyses the hydro-
lysis of organophosphate esters, aromatic carboxylic 
acid esters and carbamates in a calcium dependent 
manner [12]. Although the natural substrate for 
PON-1 is stilt unknown, several groups have reported 
that the enzyme protein has the capacity to retard 
the accumulation of lipid peroxides in low-density 
lipoprotein (LDL) and this Is mainly due to the ability 
of the enzyme to reduce hydroperoxides [13]. 
Aviram et al. [14] have shown an inverse correlation 
between the esterolytic activity of PON-1 in serum 
and susceptibility of HDL to oxidation. The Meta-
bolic Syndrome is well characterised by the pre-
sence of smaller, denser lipoprotein particles that 
increase their susceptibility to oxidative modifica-
tion and a diminished serum PON-1 which is a major 
determinant of the antioxidant capacity of HDL. 
These may be contributory factors to the increased 
presence and severity of coronary diseases in such 
patients [8]. 
We through the present study, therefore have 
examined the kinetics of in vitro oxidation of sdLDL 
after isolating it from the serum of volunteers. 
Attention was focused on the peak obtained for 
oxidized sdLDL. The arylesterase activity of PON-1 
was also recorded in the respective volunteers. 
Subjects and methods 
A total of 120 subjects were recruited on a consecu-
tive basis for a screening program to check the pre-
valence of Metabolic Syndrome at the J.N. Medical 
College, A.M.U. Men and women aged 30-75 yrs 
participatedinthisstudy. All the volunteers, unaware 
of their health status and not observing any medica-
tion schedule for either diabetes or hypertension, 
were randomly selected and divided into three cate-
gories: diabetics (those having fasting plasma glucose 
level >110mg/dL but no hypertension), hyperten-
sives (those having BP >130/80 mmHg but no dia-
betes) and controls (those having neither diabetes 
nor hypertension). Demographic information and 
clinical history was obtained after getting informed 
consent. Waist circumference of all volunteers was 
measured using standard techniques. Fasting blood 
specimens were obtained for determination of 
plasma glucose, serum cholesterol, serum triglycer-
ides (TGs), serum HDL and LDL cholesterol. 
Plasma glucose was determined by the glucose 
oxidase peroxidase method [15] and the concentra-
tion of serum cholesterol, serum triglycerides, and 
HDL cholesterol were measured by an enzymatic 
colorimetric test using commercial kits from Ran-
baxy Diagnostic Division, HP. LDL cholesterol was 
calculated using the Friedewald equation [16]. 
Small dense LDL-C assay 
The details and validation of this experiment have 
been described elsewhere [17]. in brief, the pre-
cipitation reagent (0.1 mL) containing 150 U/mL of 
heparin sodium salt and 90 mmol/L MgCl2 was added 
to a serum sample (0.1 mL) and the samples were 
incubated for lOmin at 37 °C after mixing. Then 
each sample was placed in an ice-bath and allowed 
to stand for 15min after which the precipitates 
were collected by centrifugation at 15,000 rpm 
for 15min at 4°C. The precipitates were always 
sdLDL oxidation in hypertensives and diabetics and prediction of Metabolic Syndrome 23 
packed tightly at the bottom of the tube and the 
supernatant was clear. This heparin-Mg^* superna-
tant contains sdLDL cholesterol with no influence of 
other lipoproteins [18]. Nitrogen gas was bubbled 
through the supernatant collected in separate tubes 
which are then closed tightly with parafilm and kept 
at 4 °C in dark to protect it from oxidative modifica-
tion. 
Oxidation of small dense LDL 
The procedure for oxidation of small dense LDL was 
adapted from the method described by Esterbauer 
et al. [19] for LDL oxidation. 10 |xL of supernatant 
containing sdLDL, collected above, oxygenated PBS 
and 32 nL of 1 mM CUCI2 was added to a 2 mL quartz 
cuvette and the oxidation reaction products, the 
conjugated dienes, were monitored continuously at 
37 °C on a UV spectrophotometer at 234 nm [20]. 
Measurement of arylesterase activity of 
PON-1 using phenylacetate as a substrate 
Initial rates of hydrolysis were determined sjsectro-
photometrically at 270 nm in a power wave 200 
microtitre scanning spectrophotometer. The assays 
were performed in a final volume of 250 \iL contain-
ing 1 mmol/L phenylacetate and 2 mmol/L CaClz in 
20 mmol/LTris-HCl buffer, pH 8.0 in the presence of 
0.1 JJLL of serum. The extinction coefficient at 
270 nm for the reaction was 1307mol/L/cm. One 
unit of arylesterase activity is equal to 1 (xL of 
phenylacetate hydrolysed per milliliter per minute 
[21]. 
Statistical analysis 
Analysis was performed using origin 6.1 statistical 
package for windows. Continuous variables were 
expressed as mean ± S.D. and qualitative data were 
expressed in percentages. Lipid profile, waist cir-
cumference, oxidation of sdLDL and arylesterase 
activity of PON-1 were compared by Student's 
t-test. P-value less than 0.05 were considered to 
be significant. 
Results 
A total of 120 subjects were included in the study 
and were divided into three categories, i.e. dia-
betics, hypertensives and controls (those having 
neither diabetes nor hypertension). Fig. 1 shows 
that among them 30% were diabetic, 13% were 
hypertensives and 57% were controls (as per their 
fasting plasma glucose and BP). 
DHT 
• C 
Figure 1 Prevalence of diabetes and hypertension 
among all the volunteers. Diabetics -^ volunteers whose 
blood glucose level >110 mg/dL. Hypertensives -^ volun-
volunteers whose BP > 130/85 mmHg. Controls - . volun-
volunteers having neither diabetes nor hypertension (as 
per their clinical history). 
The information about waist circumference is an 
important parameter for the diagnosis of Metabolic 
Syndrome. Fig. 2(a and b) shows the mean waist 
circumference of men and women in all the three 
categories. It is clearly indicated that the mean waist 
circumference of diabetics (men = 105 ± 1.6, 
women = 95 ± 1.6) as well as hypertensives (men = 
104 ±1.9, women = 93 ± 2.4) was always higher 
than controls (men = 86 ± 1.5, women = 75 ± 1.6). 
Fig. 3 gives the information about family history 
of all the study subjects. As shown in Fig. 3(a), 40% 
of diabetic subjects had positive family history and 
60% had negative. Similarly, Fig. 3(b) indicates that 
among all the hypertensive subjects, 56% had the 
positive family history while 44% had negative. 
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Figure 2 Mean wa is t c i r cumfe rence of d iabet ic , hyper-
tensive and con t ro l sub jects : (a) men and (b) women . 
Waist c i rcumference > 1 0 2 c m fo r men and > 8 8 c m for 
women defines Metabol ic Syndrome (NCEP ATP III guide-
l ines). Results are mean ± 5.E.M. P < 0.05, using pai red 
t-test. 
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Figure 3 Family history of (a) diabetic and (b) hyper-
tensive subjects. Results are expressed as n{%). 
Fig. 4 shows the age related prevalence of dia-
betic and hypertensive subjects. It is indicated in 
both Fig. 4(3 and b) that the prevalence of diabetes 
and hypertension increased with age and the max-
imum prevalence was seen in the age group of 
50-59 yrs. 
The lipid profile of diabetic, hypertensive and 
control subjects is shown by determining their total 
cholesterol (TC), TGs, HDLand LDL(Fig. 5(a-d)). The 
average cholesterol of diabetics (242 ±10.1) was 
found to be maximum followed by hypertensives 
(220 ± 6.4) and controls (182 ± 5.4). Mean triglycer-
ides were highest in hypertensives (250 ± 12.9), then 
in diabetics (218 ±21.6) and lowest in controls 
(145 ± 8.9). HDL was almost stable in alt cases (dia-
betics = 45 ± 1.1, hypertensives = 44.3 ± 1.4 and 
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Figure 4 Age related prevalence of (a) diabetic and (b) 
hypertensive subjects. Results are mean ± S.E.M. 
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Figure 5 (a) Total cholesterol levels in diabetic, hyper-
tensive and control subjects. Results are mean ± S.E.M. 
P < 0.05, using paired t-test. (b) Triglycerides levels in 
diabetic, hypertensive and control subjects. TGs 
>150 mg/dL defines Metabolic Syndrome (NCEP ATP III 
guidelines). Results are mean ± S.E.M. P < 0,05, using 
paired t-test. (c) HDL levels in diabetic, hypertensive 
and control subjects. Results are mean ± S.E.M. 
P< 0.05, using paired t-test. (d) LDL levels 1n diabetic, 
hypertensive and control subjects. Results are mean 
± S.E.M. P < 0.05, using paired t-test. 
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Table 1 Average peak value of oxidation of small 
dense LDL (sdLDL) of diabetic, hypertensive and con-
trol subjects 
Peak (s) 
Hypertensives 
Diabetics 
Controls 
65.3 ±5.6 
75.7 ±3.8 
86.5 ±4.1 
Results are mean ± S.E.M. Early peak of oxidation of sdLDL of 
hypertensives shows its greater susceptibility to oxidation 1n 
them followed by diabetics and controls. 
controls = 35 ± 0.95) while LDL was highest in hyper-
tensives (150 ±5.6), followed by diabetics (140 
± 4.9) and controls (112 ± 4.3). 
Recently sdLDL has been highlighted as a new risk 
factor for coronary heart diseases (CHD). It was 
discovered that the combination of Heparin and 
Magnesium precipitated a part of LDL which 
remained in the supernatant and was Identified as 
sdLDL which was Identical to the one Isolated by 
ultracentrifugatlon. This supernatant was used as a 
source of sdLDL In the present study. It was oxidized 
in vitro by using CuCl2 as described in Section 'Sub-
jects and methods' [19] and the kinetics was 
observed in terms of peak time. Our results indicate 
the earliest peak of oxidation of sdLDL for hyper-
tensive patients followed by diabetic and control 
subjects (Table 1). 
The HDL-assoclated enzyme PON-1 has been iden-
tified as an important determinant of the capacity of 
HDL to prevent oxidative modification to LDL [14] 
and the activity of this enzyme has also been 
reported to be decreased In cardiovascular diseases 
(CVD) [22] and In diabetes [23]. Therefore we have 
also measured the arylesterase activity of PON-1 in 
all the three categories (Fig. 6). Our results have 
shown that the PON-1 activity was significantly 
reduced in case of hypertensives (0.26 ± 0.18) fol-
07 
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Figure 6 Arylesterase activity of PON-1. Results are 
mean ± S.E.M. P<0.05, using paired t-test. The F270 
for the reaction is 1307 mol/L/cm and 1 unit of arylester-
ase activity is equal tol (xmol of phenylacetate hydrolysed 
per milliliter per minute. 
lowed by diabetics (0.39 ±0.14) and then by control 
subjects (0.60 ±0.14). 
Discussion 
The clustering of multiple metabolic abnormalities 
including obesity. Insulin resistance, non-insulin 
dependent diabetes mellitus (NIDDM), hypertension 
and dyslipldemias have become known as the Insulin 
Resistance Syndrome or Multiple Metabolic Syn-
drome [24]. An elevation in blood pressure is one 
of the components of Metabolic Syndrome [25] and 
high blood pressure is a major risk factor for cardi-
ovascular diseases [26]. Therefore, the increased 
risk of cardiovascular diseases in hypertensive 
patients correlates with blood pressure and may 
be related to other factors like abnormal lipid pro-
file [27]. Studies have also shown an association 
between hypertension and the oxidation of LDL 
and particularly the fact that Its susceptibility to 
oxidation is greater in patients with essential hyper-
tension than in normotensive subjects [28,9]. It is 
suggested that oxidative modification of LDL could 
promote and accelerate the development of ather-
osclerosis [29,30]. When LDL Is chemically modified, 
an uncontrolled uptake of oxidized LDL by the sca-
venger receptors In macrophages occur. As a con-
sequence, they dedifferentiate into foam cells that 
accumulate in the arterial wall, forming early 
sclerotic lesions [31]. 
Oxidation of LDL is a process of lipid peroxidation. 
The polyunsaturated fatty acids of LDL are succes-
sively degraded to different products [32]. The oxi-
dative susceptibility of LDL is increased when 
combined with cardiovascular risk factors like the 
abnormal lipid profile [33]. It has been observed that 
patient with hypertension has a significantly lowered 
lipid peroxidation lag time compared to normoten-
sive subjects [9]. There is evidence of a genetic 
influence on the LDL sub-fraction pattern and possi-
bly the atherogenic potential [34]. Previously it has 
been reported that the sub-fraction of LDL, namely 
dense LDL, light LDL and very light LDL have different 
susceptibility for lipid peroxidation in vitro [35] The 
results of the present study therefore focuses on the 
sub-fraction of LDL, that is sdLDL as the literature 
points towards the sdLDL being particularly athero-
genic [36]. Hypertensive patients have a preponder-
ance of sdLDL particles, a phenomenon associated 
with atherogenic lipoprotein profile and a three-fold 
Increased risk of cardiovascular disease [9]. This may 
probably be due to the high susceptibility of sdLDL to 
oxidation. We have demonstrated that the peak time 
of oxidation of sdLDL was earliest in hypertensives as 
compared to controls. 
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Surprisingly, in diabetics the peak time was much 
delayed as compared to that in hypertensives. This 
probably was due to the fact that very high con-
centration of glucose in blood may act as an anti-
oxidant [37] as there is precedence in literature for 
the "antioxidant" effects of glucose and other 
sugars [38] and molar concentration of mannitol 
has long been used as a radical scavenger [39]. 
Lower concentration of glucose may facilitate or 
sustain oxygen radical production whereas very high 
concentration might be related to the ability of 
glucose to generate advanced glycation end pro-
ducts (AGE), or to initiate oxygen radical production 
[40]. The delayed peak of oxidation in diabetes may 
not be suggestive of reduced risk of cardiovascular 
diseases as the lipid profile of diabetics remains 
abnormal with serum cholesterol, LDL and TGs ele-
vated as in hypertensives. This could only be sug-
gestive of elevated glucose acting as antioxidant 
and probably leading to formation of advanced 
glycation end products. 
HDL have been shown to potentially reduce 
oxidative modifications of LDL. The prevention 
of lipoperoxide generation during copper-induced 
LDL oxidation by HDL could be due to their enzyme 
content, such as paraoxonase-1 (PON-1). The 
exact mechanism by which PON-1 exerts its pro-
tective effect is not well established. It has been 
proposed that the antioxidant effect could be 
associated with the peroxidase-like activity of this 
enzyme. Thus, by hydrolysing preformed lipid per-
oxides, PON-1 can delay or inhibit the initiation of 
oxidation induced by metal ions [41]. Our results 
have shown that the serum levels of the enzyme 
are reduced in patients with hypertension and 
diabetes being much reduced in hypertensives. 
Thus, in hypertensives, more qualitative changes 
occur to LDL which render them more susceptible 
to oxidation; coupled to a reduction in the poten-
tial antioxidant activity of HDL. This is suggestive 
of hypertensives as high-risk group for CVD as 
compared to diabetic patients. Moreover, the 
TGs, LDL cholesterol as well as waist circumfer-
ence in diabetic and hypertensive subjects 
remained elevated. So these are viewed as a 
severe form of Metabolic Syndrome patients. 
Further studies are however needed to conclu-
sively suggest the relation between oxidation of 
sdLDL and increased risk of CVD. 
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